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Summary 
 
The eye is a glucocorticoid target tissue which orchestrates expression of target genes 
through the glucocorticoid receptor (GR).  The classical function of GR involves its 
interaction with glucocorticoid to influence transcription of genes involved in numerous 
physiological processes which include inflammation.  The first line of defence in the 
ocular tissues includes the mucosal barrier and expression of receptors that recognise 
pathogen.  These mechanisms activate the innate immune response during inflammation, 
however, in the ‘normal’ eye, immunomodulatory components exist to promote immune 
privilege.  11beta hydroxysteroid dehydrogenase 1 (11β-HSD1) regulates cortisol locally 
in tissues and has already been localised to to some ocular surface and intraocular tissues.  
The aim of this thesis is to evaluate the functional role of 11β-HSD1 in the eye and the 
orbit and whether the 11β-HSD1 can be targeted to modify various disease processes in 
the eye.  An animal model was used to characterise the pre-receptor regulation of 
glucocorticoids and this was further characterised in human ocular and orbital tissues and 
cells.  The results showed that 11β-HSD1 is functional in certain ocular (corneal 
epithelial, fibroblast and conjunctival fibroblast) and orbital (orbital preadipocyte) cells.  
The data therefore emphasises the putative role of 11β-HSDs in the ocular and orbital 
microenvronment.
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1. Chapter 1 
General Introduction 
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1.1.  Introduction 
1.2. Human Eye in the Orbit 
The human eye is a complex structure which acts as our sensory receptor to focus light via 
the cornea, pupil and lens and onto the retina.  The iris can alter the size of the pupil for 
entry of light depending on the intensity of the light in the surrounding environment. The 
ciliary muscles contract to alter the shape of the lens to influence the refraction of light on 
to the retina (Figure 1-1) and the ciliary processes are responsible for aqueous humour 
production.  The aqueous humour production is known to have important roles in 
nourishing and removing waste materials from the various processes of the eye which 
include the cornea and lens which do not have access to local blood supply.  The 
conjunctiva is a mucosal surface which is able to produce mucous to lubricate and keep 
the eyeball clean while the vitreous fluid, a jelly-like fluid in the posterior part of the eye 
provides a pressure to keep the globe spherical.   
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Figure 1-1:  Diagram of the human eye depicting essential anatomy for correct 
eye vision. 
  Picture taken from(Streilein, 2003a) 
The human eye is anchored in the orbit by the attachment of extraocular muscles which 
consist of the lateral, medial, inferior and superior rectal muscles and superior and inferior 
oblique muscles from the sclera to the bony orbit (Davson, 1990).  Any spaces within the 
orbit which do not contain the globe, muscles, nerves or vessels are occupied by adipose 
tissue which anatomically can be subdivided into the retrobulbar fat, located posterior to 
the eyeball and peribulbar fat that surrounds the eyeball and acts to protect the structures 
of the eye. 
1.3. Anatomy of Ocular Surface Defence Barriers 
The ocular surface consists of tear film, the conjunctiva, cornea, and the area of transition 
known as the limbus. 
Direction of 
light 
Choroid 
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1.3.1. Conjunctiva 
The conjunctiva is a vascularised mucosal surface which is a continuous membrane but 
comprises of three main sections (Figure 1-2):  
(1) The palpebral conjunctiva, where the cells are stratified squamous in appearance and 
cover the inside of the eyelid.  This consists of three main parts, which are the 
mucocutaneous junction which is located behind the meibornian gland.  It possesses 
conjunctival associated lymphoid tissue (CALT) which consist of lymphocytes, dendritic 
cells and plasma cells located near small vessels and high endothelial venules (HEV), 
(Knop and Knop, 2000, Ono and Abelson, 2005, Rosellini et al., 2007).  
(2) The conjunctival cul-de-sac or fornix consists of the superior fornix, located at level of 
the orbital rim near the limbus; the inferior fornix and the lateral fornix where the cells 
become less squamous at the junction between the posterior of the eyelid and the eyeball.   
(3) The bulbar is composed of the scleral part which extends from the fornix to the limbus 
and the limbal part which form a ring at the junction between the conjunctival and corneal 
epithelium (Hoang-Xuan, 2001).  The cells of the bulbar conjunctiva are typically 
stratified columnar (Forrester et al., 2001, Calonge and Stern, 2004).   
The conjunctival epithelium also possesses goblet cells, cytokeratin 19 and is negative for 
cytokeratin 3 (CK3).  Cytokeratins are cytoskeletal proteins which form intermediate 
filaments during epithelial development and differentiation (Rosellini et al., 2007, Elder et 
al., 1997, Boehlke et al., 2004).  The tear film, which is present to protect the eye and 
provide nourishment for ocular surface, is composed of lipid, aqueous layers and mucin 
which is produced from the meibornian gland in the eyelids, lacrimal gland and 
conjunctival goblet cells. 
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Figure 1-2:  The Human eye and the human conjunctiva. 
 (A) Photograph of the human eye.  Picture shows the bulbar (b), palpebral (p) 
and forniceal (f) conjunctiva zones.  The limbus (l) is the area of transition 
between the conjunctiva and the cornea.  
(B) Schematic of the normal conjunctiva showing the epithelium (E), substantia 
propria (SP) and the three parts of the conjunctiva:   palpebral (P), forniceal (F) 
and bulbar (B).  The cornea (Co) and the limbus (L) are in close proximity. 
Immune cells are present in the conjunctiva which include dendritic cells, B cells 
and T cells.  Taken from(Pflugfelder et al., 2004)   
A 
B 
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1.3.2. Cornea 
The cornea is avascular and therefore needs to be nourished by the aqueous humour 
internally and externally by a thin tear film. The epithelium is non-keratinising and is 
composed of five layers consisting of basal cells which are cuboidal to columnar cells 
found in the differentiated central cornea compartment.  The corneal epithelial cells 
become flattened and form wing cells which are two to three layers thick.  The corneal 
epithelium is continuous with a highly specialised area called the limbus which houses 
stems cells vital for corneal perpetuation.  The five layers of the cornea (Figure 1-3) 
which is about 500μm in thickness are: (1) the outermost epithelium, (2) the Bowman’s 
membrane, (3) the stroma, (4) the Descemet’s membrane and (5) and the endothelium.   
  
Figure 1-3:  Haematoxylin and Eosin staining of the human cornea. 
(A) consists of (1) corneal epithelium (2), Bowman’s capsule (3), stroma at x40 
magnification and (B) consists of (4) Descemet’s capsule and (5) endothelium at x 
100 magnification. 
The corneal epithelium expresses a genotype which includes connexion 43 (Cx43), gap 
junction protein; cytokeratin 3 (CK3) marker for corneal epithelial cell differentiation; 
cytokeratin 5 (CK5); cytokeratin 12 (CK12); cytokeratin 14 (CK14); cytokeratin 19 
(CK19), marker for intermediate filaments; p63, marker for morphogenesis; Ki-63, 
marker for corneal epithelial cell differentiation and vimentin, and marker for 
1 
2 
3 
5 
4 
A 
B 
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intermediate filaments, all of which are found in the intracytoplasmic cytoskeleton of the 
epithelium (Papini et al., 2005, Ma et al., 2007, Joseph et al., 2004, Zhao et al., 2008). 
The Bowman’s membrane is an acellular matrix which lies between the basal lamina and 
the corneal stroma and it acts as a resistant barrier to trauma and bacterial invasion 
(Gordon et al., 1994, Stocum, 2006).   
The stroma or substantia propria is intricately formed and composed of mostly tightly 
bound sheets of collagen fibres orientated in a tightly regular manner in an extracellular 
matrix which includes glycosaminoglycans, type I, V and VI collagens and 
mucopolysaccharides.  Regulation of fluid movement throughout this layer is critical for 
normal transparency.  Interspersed within the stroma are fibrocytes known as keratocytes.  
These cells proliferate during corneal wound healing and are therefore crucial to the 
process.  Posterior to the stroma is the Descemet’s membrane which is a basement 
membrane of hyaline produced by the endothelial layer.  The endothelium itself is a single 
layer of flattened cuboidal endothelial cells which fluid transport is important for 
regulating the hydration of the corneal stroma (Fischbarg, 1997, Fischbarg and Diecke, 
2005). 
1.3.3. Limbus 
The limbus is found in the peripheral part of the cornea, and represents the junction 
between the cornea, the conjunctiva and the sclera.  There is strong evidence suggesting 
that corneal limbal epithelial stem cells are located in the limbus but there is still a need 
for confirmation of specific markers for the localisation of limbal epithelial stem cells that 
reside in the limbus (Lyngholm et al., 2008, Shortt et al., 2007).   
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The possibility that the basal epithelium of the limbus contains limbal epithelial stem 
cells, leads to the potential for cell renewal after corneal injury or infection.  Figure 1-4 
shows the migration of P63 positive limbal epithelial stem cells towards the central cornea 
over a period of 72 hours after 4A4 pan-63 mAb immunofluorescence staining.  Limbal 
epithelial stem cells are useful because they have a high capacity for self renewal with the 
potential for error-free cell proliferation and division and the cells have a long life span.  
The location for stem cells in the limbus is supported by the fact that the limbus contains 
the least number of differentiated cells.  The limbus also contains proliferative 
characteristics of stem cells and experimental observations have shown poor corneal 
wound healing and infiltration of conjunctival epithelial cells, vascularisation and chronic 
inflammation when the limbal epithelium is partly or completely removed (Chen et al., 
1991, Chen et al., 1990, Huang et al., 1991, Kruse et al., 1990).     
Limbal epithelial stem cells are more resistant to solar damage, heavily pigmented and 
resistant to shearing forces compared to corneal epithelial cells which indicates that limbal 
epithelial stem cells are in the ideal location to regenerate corneal epithelial cells (Dua et 
al., 2000). 
The limbus expresses the presumed limbal epithelial stem cell association markers 
ABCG2 (a ATP-binding cassette (ABC) family of cell surface transport proteins) and p63 
(Sudha et al., 2006, De Paiva et al., 2005, Reidy et al., 2004).  The limbal cells are 
distinguished from corneal epithelial cells because corneal epithelial cells do not express 
ABCG2.  The limbal cells also express CK3, CK14 and CK19 (Schlötzer-Schrehardt and 
Kruse, 2005).  However, the corneal epithelium does not express the putative 
haematopoietic stem cell markers CD34 and CD133 (Dua et al., 2003). 
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Figure 1-4:  4A4 pan-p63 mAb immunofluorescence staining performed on 
human resting corneas. 
Corneas were taken within 4 hours of death.  The basal limbal layer of the resting 
limbus is indicated by the asteriks.  The 4A4 pan-p63 mAb immunofluorescence 
staining for p63 positive cells is shown at basal limbal layer at 0 hour only.  The 
arrows show the cornea-limbus border.  At differention incubation periods of 0, 
12, 18-24, 36-48 and 60-72 hours shows the migration of p63 positive cells from 
the peripheral cornea to the central cornea. Taken from(Di Iorio et al., 2005)  
1.3.4. Anatomy of Intraocular Barriers 
1.3.4.1. Ciliary Body 
The ciliary body is important in aqueous humour production for providing nourishment to 
intraocular structures and immunological defences.  The ciliary processes that extend 
from the scleral spur to the retina and choroid at the ora serrata (Figure 1-5) are part of the 
vascular coat, which consists of a mass of capillary vessels making this the most 
vascularised area of the eye (Davson, 1990, Duane and Jaeger, 1985).   
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Figure 1-5:  Human eye showing the location of the ciliary processes in respect 
to the rest of the globe. 
The ciliary processes extend from the ora serrata to the retina and choroid.  
Picture taken from(Davson, 1990) 
The ciliary body is composed of muscle, nerve fibres, connective tissue, capillaries and 
epithelia.  Ciliary muscles are specialised smooth muscles which can be divided into three 
main types; meridonal (longitudinal) fibres which attach anteriorly from the scleral spur to 
the connective tissue of the choroid; radial (oblique) fibres which are continuous with the 
corneo-scleral trabeculae and the circular (Müller’s muscle) fibres which are the inner 
most component (Forrester et al., 2001, Ishikawa, 1962).  It is the contraction of these 
muscles that causes the inward and forward movement of the two-thirds of the ciliary 
body to create tension in the zonule during accommodation (Forrester et al., 2001, Duane 
and Jaeger, 1985).  The ciliary muscles have also been linked to preventing the 
Schlemm’s canal from collapsing, and distend the trabecular meshwork (Forrester et al., 
Ciliary processes 
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2001, Duane and Jaeger, 1985).  Innervations of the ciliary body include sympathetic, 
parasympathetic as well as sensory nerve fibres can be both of unmyelinated or 
myelinated forms.  The ciliary epithelium contains two epithelia (the pigmented and non-
pigmented) (Figure 1-6), joined at their apices and which derived from the neuroectoderm 
of the optic cup (Duane and Jaeger, 1985). 
1.3.4.2. Pigmented Ciliary Epithelium 
The pigmented ciliary epithelium (PE) is continuous with the retinal pigmented 
epithelium posteriorly, and the iris stroma anteriorly and its basal parts are in contact with 
the ciliary stroma.  The PE cells are held to adjacent cells with gap junctions, desmosomes 
and puncta adhaerentia (Raviola and Raviola, 1978) (Figure 1-6).  As a result, different 
macromolecules can pass from the fenestrated capillaries of the ciliary body stroma into 
the posterior chamber (Forrester et al., 2001, Duane and Jaeger, 1985).  The pigmented 
epithelial cells contain many ribosomes and a small number of mitochondria (Figure 1-6).  
It is considered to have minimal barrier function (Duane and Jaeger, 1985).  Evidence 
suggests that the PE maybe involved in anti-inflammatory responses where increased IL-6 
secretion from the PE is found in intraocular fluids (Fleisher et al., 2000). 
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Figure 1-6:  The ciliary epithelium. 
 (A) Layers of the ciliary epithelium.  Outer layer is the non-pigmented epithelium 
and the inner layer is the pigmented epithelium.  A blood vessel is visible 
alongside the layer.  Taken from Junqueira, 2005.  (B) schematic diagram of 
ciliary epithelium bilayer.  The non-pigmented epithelial cell contains 
mitochondria (MIT), rough endoplasmic reticulum (RER) and basal infoldings 
(BI) facing towards aqueous humour.  The pigmented epithelial cell contains 
fewer mitochondria and rough endoplasmic reticulum but contains many 
melanosomes (MEL) that give layer pigmentation.  Both pigmented and non-
pigmented epithelial cells possess tight junctions (TJ) gap junctions (GJ), 
desmosomes (DES) and ciliary channels (CC) between the two layers.  There is 
also a basement membrane (BM) at the basal side of each cell.  Picture A taken 
from(Junqueira and Carneiro, 2005)and Picture B taken from(Burnstock and 
Sillito, 2000)  
  
A 
B 
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1.3.4.3. Non-pigmented Ciliary Epithelium 
The non-pigmented epithelium (NPE) starts from the root of the iris and is continuous 
with the neural retina at the ora serrata and pigmented epithelium of the iris (Duane and 
Jaeger, 1985).  Between the double layer ciliary epithelium, there are many gap junctions 
and some puncta adhaerentia and desmosomes (Raviola and Raviola, 1978).  At the apical 
side of the NPE, there are a distribution of gap junctions, zonula adherens and zonula 
occludens (tight junctions), (Figure 1-6) which are important in the blood aqueous barrier 
function in the ciliary body (Duane and Jaeger, 1985).  In the cytoplasm of the NPE, there 
are numerous mitochondria and endoplasmic reticulum.  This layer has close relations 
with zonule fibre formation where discovery of the NPE has been found to (Figure 1-6) 
secrete fibrillins in mammalian zonular microfibril bundles (Hanssen et al., 2001).  The 
main function of the NPE is in aqueous humour secretion.     
1.3.4.4. Aqueous Humour Production 
The formation of aqueous humour requires blood plasma to be ultra filtrated by 
fenestrated capillaries and the uveoscleral outflow pathway.  The filtrate that contains 
amino acids, ions, lactate, pyruvate, ascorbate, urea and glucose is then able to be actively 
taken up by the NPE and PE and secreted with water into aqueous humour.  One of the 
main transport mechanisms involved in this process is the enzyme Na+, K+-ATPase which 
is located along the basolateral membranes of human NPE and between the PE and NPE 
layers (Holthöfer et al., 1991).   
Evidence is now emerging to confirm the presence of specific sodium channels that 
maybe involved in aqueous humour production.  An example of this is the Amiloride 
sensitive sodium epithelial channel (ENaC) which has been linked to aqueous 
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reabsorption into the NPE and regulated by serum- and glucocorticoid-regulated kinase 
isoform 1 (SGK1), (Watsky et al., 1991, Civan et al., 1996, Rauz et al., 2003c). 
1.3.4.5. Aqueous Humour Composition 
Aqueous has very specialised properties.  It has the ability to nourish the cornea, 
trabecular meshwork and the lens with nutrients and oxygen while removing toxic and 
waste substances, mediating inflammation, providing the right refractive index for light 
and creating the internal pressure in the eye known as intraocular pressure (IOP).  The 
composition of aqueous humour consists of electrolytes such as sodium, chloride, 
potassium and hydrogen carbonate; organic solutes such as ascorbate, hydrogen peroxide, 
urea, lactate and amino acids; active compounds such as prostaglandins, catecholamines, 
cortisol and fibroblast growth factor; proteins such as albumin; enzymes such as 
plasminogen activator and immunoglobulins which include IgG and IgE and cytokines 
which include IL-1β, IL-2, IL-4, IL-6, IL-10, TNFα and TGFβ (Curnow et al., 2005, Ooi 
et al., 2006, Berman, 1991).  It was discovered in the early 1920s by Seidel, that aqueous 
humour was a dynamic process.  Formation occurs from the NPE (and drainage through 
the posterior and anterior chambers) and flows past the iris, lens and cornea before 
draining into the trabecular meshwork through the Schlemm’s canal and through the 
uveoscleral outflow routes (Seidel, 1920, Johnson, 2006).  A revolutionary method for 
measuring flow rate was developed by Maurice in the 1960s who used topically applied 
fluorescein on the cornea and showed that it flows into aqueous with less than 10% 
minimal loss with a rate of between 2-3μl/min (Brubaker, 1991, Jones and Maurice, 
1966).   
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1.3.5. Mucosal Barriers to Defence 
1.3.5.1. Mechanical and Chemical 
The structures that are involved in mechanical defences in the eye are the lacrimal gland, 
tear film and the eyelids.  These anatomical structures are considered to be involved in the 
first line of defence in innate immunity.  The lacrimal gland is located above and to the 
side of the eye and functions to secrete and drain tears.  The tears flow from the lacrimal 
gland and under the eyelids before being drained through the drainage pathways (Pandit et 
al., 1999).  The tear film is composed of lipid, water and mucous and works with the 
eyelids to wash away foreign material and cell debris from the ocular surface.  Tears also 
contain defensins which have antimicrobial activity and phospholipase and lysozyme 
which are non-specific antibacterial factors responsible for destabilising bacterial 
membranes (Aho et al., 1996, Fleiszig et al., 2003). 
Mucin is produced from the goblet cells of the conjunctival and corneal epithelial surfaces 
and is also present in tear film.  Its role is to lubricate the eye during blinking and form a 
protective layer in addition to binding to microorganisms and immune cells to prevent 
microorganisms binding to the cornea (Round et al., 2002).  
Mucin is a molecule composed of carbohydrate and tandem repeats of amino acids rich in 
serine, proline and threonine which serve as O-glycosylation sites (Moniaux et al., 2001).  
The genes encoding the mucin are designated the prefix of MUC, however the numbering 
system does not necessarily represent the order in which they are found as MUC21 is the 
latest human mucin to be found and there are over 21 mucins found to date (Itoh et al., 
2008).  
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The corneal and conjunctival epithelia have shown to express the membrane-associated 
mucins MUC1, -4 and -16 on their glycocalyx (outer component of cell membrane 
containing acidic carbohydrate).  The goblet cells of the conjunctiva also express the large 
gel forming mucin MUC5A.  The secreted mucins move freely over the membrane and 
the glycocalyx due to the negative charge of the glycosylated mucins which are highly 
hydophillic (Gipson and Gipson, 2004).  This facilitates the smooth movement to prevent 
epithelial-epithelial adherence (Gipson and Gipson, 2004). 
1.3.5.2. Immunological 
The ocular mucosal surface can produce many immune components for immune 
protection.  For example, IgA is not only produced from the plasma cells of lacrimal 
glands but has recently been found to be produced from the conjunctiva and is also found 
in tear film (Erich Knop, 2005).  Secretory IgA (SIgA) is the major immunoglobulin 
found to bind antigen but there is also limited production of IgG and IgM (Bennett and 
Weissman, 2004).   
There are several mechanisms for immunological protection that exist on the ocular 
mucosal surface.  One of these is the conjunctival associated lymphoid tissue (CALT) 
which is rich in bone marrow derived cells and is distributed within the epithelium as 
intra-epithelial lymphocytes and in the subepithelial lamina propria (Chan et al., 2008).  
The conjunctiva also expresses cell surface adhesion molecule, human mucosal 
lymphocyte antigen-1 (HML-1), (Dua et al., 1994b).  Lymphocyte cells from the CALT 
system are one of the main immune cells which take part in functions which include anti-
microbial defence, hypersensitivity, allo-graft-rejection and immune tolerance 
mechanisms (Dua et al., 1994a, Zhong et al., 2007).  CD8+/HML-1+ and CD45Ro+ and 
CD25+ T lymphocytes are also expressed in human conjunctival epithelium, lacrimal 
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gland, and corneoscleral limbus and may act mainly as suppressor cells to promote 
immunosuppression (Dua et al., 1994b, Cepek et al., 1994, Hingorani et al., 1997).    
Antigen presenting cells are expressed by the conjunctiva which include CD68+ 
macrophages, dendritic cells, mast cells, neutrophils in the normal conjunctiva and 
eosinophils only in the event of an inflammatory condition such as ocular allergy 
(Hingorani et al., 1997, Razzaque et al., 2004).  The cornea expresses antigen presenting 
cells such as dendritic cells and macrophages while being infiltrated by neutrophils and 
eosinophils during inflammation (Hall et al., 1999, Hamrah et al., 2003b, Hamrah et al., 
2002). 
Antigen presentation to lymphocytes occurs when antigen is captured by the antigen 
presentation cells on the surface epithelial cell-types for example.  All antigen 
presentation cells use specialised mechanisms in which to take up antigen.  In the case of 
macrophages, it is possible that the expression of mannose receptors facilitates in this 
process which is also true for dendritic cells (Marttila-Ichihara et al., 2008, Caux and 
Dubois, 2001).  This leads to internalisation of the antigen which is a process known as 
macropinocytosis.  The antigen processing forms stable peptide-MHC class I molecules, 
which are presented to lymphocytes.  Antigen-MHC class II molecules are typically 
brought to the cell surface for presentation to CD4+ T cells while antigen-MHC class I 
molecules are presented to CD8+ cytotoxic T cells in the peripheral lymphoid tissue (Boes 
et al., 2002, Johnstone and Del Val, 2007).  Antigen presenting cells such as 
macrophages, neutrophils and dendritic cells expressing pathogenic recognition receptors 
(PRR), (Chapter 3.1.2), can facilitate activation of the innate immune response which 
induces the expression of various pro-inflammatory cytokines, chemokines, adhesion 
molecules while activating effector functions of innate immune cells such as 
phagocytosis.  This in turn can lead to activation of the adaptive immune response where 
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there is clonal expansion of lymphocytes which is antigen specific and mediated by 
antigen receptors on B and T lymphocytes that leads to immunological memory (Chang et 
al., 2006). 
In the normal substantia propria of the conjunctiva and the cornea, there is expression of 
CD45+ cells (Yamagami et al., 2006).  In conjunctival substantia propria, these are mainly 
of CD68+ phenotype which is indicative of macrophage like cells while in the corneal 
substantia propria there is predominantly CD11c+/CD16- dendritic cells (Yamagami et al., 
2006, Yamagami et al., 2005).  These cells may be involved in the innate immunity that 
can occur during inflammation in the substantia propria. 
The presence of cytokines on the ocular surface is vital for responses to different 
immunological events.  For example, epidermal growth factor (EGF) in tears, increases 
proliferation of corneal epithelial cells as well as keratinocyte growth factor (KGF) and 
hepatocyte growth factor (HGF) synthesised by the stroma.  In addition to this, research 
has shown that transforming growth factor (TGF) regulates wound healing by 
antagonising proliferation of migrating cells (Zieske et al., 2001). 
The expression of inflammatory cytokines such as Interleukin 1 alpha (IL-1α), IL-6 and 
IL-8 in the corneal epithelium and tears, increases after corneal injury, thereby facilitating 
wound healing processes such as epithelial cell migration, proliferation, expression of 
matrixmetalloproteinases (MMP) and collagenases from keratocytes and the migration 
and differentiation of inflammatory cells to the site of injury for the removal of cell debris 
and associated pathogens (Sotozono et al., 1997, Wilson et al., 2001b, Tran et al., 1996, 
Agrawal and Tsai, 2003). Conversely, TNFα is thought to suppress the migration of 
corneal epithelial cells and increase ocular surface inflammation (Okada et al., 2007, 
Saika, 2007). 
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The conjunctiva expresses cytokines that include IL-1α, IL-2, IL-6, IL-8, TNFα, IFNγ, 
TGFβ, platelet-derived growth factor (PDGF) and basic fibroblast factor (bFGF), 
(Bernauer et al., 1993, Pflugfelder et al., 1999).  The expression of these cytokines is vital 
to cell trafficking and mediating immune responses. 
There are several events which are important in corneal wound healing which are crucial 
for the cornea to retain its refractive and barrier properties.  The epithelium must be able 
to ‘cross-talk’ with fibroblast cells to enable removal of dead or destroyed cells to be 
replaced by newly proliferated epithelial cells, which adhere to the extracellular matrix 
through the formation of integrins.  The limbus area of the cornea at the corneo-scleral 
junction is responsible for providing these migrating, proliferating and differentiating 
cells to the injury.  The cells in this region are epithelial progenitor cells and have been 
postulated to be stem cells by the use of a variety of markers such as ABCG2 and p63 
(Davanger and Evensen, 1971, Schermer et al., 1986a, Cotsarelis et al., 1989, Polisetty et 
al., 2008, Lyngholm et al., 2008, Pellegrini et al., 1999, Dravida et al., 2005, Reidy et al., 
2004).  An intact basement membrane is also important to epithelium renewal as erosion 
may trigger the need for the formation of more adhesion complexes such as anchoring 
fibrils, laminin, fibronectin, and Types IV and VII collagen in addition to modifying 
intracellular signalling pathways that may result in persistent epithelial defect (Agrawal 
and Tsai, 2003, Gipson et al., 1987, Duan and Sheardown, 2007, Chen et al., 2006b).    
Depending on the type of corneal injury, different types of ophthalmic solutions and 
procedures can be used to treat corneal wound healing.  There is much controversy with 
the use of corticosteroids and the regulation of inflammation as inflammation and 
glucocorticoids have been associated with delayed wound healing.  Clinical and animal 
research has shown in some cases that corticosteroids affect keratocytes and delay stromal 
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wound healing, however, more recent data show that glucocorticoids such as 
dexamethasone have beneficial effects when used with antibiotics and show little 
interference on corneal wound healing and minimise inflammation (Ashton and Cook, 
1951, McDonald, 1970, Wu et al., 2006, Yulek et al., 2006, Sarchahi et al., 2008, Russo et 
al., 2007, Bourcier et al., 2000).   
1.3.6. Bacteria on the Ocular Surface 
1.3.6.1. Commensal Bacteria 
Commensal bacteria or non-pathogenic bacteria exist on all our surface tissues such as the 
skin and mucosal surfaces and have a symbiotic relationship where the commensal 
bacteria and our body may benefit from the interaction.  The non-pathogenic bacteria may 
play a role in maintaining health and normal function; however they are not essential for 
life.  Examples of commensal bacterial function include synthesising vitamin K and 
aiding absorption of nutrients from the intestinal tract (Andrew J. Macpherson, 2005, 
Brooks, 2004).  Commensal bacteria also colonise the surface in great numbers and 
therefore compete with pathogenic bacteria for access to the surface and remain non-
invasive until the surface is breached.  The ocular commensal bacteria can commonly 
include staphylococcus epidermis, Neisseria species, corynebacteria and  
propionibacterium acnes (Ueta et al., 2007b, Amy Li, 2000).  Staphylococcus epidermis 
are mostly commonly isolated as normal flora in the conjunctival sac and eyelid edge 
(Ueta et al., 2007a).   
1.3.6.2. Pathogenic Bacteria 
There are many bacteria that can cause ocular disease and they can do this because they 
possess virulence factors that can include toxins, adhesins and invasins.  Armed with 
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these apparatus, they cause disease when the ocular surface has been compromised by 
injury for example.  Some of these ocular pathogenic bacteria can include Pseudomonas 
aeruginosa, Streptococcus pyogenes, Staphylococcus pneumoniae, Staphylococcus aureus 
and  Chlamydia eubacteria, viral (e.g. herpes simplex and varicella zoster), fungi (e.g. 
fusarium species) and single-cell organisms such as Acanthamoeba (Tabbara et al., 2000, 
Al-Shakarchi, 2007, Basak et al., 2005, Goldblum et al., 2008, Magone et al., 2005, 
Agarwal, 2006, Thompson et al., 2008).  The common diseases of the cornea include 
keratitis where the cornea becomes infected with a micro-organism which causes the 
cornea to become inflamed and for the conjunctiva; the common disease experienced is 
conjunctivitis where micro-organisms and allergies may cause the inflammation of this 
tissue. 
1.3.7. Intraocular Defence Barriers 
1.3.7.1. Immune Privilege 
The anterior chamber in addition to the vitreous cavity and subretinal cavity is considered 
to be immune privilege (Jiang and Streilein, 1991, Wenkel et al., 1999).  Inflammation to 
the eye can have serious effects which can disrupt its primary optical function.  The 
immune privilege status enables the eye to provide immune protection against the 
majority of pathogens without the need of intense inflammation.   
There are many factors which contribute to an immune privilege state.  These include the 
absence of blood vessels from the cornea and the iris stroma; the absence of lymphatic 
drainage from the anterior chamber except for the uveoscleral outflow routes; the 
production of soluble immunomodulatory factors from aqueous humour which are 
secreted by the ciliary epithelium and released from the surrounding tissues and cells such 
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as transforming growth factor beta 2 (TGFβ2), α-melanocyte stimulating hormone (α–
MSH), vasoactive intestinal peptide (VIP), calcitonin gene related-peptide (CGRP), 
somatostatin and thrombospondin (TSP)-1 (Novak et al., 2003).; expression of 
immunomodulatory factors on the corneal endothelium and pigmented epithelium and 
provision of tolerance-promoting antigen-presenting cells in the peripheral and central 
cornea, iris and possibly the trabecular meshwork and outflow routes (Hamrah et al., 
2003a, Streilein, 2003b).   
There are different ways in which the immune privilege status of the eye can be 
investigated.  One way is the study of the anti-inflammatory and immunosuppressive 
microenvironment in the eye such as the effects of TGFβ, VIP and α–MSH.  Another 
example is that the corneal epithelial cells, endothelial cells and ciliary body can express 
Fas ligand (FasL) which can inhibit complement activation and promote apoptosis of 
CD95+ cells that come into contact with them (Griffith et al., 1995). 
Immune privilege sites are also able to produce tolerance to eye-derived antigens.  This 
occurs by a process known as anterior chamber-associated immune deviation (ACAID). 
This is defined by the ability of the anterior chamber to eliminate pathogens with the aid 
of T and B cells, in the absence of inflammation.  Studies have found that ACAID can be 
induced in mice, rats, rabbits and monkeys and there is some evidence to suggest humans 
have ACAID (Lu et al., 2008, Saban et al., 2008, Zheng et al., 2000, Eichhorn et al., 1993, 
Takeuchi et al., 2006). 
Fas-Ligand (Fas-L) is an important molecule involved in maintaining immune privilege in 
the eye.  It is a type II transmembrane protein from the TNF family and is responsible for 
inducing apoptosis of Fas+ cells (Nagata and Golstein, 1995).   
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TGFβ is found in aqueous humour in a quantity which is enough to elicit a biological 
effect and promote immune privilege (Granstein et al., 1990, Konstas et al., 2006, Chen et 
al., 1998, D'Orazio and Niederkorn, 1998, Knisely et al., 1994).  There have been three 
isoforms of TGFβ in aqueous humour found to date (TGFβ 1, 2 and 3), (Yoneda et al., 
2007).  TGFβ has been found to modulate proliferation of epithelial cell, endothelial cells, 
and induces T regulatory (Treg) function (Horwitz et al., 1999, Andersson et al., 2008, 
Zelenka and Arpitha, 2008, Chen et al., 1999).  Treg function is important for 
immunotolerance and therefore maybe involved in maintaining the immune privilege 
states in the eye (Stein-Streilein and Taylor, 2007, Zhu et al., 2007). 
1.4. Orbital Adipose Tissue in the Orbit 
1.4.1. Adipose Tissue 
The realisation that adipose tissue is much more than an energy store but also acts as an 
endocrine organ able to secrete compounds that regulate other cells, has implicated its role 
in diseases such as obesity.   
Adipose tissue is a specialised connective tissue organ capable of endocrine function.  
There are two types of adipose tissue: brown and white.  The distribution of adipose tissue 
depends on the species in question but interestingly, brown adipose exists among human 
neonates to generate heat during development but into adulthood, a very small quantity of 
brown adipose exists.  The distribution of white adipose tissue throughout the body is vast 
and is considered to be one of the largest organ tissues of the body.   
The main types of adipose tissue that have recently gained much attention are adipose 
tissues from the omentum and subcutaneous adipose.  The reason for this is that both fat 
depots have been implicated in the increased risk of obesity and the metabolic syndrome 
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which comprises of insulin sensitivity, glucose intolerance, hypertension and dyslipidemia 
(Tulloch-Reid et al., 2004, Hayashi et al., 2003, Hayashi et al., 2004, Wajchenberg, 2000, 
Fox et al., 2007).  Distribution and proportion of adipose tissue is generalised and 
different in each individual and is very much gender and genetic specific (Katzmarzyk et 
al., 1999, Bouchard et al., 1993). 
1.4.2. Morphology of Adipose 
White adipose tissue (WAT), which is the main tissue discussed in this chapter, can be 
characterised as a group of lipid storing cells called adipocytes.  WAT contains a collagen 
fibre network with fibrous connective tissue, endothelium, resident 
monocytes/macrophages, vascular smooth muscle cells and preadipocytes that are part of 
the stromal vascular cell fraction (Dardick et al., 1976).   Pluripotent adipose-tissue 
derived stromal cells (ADSC) within this fraction have the potential to be differentiated 
into other cell types in-vitro (Figure 1-7) such as bone (medium includes dexamethasone 
and ascorbic acid), cardiomyocytes (medium includes TGF-β1), cartilage (medium 
includes dexamethasone and ascorbate-2 phosphate), neurons (medium includes valproic 
acid, hydrocortisone and insulin), endothelial cells (medium includes FGF2) and adipose 
cells (medium includes dexamethasone and insulin) when cultured under specific 
conditions (Dardick et al., 1976, Zhang, 1999, Schaffler and Buchler, 2007, Gerhardt et 
al., 2001, Weisberg et al., 2003, Shoelson et al., 2006, Zuk et al., 2002, Noël et al., 2008, 
So-Jung et al., 2009, Huang et al., 2007, Hongxiu et al., 2009).   
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Figure 1-7:  Adipose-derived stromal cells (ADSC) and their pluripotent  
potential to  differentiate into different cell types. 
These include bone cells (influenced by ascorbic acid), cartilage cells (influenced 
by ascorbate-2 phosphate), neurons (influenced by valproic acid), endothelial 
cells (influenced by FGF2) and adipose cells (influenced by dexamethasone).   
During adulthood, the WAT becomes more unilocular in morphology, with a colour that 
varies from white to dark yellow.  The adipocytes have a very thin ring of cytoplasm with 
a flattened nucleus at the periphery, and a large central lipid droplet surrounded by 
smaller lipid droplets.  The cytoplasm around the nucleus has a golgi apparatus, 
mitochondria, rough endoplasmic reticulum and free polyribosomes while the thin ring of 
cytoplasm contains the small lipid droplets containing smooth endoplasmic reticulum and 
pinocytotic vesicles (Junqueira and Carneiro, 2005).  The sympathetic nervous system 
innervations of adipose tissue are via the capillaries and it is thought that these release the 
neurotransmitter, norepinephrine that activates hormone sensitive lipase which is 
necessary for the mobilisation of lipids (Bowers et al., 2004, Niijima, 1989, Cantu and 
Goodman, 1967, Bartness and Bamshad, 1998).   
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1.4.3. Metabolism of Adipose Tissue 
The lipids stored in adipose tissue are mostly triglycerides stored in very low density 
lipoprotein (VLDL) or chylomicrons.    
Free fatty acids are synthesised from glucose in adipose tissue, (a process which 
mitochondria and the smooth endoplasmic reticulum are actively involved in) and are 
stored in adipose (Junqueira and Carneiro, 2005).  This process is increased by insulin 
which regulates uptake of glucose and increases lipoprotein lipase synthesis (Yao et al., 
1999, Rosato et al., 1997, Appel and Fried, 1992).   
Triglycerides can travel from the liver to the adipose via the bloodstream in the form of 
chylomicrons.  These triglycerides can be hydrolysed by adipose synthesised lipoprotein 
lipase (LPL) which transports triglycerides to the lumen of capillaries to release free fatty 
acids and glycerol.  The fatty acids and glycerol are taken up by the adipocytes and 
resterified for storage (Reynisdottir et al., 1997, Kolehmainen et al., 2002).  Hormone 
sensitive lipases (HSL) in adipocytes are the rate limiting step in releasing free fatty acids 
and glycerol stored as triglycerides in adipose (Kolehmainen et al., 2002).  The free fatty 
acids bound to albumin can then be transported to other tissues of the body  (Reynisdottir 
et al., 1997).   
As adipose tissue distribution is thought to be regulated by neuronal and hormonal factors.  
The discovery of the obesity (ob) gene product, leptin, a 164 amino acid protein which 
signals to the brain to influence food intake, has been of increasing interest in obesity 
(Baskin et al., 1999).  Other hormonal factors involved in adipose tissue metabolism, in 
particular lipolysis, include growth hormone, thyroid stimulating hormone, parathyroid 
hormone and sex steroids (Moller et al., 1990, Müller et al., 1990, Taniguchi et al., 1987, 
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Mattsson and Olsson, 2007, Turgeon et al., 2006).  The effects that glucocorticoids have 
on adipose tissue are less well characterised, however, it is believed they are involved in 
influencing LPL and HSL action thereby modulating lipid uptake and turnover at tissue 
specific sites (Macfarlane et al., 2008).  Furthermore, glucocorticoids are responsible for 
promoting differentiation of preadipocytes to mature adipocytes (Hauner et al., 1987, 
Tomlinson et al., 2006).  There is increasing evidence for the role of 11beta 
hydroxysteroid dehydrogenase 1 (11β-HSD1) activating cortisone from cortisol 
(described further in chapter 1.7) in adipose tissue to induce preadipocytes to differentiate 
into mature-like adipocytes (Bujalska et al., 2008).  
1.4.4. Adipose Tissue Function 
The classical functional roles of adipose tissue include mechanical cushioning of internal 
organs, heat insulation and as an energy source through lipolysis when carbohydrates are 
not readily available.   
Adipose tissue expresses endocrine cytokines known as adipokines which include leptin, 
adiponectin (a protein exclusively produced from adipocytes that is involved in sensitising 
insulin to repress glucose production in the liver), angiotensinogen, PAI-I, ASP, IL-6, 
TNFα, and resistin (Table 1-1).   This enables adipose tissue to signal to distant tissue 
systems thereby influencing immune function, metabolism and neuroendocrine functions 
(Kershaw and Flier, 2004). 
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Table 1-1: Examples of some adipokines produced and secreted by adipose 
tissue 
Adipokine Function 
Angiotensinogen 
Increased levels may be contributable to increased WAT 
mass and nutrition appears to relate angiotensinogen to 
adipose tissue as levels of angiotensinogen decrease 
during fasting and increase with food intake (Frederich et 
al., 1992, Saint-Marc et al., 2001). 
PAI-I  
(Plasminogen activator inhibitor 
I) 
Primary inhibitor of fibrinolysis.  High levels are found 
after a myocardial infact and plasma levels increase with 
visceral adiposity (Hamsten et al., 1985, Shimomura et al., 
1996). 
ASP (Acylation-stimulation 
protein) 
Derived from complement C3 interaction with adipsin but 
not known to be involved in immune function.  However, 
its role is considered in stimulating triglyceride storage in 
adipose tissue (Cianflone et al., 1999, Van Harmelen et al., 
1999, Maslowska et al., 2006). 
IL-6 
Large amounts are secreted by adipose tissue and is highly 
correlated with increased body mass and decreased insulin 
sensitivity (Bastard et al., 2000, Bastard et al., 2002). 
TNFα 
Overexpressed in WAT in obesity and causes decreased 
insulin sensitivity.  Its effects on adipose tissue maybe 
more of an autocrine/paracrine fashion rather than 
endocrine (Ruan and Lodish, 2003, Guerre-Millo, 2004). 
Resistin 
Also known as adipose tissue specific secretory factor 
(ADSF) is associated with insulin resistance and thought 
to play role in the link between type II diabetes and 
obesity (Ribot et al., 2008, Berger, 2001). 
Leptin 
Protein that regulates food uptake by acting on the brain 
and influences body weight, energy expenditure and 
neuroendocrine functions (Friedman and Halaas, 1998, 
Ahima and Flier, 2000a, Ahima and Flier, 2000b). 
Adiponectin An effective sensitiser of insulin in the liver (Scherer, 2006, Maeda et al., 1996, Weyer et al., 2001). 
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1.4.5. Orbital Adipose Tissue 
Orbital adipose tissue is a type of WAT originally derived from the neuroectoderm.  It is 
found to occupy the space in the bony orbit cavity surrounding other orbital tissues which 
include muscles, blood vessel nerves and the globe of the eye.   The tissue can be split 
into two main parts depending on where it is located in the orbit; either in the retrobulbar 
area or the peribulbar area (Figure 1-8), (R. Wolfram-Gabel, 2002, Bremond-Gignac et 
al., 2004).   
The retrobulbar adipose is located posteriorly where it envelopes the extraocular muscles 
(mainly the four rectus muscles) and the optic nerve (R. Wolfram-Gabel, 2002).  It also 
accounts for the majority of adipose in the orbit.  The peribulbar adipose surrounds the 
globe of the eye superiorly, inferiorly, medially and laterally (R. Wolfram-Gabel, 2002).  
This tissue acts to support the structures of the eye including muscles, nerves and blood 
vessels in addition to aiding the slide mechanism of the eye as it rotates on its axis (R. 
Wolfram-Gabel, 2002).  In addition to this, orbital adipose tissue can also be described as 
an endocrine organ as will be discussed later in the chapter.   
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Figure 1-8:  Sketch drawing of the eyeball in the orbit. 
The areas which are green coloured represent some spaces of the orbit which may 
contain peribulbar fat around the eyeball while the yellow coloured areas 
represent the spaces that contain retrobulbar fat situated in the posterior part of 
the eyeball.  Picture taken from(Corn and Koenig, 1996)   
 
1.5. Glucocorticoids in Ophthalmology 
The eye is a glucocorticoid target tissue which orchestrates expression of target genes 
through the glucocorticoid receptor (GR).  The ability for the eye to utilise glucocorticoids 
is important as they have been shown to have a function in ocular inflammation and 
ocular autoimmune disease (Galor and Thorne, 2007).  The classical action of 
glucocorticoids is to bind to the GR or the mineralocorticoid receptor (MR).  In doing so, 
the receptor-ligand-complex is then available to translocate to the nucleus to bind to the 
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glucocorticoid response element (GRE) and elicit the transcription of genes such as MCP-
1 (Monocyte chemotactic protein-1) , SGK (Serum- and glucocorticoid-inducible kinase), 
HSP70 (Heat shock protein 70) and CCK (Cholecystokinin) (Gupta et al., 2005, Náray-
Fejes-Tóth et al., 2000, Rauz et al., 2003b).   
The GR is expressed in several ocular structures of the eye (Table 1-2).  The cornea which 
consists of the corneal epithelium, basement membrane, stroma, endothelium and 
descemet membrane has some expression of GR in the corneal epithelium, stroma and 
endothelium (Rauz et al., 2001, Suzuki et al., 2001, Mirshahi et al., 1997).  GR expression 
is found in the NPE (non-pigmented epithelium), PE (pigmented epithelium) and stroma 
(Stokes et al., 2000, Suzuki et al., 2001).  The sclera, trabecular meshwork (TM) and the 
lens have expression of the GR (Stokes et al., 2000, Suzuki et al., 2001).  In addition, 
expression of the GR was found in the retinal cell layers (e.g. PE and ganglion cell layer), 
(Suzuki et al., 2001).   
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Table 1-2: Expression of glucocorticoid and mineralocorticoid receptors in 
human ocular tissuesa 
 GR  MR  
Conjunctiva 
- Epithelium 
- Stroma 
 
? 
? 
 
Ref. 
 
 
? 
? 
 
Ref. 
Cornea 
- Epithelium 
- Stroma 
- Endothelium 
 
+/- 
+ 
+/- 
 
2,3,4 
2, 4 
2,3,4 
 
+/- 
- 
+/- 
 
2,3 
2 
2,3 
Ciliary Body 
- NPE 
- PE 
- Stroma 
 
+ 
+ 
+ 
 
2,3 
2 
2 
 
+ 
- 
- 
 
2,3 
2 
2 
TM + 1,3 - 1,3 
Lens + 2,3 - 2,3 
Retina + 2 - 2,4 
Optic Nerve + 2 - 2 
Sclera +/- 2,3 - 2,3 
Orbital Adipose 
Tissue  ?  ?  
aImmunoreactivity and/or mRNA expression is classified as +; present, -; not present, +/-
; conflicting data; ?, not known. References 1; (Rauz et al., 2001), 2; (Suzuki et al., 2001), 
3; (Stokes et al., 2000), 4; (Mirshahi et al., 1997).  
1.5.1. Therapeutic Uses of Glucocorticoids in Ophthalmology  
Glucocorticoids are known to have many physiological effects and the most frequently 
studied are their effects on metabolism such as gluconeogenesis and effects on immune 
function and inflammation.  Due to their anti-inflammatory and immunosuppressive 
effects, glucocorticoids are used abundantly in ophthalmic practice for the treatment of 
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ocular ailments such as orbital diseases for example in thyroid associated ophthalmopathy 
and idiopathic orbital inflammation (section 4.1.2) and ocular inflammatory diseases such 
as uveitis, diabetic macular oedema, and ocular surface inflammation such as allergic 
conjunctivitis and peripheral ulcerative keratitis (Leibovitch et al., 2007, Toker et al., 
2002, Grenga et al., 2008, Arcangelo and Peterson, 2005, Wahid et al., 2008).  
Glucocorticoids used systemically in thyroid associated ophthalmopathy include 
methylprednisolone acetate given intravenously and prednisone given orally (Marcocci et 
al., 2001).  They are presumed the appropriate course of treatment in moderate to severe 
thyroid associated ophthalmopathy due to the improvement in symptoms such as 
neuropathy and a reduction in acute inflammation.  The mechanism of action of 
glucocorticoids in thyroid associated ophthalmopathy are not well known, however it is 
postulated, that glucocorticoids may interfere with lymphocyte recruitment and inhibit 
inflammatory mediators such as cytokines (Heufelder and Bahn, 1994).   
Idiopathic orbital inflammation is inflammation usually confined to the orbit.  The 
condition is characterised by the infiltration of inflammatory cells and fibrous tissue into 
the soft tissues of the orbit.  Glucocorticoid treatment is the first line of treatment for this 
condition and can include oral prednisolone or intraorbital injections of corticosteroid or 
in more severe cases, intravenous methylprednisolone (Leibovitch et al., 2007, Zborowska 
et al., 2005). 
Uveitis is inflammation of part of the uvea which is made of different parts of the eye 
which include the iris, choroid and ciliary body.  The symptoms include pain, 
photophobia, and decreased visual acuity and when the specific aetiology of uveitis is not 
known, there is the need for the use of immunomodulatory agents which reduce the signs 
and symptoms of inflammation and prevent long term sequelae (Van Gelder and Kaplan, 
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1999).  The use of glucocorticoids is particular useful in uveitis and can be oral steroids or 
intravenous steroids such as methylprednisone for more severe cases (Van Gelder and 
Kaplan, 1999, Toker et al., 2002). 
During diabetic macular oedema, individuals with diabetes mellitus have a 10 percent 
chance of developing swelling in the retina with retinal thickening (Sander et al., 2002).  
This can be of two types: (1) focal macular oedema occurs due to dilated capillaries and 
leakage of microaneurysms and (2) diffuse macular oedema occurs after a breakdown in 
the generalised blood-retinal barrier with the formation of large cystoid spaces (Fernando 
and Pandit, 2005).  It is in diffuse diabetic macular oedema in which treatments including 
intravitreal corticosteroid, sub-tenons capsule injection of corticosteroid or retrobulbar 
injection of corticosteroid have promising effects (Jonas et al., 2005, Grenga et al., 2008, 
Cardillo et al., 2005, Knudsen, 2004).   
Allergic conjunctivitis can be described as inflammation of the bulbar or palpebral 
conjunctiva which is the clear membrane which covers the white part of the eye.  The 
condition can be of bacterial or viral in origin and is characterised by the symptom of 
itchy eye.  Low dose topical corticosteroids such as medrysone, prednisolone or 
dexamethasone can be used to treat inflammation but only used for the short term due to 
adverse side effects  which include cataracts and increased intraocular pressure leading to 
steroid induced glaucoma (Arcangelo and Peterson, 2005, Mohan and Muralidharan, 
1989).    
Peripheral ulcerative keratitis is a condition that can occur in rheumatoid arthritis and 
results in a corneal ulcer that can perforate the eye or cause loss of vision.  Rapid 
treatment is most important and although glucocorticoids are not the preferred treatment 
in this case, oral corticosteroid may be given in severe cases and prednisolone can be 
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given peri-operatively and post-operatively (before and after surgery) (Squirrell et al., 
1999, Wahid et al., 2008).  
1.5.2. Adverse Effects of Therapeutic Glucocorticoids 
Although the exogenous (or endogenous) use of glucocorticoids can be beneficial, they 
can also have adverse side effects.  Osteoporosis is a disease where the bones become 
weakened and fragile and increase the risk of fractures in areas which include the spine, 
wrist and hips.  In glucocorticoid-induced osteoporosis the risk of fractures is increased as 
the glucocorticoids are thought to affect bone absorption and formation.  The adverse 
effects include an overall decrease in bone formation and density with osteoid thickening, 
reduced rate of bone mineralization and decreased osteoblast activity (Dalle Carbonare et 
al., 2001).  The cellular effects involved in bone reabsorption can vary considerably, 
however, in bone formation the cellular effects include altered osteoblast cell 
differentiation, inhibition of osteoblast matrix synthesis, an increase in osteoblast 
apoptosis, decrease in gene expression that code for proteins such as osteoclacin, type I 
collagen, and several matrix proteins and an increase in osteoclast formation (Nishimura 
and Ikuyama, 2000, Bland, 2000, Manolagas et al., 1999).  Prolonged use of 
glucocorticoids in this case can rapidly have detrimental effects on bone and even after 
cessation of treatment there is only partial recovery of bone that has been lost. 
Another condition of which glucocorticoids can have adverse effects on the bone is in 
osteonecrosis.  This is when glucocorticoid-induced osteonecrosis occurs due to lipid 
blocking the microvasculature of the bone and involves apoptosis of a bone cell type 
known as osteocytes (Weinstein et al., 2000).  
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Another effect caused by the use of glucocorticoids is shown in glucocorticoid-induced 
diabetes mellitus.  Diabetes Mellitus is a condition which the pancreas inadequately 
produces and or loss of insulin sensitivity occurs.  The mechanisms involved in 
glucocorticoid-induced diabetes mellitus involve (1) effects on hepatic gluconeogenesis 
where glucocorticoids are responsible for the upregulation of regulatory proteins such as 
glucose-6-phosphatase and phosphoenolpyruvate carboxylase (PEPCK) which contributes 
to hyperglycaemia (Vander Kooi et al., 2005, McCurdy and Friedman, 2006), (2) in 
pancreatic cells, glucocorticoids may suppress insulin release from the pancreas (In-
Kyung et al., 2001), (3), glucocorticoids may provoke insulin resistance by inhibiting 
glucose transporter production in adipose cells and muscle cells (Buren et al., 2002, 
Weinstein et al., 1998) and (4) glucocorticoids are shown to raise blood glucose levels 
after fasting and after a meal (Levetan and Magee, 2000). 
Prolonged use of glucocorticoids has also been associated with obesity, a feature of 
Cushing’s disease and the metabolic syndrome.  Excess glucocorticoid such as that 
experienced during chronic stress is thought to play a role in the redistribution of 
abdominal fat in these diseases (Rosmond and Bjorntorp, 2000, Adam and Epel, 2007). 
Glucocorticoids are shown to delay wound healing, for example glucocorticoids inhibit 
keratinocyte growth factor (KGF) which is important for epithelial cell proliferation 
(Chedid et al., 1996).  It is the anti-inflammatory nature of glucocorticoids which 
contribute to inhibition of wound healing as glucocorticoids are able to regulate proteins 
involved in the repair process such as pro-inflammatory cytokines (e.g. IL-1α, IL-1β, IL-
6, and TNF-α), growth factors e.g IGF-1 and TGF-β) and matrix proteins (e.g. tenascin-C 
and stromelysin-2)  (Beer et al., 2000, Grose et al., 2002, Werner and Grose, 2003). 
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The risk of high dose glucocorticoid use is also associated with dyslipidaemia and 
atherosclerosis (Da Silva et al., 2006).  Dyslipidaemia is the result of abnormal 
concentrations of lipid or lipoprotein in the blood and atherosclerosis involves a chronic 
inflammatory response which results in fatty deposits called plaques on the walls of 
arteries.  Although high dose glucocorticoids have effects on these diseases, there is no 
evidence to suggest that low dose glucocorticoids have the same effect (Klippel, 2007).  
Due to the potential adverse effects glucocorticoids can have on physiology, there is the 
need to search for regulation of glucocorticoid dependent disease processes at a tissue 
specific level to avoid these effects.  The regulation of glucocorticoids in this case is 
performed by two short-chain alcohol dehydrogenases known as 11beta hydroxysteroid 
dehydrogenase type 1 (11β-HSD1) and 11beta hydroxysteroid dehydrogenase type 2 
(11β-HSD2) which will both be discussed later in this chapter. 
In order for this to be achieved, the study of autocrine regulators of glucocorticoids in 
ocular and orbital tissues is attractive.  The potential of this concept will rely upon the 
understanding of the classical corticosteroid regulatory mechanisms and the 
hypothalamic-pituitary-adrenal axis (HPA). 
 
1.6. Classical Corticosteroid Regulatory Mechanisms 
1.6.1. Corticosteroid Biosynthesis 
The main site for corticosteroid production and secretion in humans is from the adrenal 
gland which can be divided into the adrenal medulla and the adrenal cortex (Figure 1-9).  
The adrenal cortex is responsible for the majority of corticosteroids secreted into 
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circulation whereas the adrenal medulla’s function is for the production and secretion of 
catecholamines.   
The adrenal cortex can be divided into three further sections (Figure 1-9) which consist 
of: (i) the zona glomerulosa which is responsible for synthesising the mineralocorticoids 
from cholesterol such as aldosterone under the control of the renin-angiotensin system (ii) 
the zona fasiculata responsible for synthesising glucocorticoids such as cortisol which is 
under the control of the hypothalamopituitary axis  and (iii) the zona reticularis which is 
responsible for the synthesis of sex steroids (Brook and Marshall, 2001).   
 
Figure 1-9:  Simplified diagram of the adrenal gland.   
The adrenal gland is separated into the adrenal medulla and the adrenal cortex. 
The adrenal cortex consists of the zona glomerulosa responsible for 
mineralocorticoid production, zona fasiculata which produces glucocorticoids and 
zona reticularis which synthesises sex steroids.  Adapted from Endocrinology: an 
integrated approach, pg 123 (Nussey and Whitehead, 2001). 
 
Corticosteroids originate from the biosynthetic pathway that exists in the adrenal cortex.  
Cholesterol is a precursor to all corticosteroids (Figure 1-10) which are released into the 
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peripheral blood stream, ready to interact with their cognate receptors within target tissues 
instigating a physiological response. 
1.6.2. Cortisol and Aldosterone Metabolism and Effects on Physiology 
Cortisol was first characterised from urine in the early 1950s and was found to be the 
main corticosteroid secreted (Amelung et al., 1953).  Relatively large amounts of 
glucocorticoids are secreted into the circulation in comparison with mineralocorticoids 
(15mg/d vs. 15μg/d respectively), (Cope and Black, 1958, Esteban et al., 1991, Jones et 
al., 1959).   
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Figure 1-10: Steroid biosynthesis pathway. 
This pathway occurs in the adrenal cortex of the adrenal gland.  The pathway 
starts with cholesterol and the parts of the diagram in red represent the change in 
molecular structure from the previous molcule. (CYP11A, Cytochrome P450 
cholesterol side chain cleavage; CYP11B1, 11β-hydroxylase; CYP11B2, 
Aldosterone synthase; CYP17, 17α-hydroxylase; CYP19, Aromatase; CYP21, 21-
hydroxylase; 3β HSD 2, 3beta hydroxysteroid dehydrogenase 2; 17β HSD 1, 
17beta hydroxysteroid dehyrogenase 1; 17β HSD 2, 17beta hydroxysteroid 
dehyrogenase 2; 11β-HSD1, 11beta hydroxysteroid dehydrogenase 1).  Adapted 
from Essential Endocrinology, 4th edition, Blackwell Publishing, (Brook and 
Marshall, 2001).  
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At least 90% of circulatory cortisol is bound to cortisol binding globulin while a small 
faction of cortisol is bound to serum globulin.  The remaining unbound cortisol is 
‘biologically’ active and excreted as as urinary free cortisol (UFF) through the kidneys  in 
humans which is only about 1% of the total cortisol excretion rate (Tomlinson et al., 
2004).   
Cortisol is metabolised to dihydrocortisol and dihydrocortisone by reduction of the C4-5 
double bond by steroid 5β or 5α reductase (Figure 1-11) and is then hydroxylated on the 
3-oxo group to form 5β or 5α tetrahydrocortisol (5β or 5α/allo THF) and 5β or 5α 
tetrahydrocortisone (5β or 5α THE) (Figure 1-11) where 5β THF predominates in normal 
physiology (Cope, 1972, Jamieson et al., 1999).  At the same point, cortisol and cortisone 
can also be reduced by 20α or 20β HSD on the 20-oxo group to produce α or β cortols or 
cortolones respectively (Figure 1-11 and Figure 1-12) (Shackleton, 1993, Szymanski and 
Furfine, 1977).  In addition to this, the C6 position is hydroxylated to give 6β 
hydroxycortisol or 6β-hydroxycortisone (Figure 1-11 and Figure 1-12) while cleaving the 
THF and THE can produce C19 steroids.  Oxidation of the C21 position or cortols or 
cortolones yields cortolic or cortolonic acids (Figure 1-11 and Figure 1-12).  
Traditionally, THF, allo THF and THE is conjugated to glucuronic acid and excreted in 
urine (Monder and Bradlow, 1980). 
  67 
  
Figure 1-11:  Metabolism of cortisol. 
Cortisol can be reduced to 20β hydrocortisol by 20β OR and hydroxylated to 6β 
hydroxycortisol by 6β OH.  Cortisol can also be reduced to 5β dihydrocortisol and 
5α dihydrocortisol by 5β/5α SR respectively.  This in turn can be hydroxylated by 
3α HSD to produce 5β/5α tetrahydrocortisol.  The tetrahydrocortisols are oxidised 
to produce cortols. 20β OR, 20β oxoreductase; 6β OH, 6β hydroxylase; 5β/α SR, 
steroid 5β/α reductase; 3α HSD, 3α hydroxysteroid dehydrogenase. 
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Figure 1-12:  Metabolism of cortisone. 
Cortisone is hydroxylated to 6β hydroxycortisone by 6β OH and oxidised to 20β 
hydrocortisone by 20β OR.  In addition, cortisone is reduced to 
tetrahydrocortisone by 5β SR.  This compound is then oxidised to cortolones.   20β 
OR, 20β oxoreductase; 6β OH, 6β hydroxylase; 5β SR, steroid 5β reductase. 
Aldosterone, which has a rapid turnover, is metabolised to a variety of different 
compounds and cleared through the liver and urine.  These metabolites include 
tetrahydroaldosterone glucuronide and 21-deoxytetrahydroaldosterone (Morris, 1981, 
Luetsche.Ja et al., 1965).  
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Cortisol and aldosterone action are known to have various effects within the human body 
which include a role in glucose metabolism and blood pressure regulation (Table 1-3).  
These effects are conveyed through cognate receptors: the glucocorticoid receptor and 
mineralocorticoid receptor (GR and MR).   
Table 1-3:  Examples of the physiological role of cortisol and aldosterone in 
humans 
 Cortisol Aldosterone 
Kidney Increase in  urinary calcium secretion (Leclerc et al., 2004) 
Na+ transport in epithelia for 
water reabsorption (McCormick 
et al., 2005). 
Liver Stimulation of gluconeogenesis (Tayek and Katz, 1997) 
Physiological effects not yet 
estalished in humans 
Adipose Tissue 
Regulates adipose tissue 
differentiation, function and 
distribution (Bujalska et al., 1997) 
Physiological effects not yet 
estalished in humans 
Bone 
Increases bone reabsorption by 
stimulating osteoclasts to regulate 
bone density (Bockman and 
Weinerman, 1990) 
Physiological effects not yet 
estalished in humans 
Brain 
Feedback loop regulation via 
effects on hypothalamus and 
pituitary glands (Tasker et al., 
2006) 
Regulates sodium and potassium 
levels (Stier et al., 2002). 
Inflammation 
Reduces inflammation by 
influencing the inhibition of 
leukocytes and the apoptosis of 
lymphocytes (Tuckermann et al., 
2005) 
Acts as a proinflammatory 
mediater of inflammation via MR 
in cardiovascular tissue (Funder, 
2004, Pitt et al., 2003)   
 
 
1.6.3. Corticosteroid Receptors and their Function 
Glucocorticoid and mineralocorticoid receptors (GR and MR) belong to the nuclear 
receptor superfamily which shares a common structure.  The unbound receptors can exist 
in the nucleus or the cytoplasm and form complexes with chaperone proteins such as heat 
shock proteins 90 and 70 (Pratt, 1987).  The main domains of nuclear receptors include a 
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NH2 terminal domain for activation of transcriptional activity and confers specificity of 
the action of the receptor, a DNA binding domain, a hinge region and a ligand binding 
domain (Aranda and Pascual, 2001).  Glucocorticoids interact with both the GR and MR 
but mineralocorticoids are generally known to act specifically at the MR.   
These membrane bound receptors interact with their cognate ligand, they enable 
translocation to the nucleus and subsequent transcription of target genes mediated through 
coactivators and corepressors (Table 1-4) evoking a physiological response.  It is also 
important to add that glucocorticoid and mineralocorticoids are also involved in non-
genomic effects which require no gene transcription.  For example, corticosteroids are 
believed to affect proteins in a yeast model known as Schizosaccharomyces pombe 
(Zöllner et al., 2008).  In this model, steroid receptors are not present, however, it does 
contain regulatory mechanisms that are similar to mamamals (Bӧhmer et al., 2006, 
Zöllner et al., 2008).  As a consequence, aldosterone was found to have regulatory effects 
on proteins involved in osmotic regulation (NAD-dependent malic enzyme and glycerol-
3-phosphate-dehydrogenase) and organisation of the cytoskeleton (VIP1 and 
glyceraldehyde-3-phosphate dehydrogenase) which are also affected in the human 
HCT116 cells, an immortalised colorectal carcinoma cell-line (Bӧhmer et al., 2006) .   
Another example is of the rapid effects of glucocorticoids which are not affected by MR 
and GR blockade and/or protein synthesis inhibition is on membrane proteins such as 
Ca2+ trafficking and cytoplasmic proteins which include mitogen-activated protein kinase 
(MAPK) and  phospholipases (Haller et al., 2008, Sze and Iqbal, 1994, Ai-Qun et al., 
2005). 
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Table 1-4:  Glucocorticoid and mineralocorticoid receptor cofactors 
 Nuclear receptor target Function 
SRC-1/NCoA-1 
Coactivators 
 
TIF2/ NCoA-2/ GRIP1 
 
P300 
CBP 
 
GR1, 5, 6, 7, MR8 
 
GR3,4,, MR9, 10 
 
GR12, MR 9 
GR2, 11 , MR9 
 
Acetyltransferase activity 
Interacts with CBP 
Mediates AF-2 activation of 
NR 
 
Inhibits NFκB activity 
Inhibits AP-1 activity 
NCoR/SMRT 
Corepressor  
GR13, MR10 
 
 
Binds to N terminus of NR  
for full antagonist activity 
Regulatory proteins found to influence GR or MR activity in mammalian species. 1: 
(Collingwood et al., 1999); 2: (Kamei et al., 1996); 3: (Voegel et al., 1996); 4: (Hong et 
al., 1999); 5: (Li et al., 2003); 6: (Ding et al., 1998); 7: (Yao et al., 1996); 8: (Li et al., 
2005); 9: (Fuse et al., 2000); 10: (Wang et al., 2004); 11: (Sheppard et al., 1998); 12: 
(Kino et al., 1999); 13: (Schulz et al., 2002) 
1.6.4. Synthesis and Release of Glucocorticoids and Mineralocorticoids 
1.6.4.1. Cortisol 
Glucocorticoids are regulated systemically by a negative feedback loop known as the 
hypothalamus-pituitary-adrenal axis.  The hypothalamus is activated by an external 
stimulus to produce and release corticotrophin releasing hormone (CRH) (Figure 1-13).  
CRH stimulates the anterior pituitary to synthesise and release adrenocorticotrophin 
(ACTH) which in turn stimulates the adrenal cortex to release cortisol from the zona 
fasiculata.  The increasing levels of cortisol feedback to the hypothalamus decreasing 
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CRH release and on the pituitary to decrease ACTH release (Tasker et al., 2006) (Figure 
1-13). 
    
 
Figure 1-13:  Hypothalamus-pituitay-adrenal cortex axis. 
The hypothalamus is stimulated to produce corticotrophin releasing hormone 
(CRH) which acts on the pituitary to produce adrenocorticotrophin (ACTH). 
ACTH then acts on the adrenal cortex to produce cortisol.  Cortisol negatively 
feeds back on the hypothalamus and pituitary to decrease CRH and ACTH 
production respectively.  
1.6.4.2. Aldosterone 
Mineralocorticoids are synthesised in the zona glomerulosa under the control of the renin-
angiotensin system.  Stimuli such as decreased sodium in the blood, hypotension and 
sympathetic innervations, stimulate the juxtaglomerular cells of the kidney to release 
renin into the bloodstream.  Renin proteolytically cleaves angiotensinogen to angiotensin I 
which in turn is cleaved by angiotensin converting enzyme (ACE) to produce angiotensin 
II.  Active angiotensin II stimulates the adrenal cortex to produce aldosterone which 
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+
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serves to regulate sodium transporting systems such as those within the kidney and the 
salivary glands (Figure 1-14). Natriuretic peptide produced from the heart and vasculature 
and somatostatin principally produced from the hypothalamus and cells of the intestine 
are able to inhibit angiotensin II induced aldosterone synthesis (Liang et al., 2007a, 
Aguilera et al., 1981)  
 
Figure 1-14:  Renin-angiotensin system.  
Renin released from the juxtaglomerular cells of the kidney cleaves 
angiotensinogen to angiotensin I.  Angiotensin I is converted to angiotensin II by 
angiotensin converting enzyme (ACE).  Angiotensin II stimulates the adrenal 
cortex to produce aldosterone. In addition to this,  aldosterone can be inhibited by 
somatostatin and natriuretic peptide. 
In addition to systemic regulation of corticosteroids, there is a need for the regulation of 
corticosteroids at a tissue specifc level so that the effects can be controlled locally.  In the 
case of cortisol this is performed by 11beta hydroxysteroid dehydrogenase enzymes. 
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1.7. Tissue Specific Regulator of Glucocorticoids 
1.7.1. Pre-receptor Regulation of Glucocorticoids and Mineralocorticoids 
Glucocorticoid and mineralocorticoid activity are regulated locally in tissues by an 
autocrine feedback loop (Figure 1-15).  In the case of cortisol, this regulation is mediated 
by the 11beta hydroxysteroid dehydrogenases which are part of the short chain alcohol 
dehydrogenase superfamily (SDR).  There are two isozymes that have been characterised: 
11beta hydroxysteroid dehydrogenase 1 (11β-HSD1) and 11beta hydroxysteroid 
dehydrogenase 2 (11β-HSD2). 
 
Figure 1-15:  Pre-receptor regulation of glucocorticoids. 
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Cortisol and cortisone enter the cell from the circulation. 2. The active cortisol 
from circulation can bind directly to the glucocorticoid receptor or 3. 11β-HSD1 
can reactivate cortisol from cortsone using NADPH provided for by H6PDH.  
H6PDH utilises G6P for this reaction.  G6P is transported into the cell by G6PT.   
4.  Activated GR can translocate to the nucleus.  5.  Transcription is mediated by 
GR. 6. This leads to transcription of specific target genes.  (E, cortisone; F, 
cortisol; GR, glucocorticoid receptor; 11β-HSD1, 11beta hydroxysteroid 
dehydrogenase; H6PDH, hexose 6 phosphate; G6P, glucose 6 phosphate; 6GPL, 
6 phosphogluconate; G6PT, glucose 6 phosphate transporter) 
When cortisol enters the cell from the circulation or cortisone is activated to cortisol 
intracellularly, it can bind to the glucocorticoid receptor and upon GR activation can 
allow the GR-cortisol complex to translocate to the nucleus to influence transcription of 
genes.  Glucocorticoid activation specifically takes place in the endoplasmic reticulum by 
membrane bound 11β-HSD.  Hexose-6-phosphate dehydrogenase (H6PDH) utilises the 
substrate glucose-6-phosphate (G6P), (Kimura et al., 1979, Stegeman and Klotz, 1979, 
Ozols, 1993) in the endoplasmic reticulum lumen to govern the directionality of 11β-
HSD1 (Figure 1-16) by providing the cofactor NADPH (Sherbet et al., 2007, Bujalska et 
al., 2005). 
1.7.2. 11β-HSD1 Expression and Distribution 
11β-HSD1, which was the first isoform discovered, was characterised in the late 1980s 
and cloned from rat liver (Lakshmi and Monder, 1988, Agarwal et al., 1989).  The 
enzyme is located in the lumenal side of the endoplasmic reticulum (Ozols, 1995) and is 
found to be bidirectional, capable of catalysing the interconversion between hormonally 
inactive cortisone and active cortisol (Figure 1-16) with low affinity (Amelung et al., 
1953, Bush et al., 1968, Lakshmi and Monder, 1988);   
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Figure 1-16:  Interconversion of cortisol and cortisone by 11beta hydrosteroid 
dehydrogenase enzymes (11β-HSD). 
11β-HSD1 predominantly converts cortisone to cortisol in intact cells while 
converting cortisone to cortisol in disrupted cells.  11β-HSD2 only converts 
cortisol to cortisone. 
 
Previous research has shown that 11β-HSD1 acts predominantly in intact cells as a 
reduced nicotinamide adenine dinucleotide phosphate (NADPH) dependent oxo-reductase 
which in-vivo or in intact cells, converts inactive cortisone to active cortisol (Tomlinson 
et al., 2004, Nikkila et al., 1993, Jamieson et al., 1995, Brem et al., 1995, Bujalska et al., 
1997).  However, some tissue homogenates and microsomes exhibit a nicotinamide 
adenine dinucleotide phosphate (NADP+) dependent dehydrogenase reaction where 
cortisol is converted to cortisone (Abramovitz et al., 1982, Bernal et al., 1982, Lakshmi 
and Monder, 1988) (Figure 1-16).   
Kinetic analysis of 11β-HSD1 shows that a Michaelis constant of 17.3 ± 2.24μM can be 
seen for cortisol in microsomes which, is much lower than its dehydrogenase form 
(Lakshmi and Monder, 1988, Monder and Lakshmi, 1989, Koerner, 1969).  
The 11β-HSD1 gene has been mapped to chromosome location 1q32.2 using rat 11β-HSD 
cDNA to probe a human testis cDNA library and is found to consist of 6 exons and 5 
cortisol
O
O
CH3
CH3
OH
HO
OH
O
O
CH3
CH3
OH
OH
O
cortisone
11β-HSD1 oxo-reductase activity 
NADPH dependent
11β-HSD1 dehydrogenase activity 
NADP+ dependent
11β-HSD2 dehydrogenase activity 
NAD+ dependent
  77 
introns (Tannin et al., 1991).  The 34kDa protein is found to be highly expressed in a 
variety of tissues regarded as glucocorticoid target tissues including human liver, adipose, 
gonads and placenta (Table 1-5). 
 
In human adipose tissue, 11β-HSD1 is expressed in subcutaneous (SC) and omental (OM) 
adipose tissue (Table 1-5) with predominantly has greater oxo-reductase activity in OM 
compared to SC (Bujalska et al., 1997, Bujalska et al., 2002b) and has been linked to the 
complex pathogenesis of obesity (De Sousa Peixoto et al., 2008, Tomlinson et al., 2002).  
In the human adrenal gland, 11β-HSD1 is expressed mainly in the zona reticularis of the 
adrenal cortex, although there is some expression within the zona glomerulosa and zona 
fasiculata (Table 1-5).  The role of this enzyme at this site remains unclear (Ricketts et al., 
1998a). 
11β-HSD1 expression in human bone (Table 1-5) was found in both osteoclasts and 
osteoblasts (Bland et al., 1999, Cooper et al., 2000).  The function of glucocorticoids in 
this tissue is to facilitate osteoblast differentiation, but can also adversely promote 
osteoblast apoptosis and decrease proliferation at high doses causing osteoporosis and 
bone metabolism (Cooper et al., 1999, Delany et al., 1995, Hong et al., 2008, Kim et al., 
2007).  Fibroblasts from the synovium have a higher expression of 11β-HSD1 in synovial 
fibroblasts compared to dermal fibroblasts and may have an important role in autocrine 
activation of glucocorticoids (Hardy et al., 2006). 
11β-HSD1 has also been characterised to the human colon where it has been localised to 
the lamina propria and mucosal epithelium (Whorwood et al., 1994) and recent data has 
suggested a role for induction of 11β-HSD1 in colonic inflammation (Zbankova et al., 
2007).  
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Table 1-5: 11β-HSD1 expression and activity in physiology 
Tissue 11β-HSD1 Expression and or Activity References 
Adipose 
+ (Yang et al., 1997, Bujalska et al., 1997, 
Balachandran et al., 2008, Bujalska et al., 
2006, Bujalska et al., 2002b) 
Adrenal Adrenal cortex: +; adrenal medulla: +/- (Ricketts et al., 1998a, Albertin et al., 2002) 
Bone Osteoblast: +; osteoclast: +; synovial fibroblasts 
(Bland et al., 1999, Cooper et al., 2000, Hardy 
et al., 2006) 
Colon Rectal colon: -; surface epithelia; +; lamina propria: + 
(Whorwood et al., 1994) 
CNS Cerebellum: + (Whorwood et al., 1995) 
Eye 
NPE: +,;corneal endothelium: +; TM: +/-; 
Lens: +/-, Corneal epithelium: +/- 
(Stokes et al., 2000, Rauz et al., 2001, Rauz et 
al., 2003, Suzuki et al., 2001, Mirshahi et al., 
1997)  
Gonad Testis: +; ovary: + (Ricketts et al., 1998a, Tannin et al., 1991) 
Heart Aortic smooth muscle cells: + (Hatakeyama et al., 2001) 
Kidney Medulla: + (Albiston et al., 1994) 
Liver + (Ricketts et al., 1998a) 
Lung Lung epithelial cell: -; foetal lung tissue: - (Garbrecht et al., 2006) 
Immune Cell Macrophage: + (Makkonen et al., 2007) 
Lymphoid Spleen: + (Whorwood et al., 1995, Thieringer et al., 2001b) 
Pancreas Islets of Langerhan: + (Davani et al., 2000) 
Pituitary Folliculo-stellate cells: +; corticotrophs: - (Korbonits et al., 2001) 
Placenta + (Bernal et al., 1980) 
Skin Epidermis: +; fibroblasts: + (Hardy et al., 2006, Teelucksingh et al., 1990) 
Decidua + (Arcuri et al., 1996, Ricketts et al., 1998a) 
+: present; -: absent; +/-: conflicting 
 
 
There have been several studies into the expression of 11β-HSD1 in the rat brain (Moisan 
et al., 1990) and rabbit brain (Sinclair et al., 2007) but very little in the human brain 
except for mRNA expression in the human cerebellum (Whorwood et al., 1995).  Gene 
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expression for MR and GR can be found in the foetal human brain suggesting 
glucocorticoids can bind to these receptors during development and may have an impact 
on HPA activity (C.W. Noorlander, 2006). However, 11β-HSD1 activity has been 
established in foetal hippocampal cells showing predominant oxo-reductase activity 
(Rajan et al., 1996).   
In human gonads, the testis and the ovaries express 11β-HSD1 (Table 1-5), (Ricketts et 
al., 1998a, Tannin et al., 1991).  Both reductase and dehydrogenase can be found in these 
regions and it has been shown that in the mouse testis, glucocorticoids reduce testosterone 
production (Payne and Sha, 1991) and in the mouse ovaries, glucocorticoids can inhibit 
FSH-stimulated aromatase activity (Hsueh and Erickson, 1978).  Prolactin and growth 
hormone secreting cells of the pituitary as well as folliculo-stellate cells have been shown 
to express 11β-HSD1 but 11β-HSD1 is absent from ACTH and FSH secreting cells, 
suggesting that the isozyme is not important for the regulation of the hypothalamus-
pituitary-axis by glucocorticoids (Korbonits et al., 2001).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
In addition, 11β-HSD1 has been established in human aortic smooth muscle cells (Table 
1-5), (Hatakeyama et al., 2001) and this can be affected by inflammatory stimuli 
indicating a role in inflammatory conditions such as atherosclerosis (Cai et al., 2001).  
This may have physiological significance as glucocorticoids are known to increase 
vascular tone and therefore local action of 11β-HSD1 may influence this function 
(Hatakeyama et al., 2001).  
11β-HSD1 was the first isozyme to be characterised in the kidney (Table 1-5) and was 
shown to have little expression which is restricted to the medulla and functions as a 
dehydrogenase (Albiston et al., 1994, Gong et al., 2008, Stewart et al., 1994, Brem et al., 
1997).   
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The highest expression of 11β-HSD1 is found in the liver (Table 1-5) which 
predominantly converts cortisone to cortisol and also possesses a high population of 
glucocorticoid receptors (GR).  This was established after it was found that hepatic 
venous blood has a higher F/E ratio compared to renal venous blood (Walker et al., 1993).  
The 11β-HSD1 isozyme is localised maximally and radially from the central vein in the 
liver (Ricketts et al., 1998a).  A major role for the liver is to provide glucose during 
fasting and 11β-HSD1 increases gluconeogenic enzymes and therefore enhances glucose 
output (Walker et al., 2007, Kotelevtsev et al., 1997).  Elevated 11β-HSD1 is involved in 
the metabolic syndrome and has been linked to fatty liver and insulin resistance 
(Johansson et al., 2001, Paterson et al., 2004).  
Expression of 11β-HSD1 has also been localised to lymphoid tissue (Table 1-5) such as 
the spleen (Whorwood et al., 1995) and 11β-HSD1 is induced after differentiation of 
monocytes to macrophages and after treatment with IL-4 and IL-13 (Thieringer et al., 
2001b).  A previous study shows the expression of 11β-HSD1 in the islets of Langerhan 
of the pancreas (Table 1-5) and it is thought to have a role in glucocorticoid mediated 
inhibition of insulin release (Davani et al., 2000).   
Placental tissue express 11β-HSD1 but shows negligible reductase activity and 
predominant dehydrogenase activity suggesting that its role may be to regulate cortisol 
excess to the foetus (Bernal et al., 1980).  In addition to this, the decidua expresses 11β-
HSD1 which may be important in preventing immune rejection of the foetus (Arcuri et al., 
1996). 
The skin epidermis (Teelucksingh et al., 1990) and skin fibroblasts (Hardy et al., 2006) 
express 11β-HSD1 (Table 1-5) and cortisol decreased IL-6 expression suggesting that 
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skin fibroblasts may have the capacity to respond to inflammatory stimulation such as that 
in leprosy (Andersson et al., 2007, Hardy et al., 2006).  
1.7.3. Regulation of 11β-HSD1 Activity 
There are many regulators of 11β-HSD1 in humans and these are summarised and 
described briefly in Table 1-6.  Inflammatory stimuli can also regulate 11β-HSD1 for 
example IL-1α, IL-1β, IL-6, TNFα, IL-4 and IL-13 can up-regulate oxo-reductase activity 
and thus locally promote availability of cortisol in the tissues such as the liver, adipose 
and bone (Yong et al., 2002, Escher et al., 1997a, Thieringer et al., 2001a, Evagelatou et 
al., 1997, Hardy et al., 2006).  GH treatment of hypopituitary male and females found that 
urinary THF/THE ratios decreased while being treated with a particular course of 
hydrocortisone (Gelding et al., 1998).  Moreover, it has emerged that IGF-I may be 
mediating effects on 11β-HSD1 via GH after in-vitro studies on omental preadipocytes 
showed a decrease in cortisone to cortisol conversion from dose dependent IGF-I and not 
GH (Moore et al., 1999) 
 
Other factors such as insulin have differential effects on 11β-HSD1 oxo-reductase activity 
depending on the cell type.  For example insulin increases or has no effect on 11β-HSD1 
oxo-reductase activity in human adipose (Wake et al., 2006, Handoko et al., 2000) and 
decrease activity in skin fibroblasts  (Hammami and Siiteri, 1991).  Glucocorticoids such 
as cortisol and dexamethasone can increase 11β-HSD1 expression in adipose and amnion 
fibroblasts respectively (Li et al., 2006, Sun and Myatt, 2003).  This occurs indirectly 
through C/EBP(beta) (Sai et al., 2008). The sex steroids medroxyprogesterone acetate and 
estradiol can increase 11β-HSD1 expression while progesterone decreases 11β-HSD1 
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expression in ovarian epithelium or has no effect on 11β-HSD1 expression in human 
hepatocytes (Arcuri et al., 1996, Fegan et al., 2008, Ricketts et al., 1998b).   
Table 1-6: Regulators of 11β-HSD1 
Regulatory Factor Effect on Human 11β-HSD1 Ref. 
IL-1 ↑ (e.g. ovary) (Yong et al., 2002) 
IL-6 ↑ (e.g. adipose) (Tomlinson et al., 2001b) 
TNFα ↑ (e.g. aorta)  
← (e.g. monocytes) 
(Thieringer et al., 2001b, Cai et al., 2001) 
IL-4 ↑ (e.g. monocytes)  
← (e.g. synovium) 
(Hardy et al., 2006, Thieringer et al., 
2001b) 
IL-13 ↑ (monocytes) (Thieringer et al., 2001b) 
GH ↓ (e.g. adipose) (Paulsen et al., 2006, Sigurjonsdottir et al., 
2006, Tomlinson et al., 2001b) 
IGF-I ↓ (adipose) (Moore et al., 1999, Tomlinson et al., 
2001b) 
Insulin ↑ (e.g. adipose) 
← (e.g. adipose) 
↓ (e.g. skin fibroblasts) 
(Handoko et al., 2000, Wake et al., 2006, 
Hammami and Siiteri, 1991) 
Cortisol ↑ (e.g. adipose) (Tomlinson et al., 2002, Li et al., 2006) 
Dexamethasone ↑ (e.g. amnion fibroblasts) (Sun and Myatt, 2003) 
Estradiol ↑ (e.g. ovary) (Arcuri et al., 1997) 
Medroxyprogesterone Acetate ↑ (e.g. ovary) (Arcuri et al., 1996) 
Progesterone ↓ (e.g. ovary) 
← (e.g. hepatocytes) 
(Fegan et al., 2008, Rae et al., 2004, 
Ricketts et al., 1998b) 
Thyrotropin ← (e.g. hepatocytes) (Ricketts et al., 1998b) 
Effects on 11β-HSD1 are classified as ↑, increase; ↓, decrease and ←, no effect. 
Thyrotropin (T3) has been shown not to have an effect on 11β-HSD1 expression in human 
hepatocytes (Ricketts et al., 1998b). 
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1.7.4. 11β-HSD2 Expression and Distribution 
The 11β-HSD2 isoform is a unidirectional nicotinamide adenine dinucleotide (NAD+) 
dependent dehydrogenase with high affinity for cortisol.  The gene for this enzyme was 
cloned in the mid 1990s and is mapped to chromosome 16q22 (Albiston et al., 1994).   
11β-HSD2 is commonly expressed in tissues rich in mineralocorticoid receptors such as 
the kidney, placenta (Krozowski et al., 1995, Brown et al., 1993, Stewart et al., 1995), 
salivary gland (Smith et al., 1996) and colon (Whorwood et al., 1994, Hirasawa et al., 
1997).  In the human kidney, 11β-HSD2 is localised to the collecting ducts of the cortex 
and medulla as well as the distal convoluted tubules.  The primary role of this isoform is 
to protect the mineralocorticoid receptor from cortisol excess, thereby allowing 
aldosterone to genomically mediate transcription.  The two genes known to be 
genomically regulated by aldosterone are the epithelium sodium channel (ENaC) and 
serum and glucocorticoid induced kinase (SGK) which are involved in the transport of 
sodium across the epithelia, permits water reabsorption from the kidney tubule to the 
capillary bed (Figure 1-17).  SGK is postulated to modulate ENaC activity by interacting 
with accessory proteins such as Nedd4-2 which is known to interact with and 
downregulate ENaC (Snyder et al., 2002, Fejes-Toth et al., 2008).   
Similar mechanisms exist in the salivary glands (Rauh et al., 2006) and colon (Matos et 
al., 2007, Coric et al., 2004) where expression of the enzyme is restricted to the 
intercalating and striated ducts of the salivary glands, and columnar epithelial cells of the 
distal colon.  In the placenta, localisation of 11β-HSD2 within the syncytial trophoblast 
cells (Krozowski et al., 1995) protects the developing foetus from high levels of 
circulating maternal cortisol (Krozowski, 1999, Sun et al., 1998, Driver et al., 2003).  11β-
HSD2 is also important during pregnancy, maintaining the foetus and facilitating 
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maturation (Sato et al., 2008b).  However, this is thought to be regulated in part by 
progesterone, which decreases 11β-HSD2 expression.   
 
Figure 1-17:  Aldosterone effects on sodium/water movement in the kidney tubule 
epithelial cell (KTEC). 
Cortisol(F) from the vascular bed is inactivated to cortisone (E) by 11β-HSD2  in 
the cell allowing aldosterone A) to bind to the mineralococrticoid receptor (MR) 
and initiate transcription of a series of genes involved in sodium transport e.g. 
epithelial sodium channel (ENaC).  This ultimately results in water reabsorbtion. 
1.7.5. Regulation of 11β-HSD2 
Circulating sex steroids can regulate 11β-HSD2 expression and activity.  For example, 
progesterone inhibits 11β-HSD2 activity in human placental trophoblast cells (Sato et al., 
2008a) and estradiol increases 11β-HSD2 activity in the human endometrial cell-line 
(Darnel et al., 1999).  Other factors include EGF which causes a decrease in 11β-HSD2 
activity in the human endometrial cell-line (Darnel et al., 1999) 
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1.8. 11β-HSD in the Eye and the Orbit 
In the human eye, 11β-HSD1 has been localised to several anatomical areas of the eye 
which are briefly reported in Table 1-7.   
Table 1-7: Expression of 11beta hydroxystroid dehydrogenase 1 and 2  in 
human ocular tissuesa 
 11β-HSD1  11β-HSD2  
Conjunctiva 
Epithelium 
Stroma 
 
? 
? 
 
Ref.  
? 
? 
 
Ref. 
 
Cornea 
Epithelium 
Stroma 
Endothelium 
 
+/- 
- 
+/- 
 
1,3,4 
3 
3,4 
 
- 
- 
+/- 
 
3, 4 
3 
1,3,4 
Ciliary Body 
NPE 
PE 
Stroma 
 
+/- 
- 
- 
 
1,2,3,4 
1,3,4 
3 
 
+/- 
- 
- 
 
1,3,4 
1,3 
3 
TM +/- 1,4 - 1,4 
Lens +/- 1,3,4 - 1,3,4 
Retina - 3 - 3 
Optic Nerve - 3 - 3 
Sclera - 3,4 - 3,4 
Orbital Adipose 
Tissue  ?  ?  
aImmunoreactivity and/or mRNA expression is classified as +; present, -; not present, +/-
; conflicting data; ?, not known. References 1; (Rauz et al., 2001), 2; (Rauz et al., 2003), 
3; (Suzuki et al., 2001), 4; (Stokes et al., 2000).  
The cornea which consists of the corneal epithelium, Bowman’s capsule, stroma, 
endothelium and descemet’s membrane has some expression of 11β-HSD1.  Expression 
of 11β-HSD1 is found in the corneal epithelial cells (Rauz et al., 2001, Stokes et al., 2000) 
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but there are some conflicting reports (Suzuki et al., 2001).  There are no reports of 11β-
HSD1 expression in the stroma or endothelium (Rauz et al., 2001, Suzuki et al., 2001, 
Stokes et al., 2000).    
The expression of 11β-HSD1 can be found in the non-pigmented epithelium (NPE) of the 
ciliary body (Rauz et al., 2003a, Rauz et al., 2001, Stokes et al., 2000).  There is no 
expression of 11β-HSD1 expression in the pigmented epithelium (PE) of the ciliary body 
(Stokes et al., 2000, Rauz et al., 2001, Suzuki et al., 2001) and no expression in the ciliary 
body stroma (Suzuki et al., 2001).  There are also conflicting reports of 11β-HSD1 
expression in the NPE (Stokes et al., 2000, Suzuki et al., 2001).  MR expression is found 
in the NPE (Suzuki et al., 2001, Stokes et al., 2000) but not in the PE or stroma of the 
ciliary body (Suzuki et al., 2001).  The regeneration of the glucocorticoid, cortisol in these 
systems (the cornea and NPE) by 11β-HSD1 may be involved in stimulating apical 
sodium channels and basolateral Na+-K+-ATPase in the regulation of water and solute 
movement and in immunoprotection. 
The trabecular meshwork (TM) has expression of 11β-HSD1 (Rauz et al., 2001) but no 
expression of 11β-HSD2 and MR.  There is some evidence of 11β-HSD1 expression in 
the lens epithelium (Stokes et al., 2000) (Stokes et al., 2000, Rauz et al., 2001, Suzuki et 
al., 2001). Expression of 11β-HSD1 (Suzuki et al., 2001) was not found in any of the 
retinal cells.  The optic nerve also showed no evidence of expression for 11β-HSD1 
(Suzuki et al., 2001).  Within the sclera there is no expression of 11β-HSD1 (Suzuki et al., 
2001, Stokes et al., 2000).  With respect to orbital adipose tissue, it has recently been 
found that 11β-HSD1 was expressed and was able to actively produce cortisol from 
cortisone (Bujalska et al., 2007). 
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11β-HSD2 expression in the cornea is conflicting. No expression of this enzyme has been 
found in corneal endothelial cells (Rauz et al., 2001, Stokes et al., 2000) or the stroma 
(Rauz et al., 2001, Suzuki et al., 2001), however, there is conflicting evidence suggesting 
expression in the corneal epithelium and corneal epithelial cells (Stokes et al., 2000).  
There is no expression of 11β-HSD2 and MR in the lens (Suzuki et al., 2001, Stokes et 
al., 2000).  11β-HSD2 (Suzuki et al., 2001) and MR (Suzuki et al., 2001) were not found 
to be expressed in any of the retinal cells or optic nerve.  The sclera had no expression of 
11β-HSD2 or MR (Suzuki et al., 2001, Stokes et al., 2000) and no expression of 11β-
HSD2 can be found in orbital adipose tissue (Bujalska et al., 2007). 
 
Little is known about 11β-HSD in the eye, especially in the orbit.  There are few studies 
detailing the distribution and expression of 11β-HSD in the eye and there have been no 
reports on 11β-HSD in the orbit but there is the incidence of 11β-HSD in orbital adipose 
tissue from the orbit (section 4.3.3.1), (Bujalska et al., 2007). 
11β-HSD1 may have a beneficial role for local tissue specific regulation of 
glucocorticoids in inflammation, however, overexpression of 11β-HSD1 may up-regulate 
glucocorticoid-induced adverse effects such as those seen in glaucoma. 
1.8.1. Potential Applications of 11β-HSD1  
The establishment of 11β-HSD1 in disease may provide a potential target for different 
therapeutic interventions.  These may include manipulation of 11β-HSD1 for the 
regulation of glucocorticoids which have effects on ocular surface disease, intraocular 
immune privilege and orbital disease states. 
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1.8.2. Ocular and Orbital Disease States 
Regulation of 11β-HSD on ocular surfaces which include the cornea and intraocular 
environments such as the ciliary epithelium may have influences upon regulating 
inflammation and cell repair which is vital for normal eye function.  The significance of 
the specific regulation of 11β-HSD1 in the corneal epithelium and conjunctival epithelium 
could suggest a role in the regulation of ocular surface inflammatory diseases such as 
infective keratitis where inhibition of 11β-HSD1 could provide a therapeutic target for 
reduced inflammation especially in autoimmune eye disease.  For example, a specific 
11β-HSD1 inhibitor, compound 544 was successfully used to inhibit 11β-HSD1 within 
insulin resistant mice and improved their insulin sensitivity (Hermanowski-Vosatka et al., 
2005). 
Cortisol is produced in human and rabbit aqueous humour in the anterior chamber of the 
eye (Rauz et al., 2001, Obenberger et al., 1971, Stárka et al., 1975).  11β-HSD1 involved 
in the generation of glucocorticoids may potentially be regulating local production of 
cortisol from the ciliary NPE which may be important for intraocular immunoprotection.  
Immune privilege sites in the eye exist for example where there is no blood supply such as 
that found in the central cornea and where there are vascular barriers such as that in the 
ciliary body (Koevary, 2000).  It is hypothesised that immune privilege is achieved 
because antigens are isolated from being presented to cells of the immune system.  
Manipulation of 11β-HSD1 for the generation of glucocorticoids in immune privilege 
sites may protect these sites from immune intervention and promote other factors essential 
to maintaining the immune privilege state (chapter 1.3.7.1).   
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Glucocorticoid therapy for thyroid associated ophthalmopathy can cause adverse effects 
when used systemically.  Local generation of glucocorticoids by 11β-HSD1 in inflamed 
orbital adipose tissue may taper inflammation without severe side effects and could 
provide a novel therapeutic target for treatment of thyroid associated ophthalmopathy. 
1.9. Hypothesis and Aims 
This thesis was designed to evaluate the functional role of 11β-HSD in the eye and the 
orbit and whether the 11β-HSD1 can be targeted to modify various disease processes in 
the eye (Figure 1-18).   
 
Figure 1-18:  Hypothesis diagram.   
Cortisone Cortisol11β–HSD1
Ocular surface Ciliary NPE Orbital adipose 
Cortisol 
generation
+ pro-inflammatory 
cytokine
+ pro-inflammatory 
cytokine
↑ Cortisol in 
cornea
↑ Cortisol in 
Orbital Adipose
Therapeutic manipulation for 
Ocular and Orbital 
Inflammatory Diseases?
Corneal 
epithelium
Conjunctival 
epithelium
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Cortisol levels are regulated by 11β-HSD1.  11β-HSD1 is hypothesised to be 
involved in the local generation of cortisol in corneal and ciliary epithelium and 
orbital adipose tissue.  Cortisol generation further increased from corneal 
epithelium and orbital adipose by pro-inflammatory cytokines.  The inflammatory 
insult together with the increased local cortisol production in tissue may 
contribute to the pathology of ocular surface and orbital inflammatory disease.  
11β-HSD1 and pro-inflammatory cytokines may provide therapeutic targets in 
ocular and orbital inflammatory diseases.  11β-HSD1, 11 beta hydroxysteroid 
dehydrogenase 1.   
The first part of the results in this thesis will focus on 11β-HSD1 on the ocular surface 
and intraocular environment and will include: 
 
• The animal model, New Zealand White Albino Rabbit (NZWAR), used to 
confirm expression of 11β-HSD1 in the corneal epithelium, conjunctival 
epithelium and ciliary NPE.   
• Evaluation of intraocular generation of cortisol from ciliary body and 
epithelium.   
• Evaluation of the human ocular surface which will include study of the cornea to 
confirm 11β-HSD1 expression and activity in corneal epithelium and other cell-
types that include fibroblasts from the conjunctiva and cornea.  
• Studying the effects of cytokines on 11β-HSD1 activity in corneal epithelial 
cells which may have significance in ocular surface defence.  
• Consideration of corneal epithelial cell biology and studying the effects of 
glucocorticoids on cell proliferation and what implication this may have on 
ocular physiology.   
The last part of the results will focus on 11β-HSD1 in orbital adipose tissue of the 
orbit and will include: 
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• Detailed analysis of the human orbital adipose tissue depot and comparing this 
to well characterised adipose tissue depots, namely, omental (OM) and 
subcutaneous (SC) adipose.   
• Evaluation of 11β-HSD1 expression in orbital adipose tissue.   
• Evaluation of the pre-receptor regulation of glucocorticoids in ‘control’ orbital 
adipose preadipocytes compared to ‘thyroid’ orbital adipose preadipocytes. 
• Cytokine profiling of orbital adipose will be compared to OM and SC and the 
effects of pro-inflammatory cytokines on the orbital preadipocyte 11β-HSD1 
oxo-reductase activity will be shown.   
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2. Chapter 2  
General Material and Methods 
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2.1. Introduction  
The general chemicals and solutions used during the course of this research were obtained 
from Sigma-Aldrich Company (Sigma-Aldrich Company Ltd, Dorset, UK) and Fisher 
Scientific UK Ltd (Loughborough, Leicestershire, UK).  Phosphate buffered saline (PBS) 
and distilled water were autoclaved before using for cell culture stock solutions.  
Solutions of unlabelled cortisol (F), cortisone (E) and glycyrrhetinic acid (GE) were all 
from Sigma-Aldrich Company Ltd, Dorset, UK, were made in absolute ethanol in stock 
solutions of 10-2 M and stored at -20ºC.  The radiolabelled hydrocortisone (cortisol) 
[1,2,6,7-3 H (N)] – 2.6 TBq/mmol (70.00 Ci/mmol) was obtained from New England 
Nuclear-Dupont Ltd (Herts, UK) and was stored at -20ºC.   
2.2. Tissue Ethics Approval 
2.2.1. Animal Legislation 
Ocular tissues were harvested from the NZWAR in accordance with the FRAME 
Guidelines on research involving the use of laboratory animals, the UFAW Handbook on 
the care and management of laboratory animals and the ARVO Statement for the use of 
animals in ophthalmic and vision research.  The rabbits which were female were housed 
in pens in groups of two or three.  Their approximate age was 5 months and their weight 
was up to 1.5kg.   The rabbits were fed with a standard pelleted diet which was given at a 
rate of about 60-80g/kg body weight/day and given water daily.  They were provided with 
hay which they ate and used for bedding.  The rabbits were kept in recommended lighting 
requirements of 12h: 12h light/dark cycle. 
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2.2.2. Human Tissue Ethics 
The collection of human corneoscleral discs, eye, liver, kidney and orbital adipose tissues 
for in-vitro investigation was approved by the local research ethics committee (LREC). 
Informed consent was obtained from all patient volunteers or their relatives. 
All human orbital adipose tissue (HOAT) specimens (n=87) were obtained from BMEC 
and Moorfields Eye Hospital (MEH) with informed consent and following ethical 
approval.    
2.2.3. Preparation and Storage of Human and Rabbit Tissues 
2.2.3.1. New Zealand White Albino Rabbit (NZWAR) Tissue Collection, 
Preparation and Storage 
All NZWARs (n=6) were housed in the Biomedical Services Unit (BMSU), University of 
Birmingham, UK.  Liver and kidney sections were taken and fixed and the remaining 
tissue stored in RNA-later (Ambion - Europe Ltd, Cambridgeshire, UK) at -80ºC and 
fixed in 10% formalin (Sigma-Aldrich Company Ltd, Dorset, UK).  A section of 
conjunctiva was surgically dissected from the NZWAR globes (n=12) and fixed in 
formalin or stored in a sterile container for primary culture.  One globe of each rabbit was 
fixed in formalin. The remaining globes were bisected in the coronal plane separating the 
anterior and posterior segments of the eye.  The ciliary body and corneal scleral rim were 
carefully dissected from the anterior segment with the aid of a dissecting 
stereomicroscope.  
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2.2.3.2. Human Tissue Collection, Preparation and Storage 
Human corneoscleral discs, central corneal buttons (transplant waste), whole eye, liver 
and kidney were obtained from the Birmingham Midland Eye Centre (BMEC).  Human 
eye tissue was also obtained from either healthy anterior segments of human eyes being 
enucleated for pathology of the posterior part of the eye or corneoscleral discs and sentral 
corneal buttons (transplant waste) from penetrating and lamellar keratopathy surgical 
procedures.   The human corneoscleral disc, whole eye, liver and kidney tissues were kept 
in organ culture medium at room temperature before placing in either 10% formalin for 
fixing or primary culture media for corneal fibroblasts, conjunctival fibroblasts and 
corneal epithelial cells. 
 
The HOAT specimens were obtained from patients undergoing routine surgery which 
included orbital decompression surgery and eyelid surgery (blepharoplasty).  The qHOAT 
from patients were free from inflammation and had not used topical or systemic 
glucocorticoids for three months prior to surgery. No patients were on systemic GC-
sparing immunosuppression, and none had undergone previous orbital radiotherapy.  
Subcutaneous and omental tissue were obtained from patients undergoing elective 
laparotomy.  These samples were either fixed in 10% formalin before sectioning or placed 
in RNA later and stored at -20ºC (Ambion - Europe Ltd, Cambridgeshire, UK).   
 
HOAT were placed in a sterile container and transported at room temperature to the 
laboratory after harvesting.  A proportion of the HOAT samples were divided into two or 
three pieces (depending on the size of the specimen) and one piece placed in RNA later 
and stored at -20ºC (Ambion - Europe Ltd, Cambridgeshire, UK), while the other section 
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was cultured within 24 hours.  If the specimen was too small, it was used either in its 
entirety for cell culture, RNA extraction or placed in formalin for tissue sectioning.  
 
2.3. Cell Culture 
Cell culture medium was obtained in 1x solution form in 500ml bottles from Sigma-
Aldrich Company Ltd, Dorset, UK or Gibco-Life Technologies, Invitrogen Paisley, UK.  
Heat inactivated foetal calf serum was acquired from Sigma-Aldrich Company Ltd, 
filtered through a 0.2μm sterile filter and stored as 50ml aliquots at -20°C.  Trypsin (stock 
concentration of 0.25% v/v) was prepared by diluting 20ml trypsin (10x concentration) in 
480ml 1x PBS/0.5M EDTA and aliquots were stored at -20°C. 
2.3.1.1. Human and NZWAR Corneal Epithelial Primary Cell Culture 
Corneoscleral buttons were incubated with Dispase (Invitrogen Ltd, Paisley, UK) at 37ºC 
for two hours to dislodge cells.  Cells transferred to 48 well plates were maintained in 
keratinocyte–SFM medium with L-glutamine, EGF-1, bovine pituitary extract (Invitrogen 
Ltd, Paisley, UK), 10% fetal bovine serum (FBS) and 100 IU/ml penicillin, 100 µg/ml 
streptomycin (Invitrogen Ltd, Paisley, UK) at 37ºC in a humidified atmosphere containing 
5% CO2 and 95% O2.  Cells were maintained to approximately 80-90% confluency 
(controlled under microscope for characteristic hexahedral architecture) for approximately 
7-14 days to obtain the maximal amount of cells until 11β-HSD enzyme assay was 
performed.  After 11β-HSD enzyme assay was performed for both 11β-HSD1 and 2, the 
cells were stored in PBS at -80ºC while the assay solution was processed through thin 
layer chromatography (TLC).  
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2.3.1.2. Human and NZWAR Corneal Fibroblast Primary Culture 
Primary cultures were established by incubating central corneal buttons (dissected away 
from the remnant corneal–scleral disc used for deriving primary corneal epithelial cells) in 
serum-free conditions consisting of DMEM with glutamax, 1000 mg/ml glucose, 100 
IU/ml penicillin, 100 µg/ml streptomycin and sodium pyruvate (Invitrogen Ltd, Paisley, 
UK) in a humidified atmosphere set at 37°C with 5% CO2 (Lee et al., 2008). Corneal 
fibroblasts were distinguised from corneal epithelial cells due to their distinctive 
elongated morphology.  Confluent corneal fibroblast cultures were established after 14 
days and were subcultured as required. All experiments were carried out on passages 1 
and 2.  After 11β-HSD enzyme assay was performed, cells were stored in PBS at -80ºC. 
2.3.1.3. Human and NZWAR Conjunctival Fibroblast Primary Cell Culture 
Surgically removed human and NZWAR conjunctiva tissues were placed in 6 well plates 
and cultured in Dulbecco's Modified Eagle Medium (DMEM) (Invitrogen Ltd, Paisley, 
UK) containing 10% FBS and 100 IU/ml penicillin, 100 µg/ml streptomycin at 37ºC in a 
humidified atmosphere containing 5% CO2 and 95% O2.  The medium of the cells was 
changed every 2-3 days and the cells were maintained to approximately 90% confluency 
before passaging.  After 11β-HSD enzyme assay was performed, cells were stored in PBS 
at -80ºC. 
2.3.1.4. Storage and Recovery of Human SV40 Immortalised Corneal 
Epithelial Cells 
Human SV40 immortalised corneal epithelial cell-line (HCEC) was obtained as a gift 
from Graham Wallace.  The cells were trypsinised when approximately 80-90% 
confluent.  Cells were washed with 1x PBS before using 1ml 0.25% trypsin for a 25cm2 
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flask.  Cells were then centrifuged at 1000 x g before washing in 1x PBS.  Cells were 
resuspended in 1ml foetal calf serum containing 10% (v/v) dimethylsulphoxide (DMSO) 
and transferred to a cryovial.  Vials were kept in an ice cold methanol bath at -80°C for 24 
hours before transferring to liquid nitrogen storage at -140°C. 
Cell-lines in 1ml vials were thawed gently in a 37°C waterbath for less than 5 minutes 
before being transferred to 50ml centrifuge tube.  In a drop wise manner, 5ml of culture 
media were added to the cells and gently mixed.  The cells were centrifuged at 1000 x g 
before the supernatant was discarded and the cell pellet was resuspended in 5ml culture 
media and placed in a 25cm2 flask. 
2.3.1.5. Primary Culture of Human Orbital Adipose Tissue (HOAT) 
HOAT samples were finely chopped and treated with collagenase digestion solution 
(Worthington Biochemical Corporation, Lakewood, New Jersey).  The method was 
adapted from the paper by Crisp and collegues (Crisp et al., 2000).  The HOAT samples 
were disaggregated in a shaking 37ºC water bath for approximately 1 hour or until the 
sample appeared digested.  The resulting HOAT suspension was centrifuged at 1500 rpm 
for 5 minutes at room temperature to separate the preadipocytes from the lipid and the 
adipocytes (Figure 2-1).  The lipid, adipocyte and collagenase layers were removed using 
a pipette to leave the preadipocytes in the stromal pellet.  The pellet was resuspended in 
growth medium consisting of DMEM nutrient mixture HAM F-12 1:1 (Invitrogen Ltd, 
Paisley, UK) containing 10% FBS and 100 IU/ml penicillin, 100 µg/ml streptomycin and 
plated into two or four wells in 24 or 48 well plates depending on the size of the sample.  
The cells were then incubated at 37ºC in the presence of humidified atmosphere 
containing 5% CO2 and 95% O2 and the medium was changed at intervals of every 2 
days.  The cells were maintained to about 80-90% confluency before the 11β HSD 
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enzyme assay was performed.  After the 11β-HSD enzyme assay was performed, the cells 
adhered to the plates were stored at -80ºC.    
  
Figure 2-1:  Tissue fractionates formed after centrifugation of HOAT with 
collagenase. 
  Preadipocytes were collected in the stromal pellet. 
2.3.1.6. Preadipocyte Differentiation   
Once the cells had reached 80-90% confluency, the medium was removed from the orbital 
preadipocytes before washing in PBS.  Chemically defined medium (DMEM nutrient 
mixture HAM F-12 1:1; 10% FBS; 100 IU/ml penicillin, 100 µg/ml streptomycin; 3-
isobutyl-1-methylxanthine (IBMX); 10-4M cortisol; 0.2M insulin) was placed on the cells 
and incubated at 37ºC in humidified atmosphere containing 5% CO2 and 95% O2.  The 
medium was changed on day 5 to the above medium but without IBMX.  The cells were 
then maintained for a further 9 days until an 11β-HSD enzyme assay was performed on 
what was termed ‘day 14’ of differentiation. 
 
  100 
2.4. RNA Extraction and Reverse Transcription 
2.4.1. RNA Extraction 
Primary human orbital adipose tissue, human primary corneal epithelial cells, corneal 
fibroblast cells, conjunctival fibroblast cells and human SV40 immortalized corneal 
epithelial cell-line were washed in 1x PBS before extracting with Tri-reagent.  Human 
tissue was either snap frozen in liquid nitrogen and stored at -80°C or stored in RNA later 
(Ambion - Europe Ltd, Cambridgeshire, UK) and left to equilibrate in the fridge for 24 
hours before long term storage at -20°C.  Tissue samples on ice were homogenised using 
a rotor-stator blade in a class 2 laminar flow cell culture hood.  The homogenate was 
centrifuged at 12,000 x g for 10 minutes to remove insoluble material leaving the 
supernatant that contains the RNA and protein.   
Isolation of RNA from samples was performed using a 200μl of chloroform per ml of tri-
reagent to create an aqueous interface (Sigma-Aldrich Company Ltd, Dorset, UK,) after 
shaking vigorously for 15 seconds and allowed to stand for 10 minutes.  Centrifugation 
was carried out at 12,000 x g for 30 minutes at 4°C and the aqueous phase was removed.  
The inorganic phase was centrifuged again at 12,000 x g for 15 minutes and the aqueous 
phase removed.  The RNA was precipitated using 500μl of isopropanol per ml of tri-
reagent (Sigma-Aldrich Company Ltd, Dorset, UK,).  The supernatant was kept at room 
temperature for 1 hour before centrifuging at 12,000 x g for 30 minutes at 4°C.  The 
supernatant was removed using a speed vac to leave a resultant RNA pellet which was 
washed in 1ml of 70% ethanol per ml of tri-reagent before removing the supernatant and 
leaving to dry for 5 minutes.  The pellet was resuspended in 20-50μl of nuclease free 
water and stored at -80ºC.  RNA quantification was analysed by using a 
spectrophotometer (Spectronic Unicam, Cambridge, UK) and RNA quality was visually 
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verified following electrophoresis of a 1% agarose gel containing ethidium bromide.  
Visualisation was by means of a UV camera.  Pictures taken were checked for bands, 
usually, a distinct 28s and a 18s band can be seen without smearing suggest less 
degradation of the RNA.  
2.4.2. Reverse Transcription 
Reverse transcription was carried out in 20μl final volume according to manufacturer’s 
protocol (Applied Biosystems, Foster City, CA) where up to 1μg total RNA was 
combined with random hexamers (2.5μM final), 10x Taqman RT buffer (1x final 
concentration), 25mM Magnesium Chloride (MgCl2, 5.5mM final), dNTP (500μM final), 
RNase inhibitor (0.4U/μl final concentration), 50U/μl Multiscribe Reverse Transcriptase 
(1.25U/μl final concentration) and made up to a total volume of 50μl with nuclease free 
water.  Conditions used for the RT cycle were 25ºC for 10 minutes, 37ºC for 60 minutes, 
48ºC for 30 minutes, 95ºC for 5 minutes and cooled to 4 ºC.  The resultant cDNA was 
kept for long term storage at -20 ºC. 
 
2.5. Conventional and Real-Time PCR 
2.5.1. Conventional PCR 
Reactions were performed using 1X (final concentration) PCR buffer containing 
2.5mmol/l dNTP, 2mmol/l MgCl2, 0.5pmol/μl each of forward and reverse primers for 
gene of interest and 1U Taq polymerase made up to a final volume of 20μl using nuclease 
free water.  Samples were amplified using cycle conditions specific to each gene primer.  
Gene expression was compared to the housekeeping gene 18s rRNA supplied by Ambion, 
Austin, TX.  The cycle conditions for 18s were an initial denaturation cycle of 94ºC for 5 
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minutes, 30 cycles of 94ºC (30 seconds), 60ºC (30 seconds), 72ºC (30 seconds) followed 
by a final elongation step at 72ºC for 7 minutes.  PCR products were visualised following 
electrophoresis of a 1% agarose gel containing ethidium bromide.  Visualisation was by 
means of a UV camera. 
2.5.2. Real-Time PCR 
Real-time PCR was performed using an ABI 7700 system (Perkin-Elmer, Biosystems, 
Warrington, UK).  PCR was performed in 25μl reactions on 96-well plates.  Reactions 
contained 1x Taqman universal PCR master mix (Applied Biosystems, Warrington, 
Cheshire, UK) 10nM primers, 250nM Taqman probe and 100pg-50ng cDNA.  Reactions 
were performed multiplex, using 18s rRNA as an internal reference. All target gene 
probes were labelled with fluorescent label FAM, and the 18s probe with fluorescent label 
VIC.  The cycle conditions were 50ºC for 2 minutes, 95ºC for 10 minutes and then 44 
cycles of 95ºC for 15 seconds and 60ºC for 1 minute. Data was analysed according to the 
manufacturer’s guidelines and were quantified using the Ct value which is the cycle 
number at which logarithmic plots cross a calculated threshold value.  Ct value was used 
to determine dCt values (dCt = Ct of the target gene minus Ct of the internal reference, 
18s).  All of the oligonucleotide primers and probes except 11β-HSD1 and 11β-HSD2 
were designed and made by Applied Biosystems of which the sequences are not known to 
the public domain.  Primers for 11β-HSD1 and 11β-HSD2 were designed in house and 
made by Alta Bioscences, Birmingham UK.  
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2.6. Immunohistochemistry 
2.6.1. Tissue Section Preparation  
Human eye, rabbit eye, conjunctiva, subcutaneous, omental and orbital adipose tissues 
fixed in 10% formalin (Sigma-Aldrich Company Ltd, Dorset, UK) and embedded in 
paraffin wax were obtained from the Academic Unit, Birmingham University, City 
Hospital.  Human samples were acquired in accordance with the local ethical committee.  
Five microns thick sections of tissue were placed on microscope slides dried in a 60ºC 
oven before dewaxing in xylene (Genta Medical, York, UK), rehydrating in 100% 
ethanol, 95% ethanol and rinsed in water before the immunohistochemistry procedure. 
2.6.2. Haematoxylin and Eosin Staining 
Dewaxed and rehydrated sections were placed on a flat staining rack and incubated with 
Meyer’s haematoxylin stain for 5 minutes then rinsed in water for several minutes.  A few 
drops of 1% acid alcohol were added to the section and immediately removed and rinsed 
with water for several minutes.  Eosin stain (Surgipath-Europe Ltd, Peterborough, UK) 
was then added to each section and incubated for about 2 minutes.  The sections were then 
rinsed in water before processing through a series of washes consisting of 100% ethanol 
and xylene.  The sections were then mounted on to coverslips using dibutyl-polystyrene-
xylene (DPX) from BDH laboratory supplies, Poole, UK and stored at room temperature. 
2.6.3. 11β-HSD1 Protocol 
Tissues were fixed in 10% formalin before embedding in paraffin wax.  Tissue cut to 3 
microns thickness were placed on microscope slides coated with poly-lysine coated or X-
tra adhesive (Surgipath, Peterborough, UK)  The sections were then dried in a 60ºC oven 
before dewaxing in xylene (Genta Medical, York, UK), rehydrating in 100% ethanol, 95% 
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ethanol and rinsed in water ready for immunohistochemistry.  Dewaxed and rehydrated 
sections were incubated with methanol hydrogen peroxidase (56.25:1 v/v) to block 
endogenous peroxidase activity.  The sections were rinsed in water, washed with 
phosphate buffered saline (PBS) and incubated with 10% normal donkey serum (NDS) in 
PBS before incubation with primary antibody (1:100 or 1:50 dilution of polyclonal 
antibody raised against human 11β-HSD1) in 10% NDS/PBS for 90 minutes at room 
temperature.  Negative control sections were incubated with 11β-HSD1 immunising 
peptide (Alta biosciences, Birmingham, UK) at 100 fold excess of antibody in 10% NDS 
in PBS.  The washes and incubation of antibodies was performed using the Shandon 
sequenza (Thermo Scientific, Pittsburg, PA, US).   
After incubation, slides were washed in PBS at least three times before incubation with 
secondary antibody (1:100 dilution of donkey anti-sheep IgG peroxidase conjugate from 
the Binding Site Limited, Birmingham, UK) for 30 minutes at room temperature.  The 
sections were washed in water prior to chromagen visualisation with 3, 3’-
Diaminobenzidine (DAB from Sigma-Aldrich Company Ltd, Dorset, UK) tablet dissolved 
in water (1mg/ml concentration).  The DAB was left to develop for the desired time which 
was usually between 5 and 15 minutes before being washed in water and counterstained 
with Meyer’s haematoxylin stain for 30 seconds and rinsed again.  The sections were put 
through a series of washes consisting of 100% ethanol and xylene before mounting on 
coverslips using DPX. 
2.6.4. 11β-HSD2 Protocol 
Dewaxed and rehydrated sections were put through an antigen retrieval process by placing 
sections in 0.01M citrate buffer (pH 6) and heating to 95°C using a hot water bath.  The 
sections were washed in water after cooling to room temperature. The slides were 
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incubated with methanol hydrogen peroxidase (56.25:1 v/v) to block endogenous 
peroxidase activity.  The sections were rinsed in water, washed with phosphate buffered 
saline (PBS) and then incubated with primary antibody (1:100 dilution of polyclonal 
antibody raised against human 11β-HSD2) in 10% NDS/PBS for 60 minutes at room 
temperature.  Negative control sections were incubated in 10% NDS in PBS without 
primary antibody.  The washes and incubation of antibodies was performed using the 
Shandon sequenza.  The sections were then rinsed in PBS and incubated with secondary 
antibody (1:100 dilution of donkey anti-sheep IgG peroxidase conjugate) for 30 minutes 
at room temperature.  The sections were then washed in PBS before visualisation.  
Visualisation of the sections was achieved by using DAB for between 10 and 15 minutes 
before being washed in water and counterstained with Meyer’s haematoxylin stain for 30 
seconds.  The sections were put through a series of washes consisting of 100% ethanol 
and xylene before mounting on coverslips using DPX. 
2.6.5. CD68 Protocol 
CD68 immunohistochemistry was also performed on inactive TAO, active TAO and 
control specimens.  The procedure was as follows: dewaxed and rehydrated slides were 
blocked with endogenous biotin for 10 minutes using the Zymed avidin/biotin blocking 
kit (Invitrogen Ltd, Paisley, UK).  All incubations and washes were performed using the 
Shandon sequenza (Thermo scientific, UK).  Antigen retrieval was then performed using 
tris buffered saline (TBS) and EDTA at pH 7.8 and a microwave at full power (900W) for 
15 minutes.  The sections were then allowed to cool to room temperature before being 
rinsed in water and incubated with primary antibody (CD68 clone PG-M1 1:100 dilution; 
Dakocytomation, Carpinteria, California) in normal swine serum (NSS) in TBS buffer 
(pH 7.8) for 60 minutes.  Negative control sections were incubated in TBS buffer without 
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primary antibody.  The positive control sections used were human tonsil tissue.  The 
sections were then washed in TBS buffer (pH 7.8) before incubating in Link reagent 
(Dakocytomation, Carpinteria, California) for 10 minutes.  The sections were then rinsed 
again in TBS buffer (pH 7.8) and then incubated with streptavidin reagent 
(Dakocytomation, Carpinteria, California) for 10 minutes.  Sections were then rinsed in 
TBS buffer (pH 7.8) before incubating with CheMate liquid DAB (DAB: substrate buffer, 
diluted 1:50; Sigma-Aldrich Company Ltd, Dorset, UK) for approximately 10 minutes.  
The sections were then washed in water before counterstaining with Meyer’s 
haematoxylin (Sigma-Aldrich Company Ltd, Dorset, UK) for 45 seconds.  The sections 
were washed again with water before processing through the last series of washes 
consisting of 100% ethanol and xylene.  Sections were mounted on to coverslips using 
DPX (BDH laboratory supplies, Poole, UK) and viewed under a light microscope.  
Photographs of the immunoreactivity from all immunohistochemistries performed and 
control sections were captured using the Olympus BHR-RFCA microscope (London, UK) 
and a Microfire camera (Optronics). 
2.7. Immunocytochemistry 
2.7.1. 11β-HSD1, 11β-HSD2 and Cytokeratin 3 Protocol 
NZWAR and human corneal epithelial cell suspensions were seeded onto chamber slides 
coated with poly-D-lysine (ICN Biomedicals) and collagen IV (ATCC) and grown until 
50% confluent. Cells were washed with PBS, and fixed in pre-cooled methanol by 
incubating for 10 min at -20°C followed by a further incubation in pre-cooled acetone at -
20ºC for 1 min. Fixed corneal epithelial cells were washed in TBS [3 x 5 min]. Cells were 
blocked with 5% normal donkey serum in TBS for 30 minutes at 37ºC in a CO2 incubator, 
and incubate with primary antibody (1:48 for NZWAR corneal epithelial cells and 1:24 
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for human corneal epithelial cells of mouse monoclonal anti-cytokeratin 3 (CK3) in 5% 
NDS (AE5 - ICN, Biomedicals); 1:24 for in-house generated human polyclonal anti-11β-
HSD1 and 2) at 37ºC for 1 hour.  Anti-CK3 is against specific 64K keratin found in 
corneal epithelial cells and limbal area of the cornea.  It was used to distinguish corneal 
epithelial cultures form other cell types (Schermer et al., 1986b).  Cells were washed in 
TBS [3 x 5 min] and incubated with secondary antibody (FITC labelled sheep anti-mouse 
(Binding site) for CK3 primary, donkey anti-sheep for 11β-HSD1 and 11β-HSD2 primary 
antibodies, all at 1:16 dilutions) at 37ºC for 30 minutes in a dark chamber.  Finally, cells 
were washed in TBS [3 x 5 min], and counterstained with Prolong Gold anti-fade reagent 
with DAPI (Molecular Probes) which shows the cells nuclei as blue. The resulting slide 
was then covered in foil and stored in the refrigerator until visualization using appropriate 
filters for DAPI and FITC. Control sections consisted of the use of no antibody or 
antibody pre-treated with immunising peptide (1:1).  Counterstained slides were viewed 
using an Olympus-BH2-RFC microscope (Olympus UK Ltd, Southall, Middx, UK) and a 
MicrofireTM - S99808 camera (Indigo Scientific, Baldock, Herts, UK). 
2.7.2. CD90 Protocol 
The fibroblasts (conjunctival and corneal) were seeded in chamber slides, with a two 
wells for positive and negative staining for each cell type.  Once about 50% confluent, the 
cells were fixed by incubating cells with 100 μl ice cold methanol (Sigma, Poole, UK) at -
20°C for 5 minutes.  Following this, the methanol was removed and 100 μl ice cold 
acetone (Sigma, Poole, UK) was incubated with the cells for 1 minute.  The acetone was 
evaporated and chamber slides stored at -20ºC until immunocytochemistry was 
performed.   
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At the time of staining, the chamber slide was allowed to equilibrate to room temperature.  
The fibroblasts were rehydrated with 100 μl PBS while shaking on an orbital shaker for 5 
minutes.  This was repeated three times.  The PBS removed and 5% donkey serum (DS, 
GibcoTM, Invitrogen Corp., Paisley UK) in PBS was added for 10 minutes.  The PBS 
was removed and 75-100 μl of CD90 (ASO2) primary antibody (Invitrogen, Paisley, UK) 
(1:100 dilution) was added to all the wells.  The negative control well contained 5% DS in 
PBS.  The chamber slides were kept at 4ºC for 24 h.   
The supernatant was removed from all of the wells and washed in PBS three times.  The 
secondary anti-mouse IgG1 antibody Alexa 633 anti-serum (75-100 μl) (Invitrogen, 
Paisley, UK), (1:100 dilution) was added to the wells of the chamber slide and incubated 
at room temperature on an orbital shaker.  After incubation, the plastic wells of the 
chamber slide were removed to leave the cells on the glass slide.  The cells were washed 
in PBS for 15 minutes.  All excess PBS was removed and the fibroblasts were 
counterstained with Hoechst nuclear stain (Invitrogen, Paisley, UK) for 2 minutes at room 
temperature.  The slide was washed again in PBS, for 15 minutes and after removing all 
excess PBS, a drop of 1, 4-diazabicyclo[2.2.2]octane (DABCO, Invitrogen, Paisley, UK) 
was added to each area of cells, and a coverslip was placed over the slide.  The glass slide 
was stored at -20ºC in the dark until visualisation or visualised immediately on a confocal 
microscope.   
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2.8. Histomorphometric Analyses of Human Orbital Adipose Tissue 
(HOAT), SC and OM Tissue Explants 
Paired samples of SC and OM adipose tissue were obtained from 8 patients undergoing 
elective laparotomy.  The control HOAT samples were taken from 14 patients undergoing 
lid ptosis or lid blepharoplasty, 15 quiescent HOAT (qHOAT) samples from patients 
undergoing procedures that include decompression surgery and 5 inflamed HOAT 
(iHOAT) samples.  Sections were cut and stained with haematoxylin and Eosin (H&E) 
and photographed in triplicate using an Olympus- BH-2-RFC microscope and 
MicroFireTM - S99808 camera.  The software package Image-ProR Plus (v4.0, Media 
Cybernetics) was used to analyse the adipocyte in the photograph.  This was achieved by 
processing the images using the green channel of the software to enhance edge 
prominence.  The software parameters were then optimized, in order to identify the visual 
edge of the cell membrane and generate an outline of the cell profiles for analysis.  The 
scaling factor was calculated by phographing a micro-grid of known dimension.  The 
descriptive variables that resulted were cell area, cell diameter, radius ratio (the ratio 
between the radius of the widest and the narrowest part of the cell), roundness, feret 
(dimensions are taken from a right angled rectangle drawn around the cell) and cell 
perimeter.  The statistics performed consisted of comparisons between groups using a 
nested general linear model (GLM) with a p value < 0.05 being significant using the 
software package MINITAB©.  The correlation function was used to calculate Pearson 
correlation coefficients.   
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2.9. Protein Assay 
2.9.1. Protein Extraction from Cells 
Cells which had grown to confluency and adhered to wells within 24 or 48 well plates 
were used to extract protein from.  Excess medium was removed from the cells and 
washed with PBS before extraction.  Cells were collected using distilled water (50μl, 
100μl, 150μl and 200μl for well surface areas of 0.75cm2, 2 cm2, 3.8 cm2, 9.6 cm2 
respectively) and the rubber end of an insulin syringe or a suitable sized cell scraper (BD 
Becton Dickinson UK Ltd, Oxford, UK) before transferring to a micro-centrifuge tube 
and centrifuging briefly.  The cell suspension was snap frozen in liquid nitrogen and 
thawed in a 37ºC water bath three times to disrupt the cells and release the protein.  The 
cell suspension was then centrifuged again for 1 minute before the supernatant was 
transferred to a fresh tube.  The protein was then used for a protein concentration 
determination assay before long-term storage at -80ºC. 
2.9.2. Detergent compatible (DC) Protein Assay 
Bovine serum albumin (BSA) standards (5μl each) obtained from Sigma-Aldrich 
Company Ltd (0mg/ml, 0.25mg/ml, 0.5mg/ml, 1.0mg/ml, 1.5mg/ml and 2mg/ml) were 
added in duplicate into a 96 well plate alongside  of protein samples (5μl each).  This 
range was used due to the nature of the protein found in the cells being of large 
concentration.  Reagent A (25μl) (Bio-Rad Laboratories Ltd, Hertfordshire, UK) and 
Reagent B (200μl) (Bio-Rad Laboratories Ltd, Hertfordshire, UK) were added to each 
well using an automated pipette and incubated at room temperature for 10 minutes.  The 
Bio-Rad protocol on the Victor3 1420 multilabel counter (Perkin Elmer, Wellesley, USA) 
was used to estimate the 680nm wavelength absorbance from protein standards and 
samples.  A standard curve was then plotted to estimate the protein concentration of 
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protein samples (Figure 2-2).  The equation derived from this standard curve was used to 
calculate the the protein concentration of the human and rabbit samples.  
 
Figure 2-2:  Protein assay standard curve. 
Graph displaying relationship between protein concentration and optical density 
at 690nm 
 
2.10. 11β-HSD Activity Assay 
2.10.1. Production of Tritiated Cortisone (3HE) 
Placental protein (1mg) was incubated with nicotinamide adenine dinucleotide (NAD) 
(10mM), 3HF (70Ci/mmol) and potassium phosphate buffer (0.1M) at 37ºC for 4 hours in 
a shaking waterbath.  The organic phase was evaporated at 55ºC under air using a sample 
concentrator.  The labelled steroids and unlabelled F and E standards used as markers 
were separated using a thin layer chromatography (TLC) plate (Fluka chemie GmbH, 
Buchs, Switzerland) and the mobile phase chloroform: ethanol (92:8).  The plate was 
scanned using a BioScan system 200 imaging detector which showed conversion of F to E 
to be at least 95% and the appearance of two peaks (F preceding E).   
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The appropriate region containing labelled E was marked using the markers and 
ultraviolet light as a guide.  The silica was then scraped and eluted in absolute ethanol 
before being vortexed, centrifuged and stored at 4ºC overnight.  The resultant supernatant 
was transferred to a fresh borosilicate tube and evaporated at 55ºC under an airflow using 
a sample concentrator and re-dissolved in 500µl absolute ethanol.  The synthesised 3H E 
was assessed for purity using BioScan imaging detector and diluted with ethanol as 
appropriate where 1µl gives approximately 2000 counts.  3HE was stored at -20ºC. 
2.10.2. Basic 11β-HSD Activity Assay 
Cells or tissue were placed in serum free medium for at least 2 hours before the assay.  
The assay mix for the assessment of oxo-reductase activity consisted of E (final 
concentration 100nM) and 3HE as a tracer in each well.  The assay mix for the assessment 
of dehydrogenase activity consisted of F (final concentration 100nM) and 3HF as a tracer 
in each well.  GE (5µM) was used in each well for the inhibition of 11β-HSD.  All assays 
were either in duplicate or triplicate and performed for a period of 24 hours.  Following 
the assay, steroid extraction from the assay medium was performed or the assay medium 
was stored at -20ºC. 
2.11. Steroid Extraction and Separation by Thin Layer Chromatography 
A mobile phase of chloroform: ethanol (92: 8 v/v) was prepared in a tank and allowed to 
equilibrate for 1 hour before use.  Steroid extraction of samples from 11β-HSD activity 
assay was carried out by the addition of 7ml dichloromethane per 1ml of sample.  The 
samples were shaken on an orbital shaker for 15 minutes before being centrifuged at 2000 
rpm for 5 minutes.  The aqueous layer was removed by aspiration and the remaining 
organic layer containing the steroids was evaporated under air flow at 55ºC for between 
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40-45 minutes using a sample concentrator.  The TLC plate was spotted with unlabelled 
cortisol and cortisone standards (1mg/ml solutions prepared in ethanol and stored at 4ºC) 
and was used as markers for the steroids extracted from samples.  The samples were re-
dissolved in dichloromethane (60μl) and applied to the TLC plate.  The TLC plate was 
placed in the mobile phase for 90-120 minutes and once dry, they were scanned using the 
BioScan system 200 imaging detector.  Figure 2-3 is an example of the TLC traces that 
are produced when plates are scanned by the Bioscan system 200 imaging detector.  
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Figure 2-3:  TLC traces 
Trace shows conversion of cortisone (E) to cortisol (F) (reductase activity), (A).  The next 
trace shows conversion of cortisol to cortisone (dehydrogenase activity), (B). 
Substrate conversion rate (picomole/milligram of protein/hour or pmol-1 mg-1 h-1) was 
calculated using the folloing equation:  
 ��% 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶100 � × ([𝑆𝑆] × 𝐶𝐶𝐶𝐶𝑣𝑣𝑣𝑣𝑣𝑣𝐶𝐶)� ÷ �𝑝𝑝𝐶𝐶𝐶𝐶𝑝𝑝𝐶𝐶𝐶𝐶𝐶𝐶𝑝𝑝𝐶𝐶𝑣𝑣𝐶𝐶  � = 𝐶𝐶𝑣𝑣𝑠𝑠𝑝𝑝𝐶𝐶𝑠𝑠𝑝𝑝𝐶𝐶 𝑐𝑐𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝐶𝐶𝑠𝑠𝑝𝑝𝐶𝐶   
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The % conversion is derived from the TLC trace.  The substrate concentration ([S]) in 
mmol/l is multiplied by the volume in millilitres (ml).  The protein in mg is derived from 
the protein assay as described in chapter 2.9.2.  The assay was performed over a 24 hour 
period. 
2.12. Proliferation Assay 
Cells were seeded in a 96 well plate and using a commercially available colorimetric 
assay for determining the number of viable cells over a given time period (CellTiter 96® 
AQueousOne, Promega Madison, WI) according to the manufacturer’s guidelines with 
appropriate control (no cells).  The CellTiter 96® AQueousOne solution contains a 
tetrazolium compound and electron coupling reagents that can bind to living cells and 
form a formazan product.  The absorbance reading of this fomazan product is directly 
proportional to the number of living cells, therefore dead or the existence of no cells will 
not produce absorbance readings.  Cells were co-incubated with cortisone, cortisol and 
vehicle in addition with the reagent for 1 h at 37ºC in a humidified 5% CO2 atmosphere.  
The absorbance reading was measured at 490nm to represent the number of living cell 
using a 96 well- ELISA plate reader.  Readings were performed in triplicate and the mean 
‘no-cell’ control reading was subtracted from the other values.   
2.13. DNA-Binding ELISA for Activated Glucocorticoid Receptor 
Glucocorticoid receptor (GR) DNA-binding activity was assessed using the TransAM GR 
transcription factor ELISA kit (Active Motif Europe, Rixensart, Belgium).  Human 
corneal epithelial SV40 immortalized cells were incubated with dexamethasone or LPS 
with or without RU486 for 1 hour in duplicate.  Nuclear extraction was performed using 
the manufacturer’s instructions which consisted of washing cells with ice cold 
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PBS/Phosphatase inhibitor buffer (PIB).  Cells were scraped into PBS/PIB before being 
transferred to a pre-cooled tube and centrifuged at 300 x g for 5 minutes.  The supernatant 
was discarded and the pellet was re-suspended into ice cold hypotonic buffer.  The cells 
were allowed to swell for 15 minutes before adding 10% Nonidet P-40 and vortexing for 
10 seconds.  Homogenate was centrifuged at 14,000 x g at 4°C for 30 seconds and 
supernatant discarded.  The pellet was re-suspended in complete lysis buffer before 
shaking on ice for 30 minutes.  The homogenate was centrifuged 14,000 x g for 10 
minutes at 4°C before the supernatant (nuclear extract) was stored at -80°C. 
The GR transcription assay was performed by incubating complete binding buffer and 
20μg nuclear extract in a 96 well plate with gentle agitation for 1 hour at room 
temperature.  HeLa nuclear extract (5μg) was used as a positive control and complete lysis 
buffer as a negative control.  Wells were washed with 1 x wash buffer and then incubated 
with GR antibody (1:1000 dilution) for 1 hour at room temperature before a further wash 
and incubation with HRP-conjugated antibody (1:1000) at room temperature for an hour.  
Wells were washed again and developed with developing solution for between 15-20 
minutes.  Stop solution was applied and the absorbance was read at 450nm within 5 
minutes on a Victor3 1420 multilabel counter (Perkin Elmer, Wellesley, USA). 
 
2.14. Statistics 
Data sets were tested for normality using the Kolmogorov-Smirnov test.  For data sets that 
were normally distributed, one-way ANOVA analysis was used and for data that was not 
normally distributed, non-parametric test such as Mann Whitney and Wilcoxon were used 
(SPSS for Windows Version 11.5.1, SPSS, Inc., Chicago, IL, USA, 2002 and Prism for 
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Windows Version 4.03c, GraphPad Software, Inc., San Diego, CA, USA).  Significance 
equal to or above 0.05 is represented by one star (*).  Significance equal to or above 0.01 
is represented by two stars (**) while significance equal to or above 0.001 is represented 
by three stars (***). 
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3. Chapter 3 
Expression and Functional Role of 11beta 
Hydroxysteroid Dehydrogenase in the Rabbit and 
Human Eye 
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3.1. Introduction 
Regulation of immune processes in the eye is essential for maintenance of the the 
anatomical and biochemical structures needed for correct function.  In light of this, 
understanding the pathogenesis of infectious diseases such as infectious keratitis and the 
immune processes that occur during immune privilege can assist in deciphering the role 
that 11β-HSD1 and cortisol may play in regulating inflammation.    
3.1.1. Infective Keratitis 
In infective keratitis, the corneal epithelial barrier is breached.  This can be caused by 
many factors which include poor sanitation, dry eye, trichiasis (in-grown eyelashes), 
entropion (eyelids fold inwards) contact lens wear, topical corticosteroid and antiviral use 
and ocular trauma (Wong et al., 2003).   
The actual prevalence of infectious keratitis is not known, however, the incidence of 
corneal ulceration per 100000 population per year is estimated to vary from 6.3 in Hong 
Kong and 11 in the USA with the incidence increasing six fold with contact lens wear 
(Lam et al., 2002, Erie et al., 1993, Thomas et al., 2007). 
Clinical features of infective keratitis involve corneal ulceration where an erosion appears 
on the corneal surface, abscess formation, perforation and intraocular inflammation which 
can appear as corneal plaques and may include anterior chamber inflammation and 
conjunctival vascular reaction (Garcia-Valenzuela and Song, 2005).  Without prompt 
treatment, the corneal scarring and endophthalmitis can lead to blindness. 
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3.1.2. Signalling Pathways for Pathogenic Bacteria 
The main pathogenic recognition receptor (PRR) pathways are RIG-like (RLR) that are 
involved in antiviral defences (Creagh and O'Neill, 2006), NOD-like receptor (NLR) 
which recognise specific cell wall components of bacteria (Sirard et al., 2007) and toll-
like receptor (TLR) pathways which recognise a whole host of pathogenic entities and 
will be discussed in further detail. 
Bacterial pathogens are equipped to try and evade actions of the host’s immune system 
and cause disease.  One such way is survival of pathogenic bacteria in macrophages.  This 
is achieved when the bacterium, mycobacterium tuberculosis, is able to produce a 
phosphatidylinositol analog to inhibit class III phosphoinositide 3-kinase which is 
involved in the maturation process of the phagosome for killing of the pathogen (Fratti et 
al., 2001).  As a consequence, the bacterium is not phagocytosed and causes an 
enhancement in the inflammatory process which increases inflammatory cytokine 
production and leads to tissue damage as more immune cells are recruited to the infection 
site.   
The cell wall of pathogenic bacteria can produce toxins which are pathogenic proteins that 
can damage or destroy the host cell when released.  These factors remain in the bacterial 
cell wall and do not cause disease until the bacterium is ultimately destroyed and the 
bacterial toxins are released.  This can result in septic shock as the toxins can mediate 
action of cytokines, complement factors and coagulation cascade factors (Wilson et al., 
2002, Verhoef and Mattsson, 1995).    
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3.1.2.1. Toll-Like Receptor (TLR) Signalling 
Gram-negative bacteria are first intercepted by the innate immune system via toll-like 
receptor (TLR) expression on the surface of the cornea.  There are 13 TLRs in mammals, 
where 11 TLRs are expressed in humans to date of which 10 are expressed on the surface 
of the cornea (Figure 3-1) which include TLR1-10 (Jin et al., 2007, Li et al., 2007, Wu et 
al., 2008, Wu et al., 2007, Jin et al., 2008).  TLR receptors are also expressed in other 
ocular tissues which include TLR4 in the bulbar conjunctiva, sclera and uvea, TLR1-5, 6 
and 9 in the retina and TLR1-6 in the conjunctival epithelium (Li et al., 2007, Chang et 
al., 2006).  Each receptor is assigned to recognise different microbial components for 
example TLR1 heterodimerises with TLR2 to recognise triacyl lipopeptide;  TLR2 is 
important in the recognition of peptidoglycans from gram-positive bacteria; TLR3 
recognises double stranded DNA from viruses; TLR5 recognises flagellin from 
flagellinated bacteria; TLR6 heterodimerises with TLR2 and can recognise di-acyl 
lipopeptides, TLR7 recognises synthetic compounds such as Imidazoquinoline; TLR8 
recognises single stranded RNA; TLR9 interacts with CpG DNA from viruses and TLR10 
has no known ligand to date (Takeda et al., 2003, Heil et al., 2004, Chang et al., 2006, 
Bell et al., 2007, Takeuchi et al., 2002).   
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Figure 3-1:  Toll-like receptors expressed in the human corneal epithelium. 
TLR1 recognises triacyl lipopeptide;  TLR2 is important in the recognition of 
peptidoglycans from gram-positive bacteria; TLR3 recognises double stranded 
(ds) DNA from viruses; TLR5 recognises flagellin from flagellinated bacteria; 
TLR6 recognises di-acyl lipopeptides, TLR7 recognises synthetic compounds such 
as Imidazoquinoline; TLR8 recognises single stranded (ssRNA) RNA; TLR9 
interacts with CpG DNA from viruses and TLR10 has no known ligand to date. 
TLR4 is important in the mechanism of interaction with Pseudomonas aeruginosa (PA), 
(Figure 3-2), since it recognises the lipopolysaccharide (LPS) component of gram 
negative bacteria.  The initiation of the innate immune response to PA involves 
opsonisation of LPS by lipopolysaccharide binding protein (LBP) which is recognised by 
the opsonic receptor CD14 expressed on the surface of the cornea (Wright et al., 1990, 
Song et al., 2001).  The LPS-LBP-CD14 complex is thought to activate TLR4.  However, 
the exact mechanism by which this occurs is not known.  Previous research has shown 
that expression of Myeloid differentiation 2 (MD2), a secreted glycoprotein which binds 
to the extracellular domain of TLR4, is thought to be important in the signalling pathway 
of TLR4 and binds to monophosphoryl lipid A of LPS (Shimazu et al., 1999, Fitzgerald 
and Golenbock, 2007, Nagai et al., 2002).  However, others have shown that this appears 
not to be essential for activation of TLR4 (Ohnishi et al., 2007, Visintin et al., 2006).  
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Figure 3-2:  LPS-TLR4 signalling pathway. 
(a) LPS interaction with CD14 with the help of LBP allows signal transduction to 
TLR4 with the aid of MD2, however, how this occurs is still not fully understood.  
(b) Activation of the MyD88 dependent pathway leads to phosphorylation and 
activation of IRAK4 which in turn activates IRAK1 to activate MAPK, TAK1.  
TAK1 ultimately leads to activation and release of NFκB from IκB.  (c) adaptor 
proteins TRAM and TRIF, associated with the intracellular domain of TLR4, 
activate IKKi/IKKε and TBK-1 kinases for the phosphorylation of IRF3 via the 
MyD88 independent pathway.  This leads to immunoregulatory of gene 
expression. (d) translocation of activated NFκB to the nucleus influences 
transcription of immunoregulatory components. 
Following binding, the TLR4 can initiate two major intracellular signalling pathways: the 
MyD88-dependent and TRIF-dependent (MyD88-independent).  The main role of the 
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TRIF-dependent pathway increases co-stimulatory molecules and type I interferons while 
in the MyD88-dependent pathway, there is increase in inflammatory cytokines such as IL-
6, IL-12 and TNFα. 
3.1.2.1.1 MyD88-Dependent Pathway 
In the MyD88 (myeloid differentiation factor 88) -dependent early pathway, both adaptor 
proteins, MyD88 and Mal (MyD88 adaptor-like protein) contain a death domain able to 
interact with the death domain of IL-1R associated protein kinase 1 (IRAK1), a 
homologue of Drosophila kinase Pelle (Wesche et al., 1997).  This kinase in turn 
hyperphosphorylates IRAK 1 whose activation leads to its interaction with another 
adaptor protein known as tumour necrosis factor associated factor 6 (TRAF6) (Medzhitov 
et al., 1998, Palsson-McDermott and O'Neill, 2004).  This protein associated with adaptor 
protein TAK-1 binding protein 2 (TAB2), activates a Mitogen-Activated Protein Kinase 
(MAPK) known as Transforming growth factor-β-activated kinase 1 (TAK1) which is 
associated with TAB1.  TAK1 activates other MAPK pathways which ultimately lead to 
the activation of nuclear factor kappa B (NFκB).  In order for this to occur, there is the 
assembly of inhibitory-binding protein κB kinase (iKK) complex comprising iKKα, iKKβ 
and the scaffolding protein iKKγ (NEMO).  This complex then phosphorylates the 
inhibitory-binding proteins κB (IκB) which causes its ubiquitination and degradation and 
the release of NFκB for its translocation to the nucleus for transcription of inflammatory 
mediators.   
3.1.2.1.2 MyD88-Independent Pathway (TRIF-Dependent Pathway) 
During the MyD88-independent late pathway, an adaptor protein TRAM, associated with 
the intracellular domain of TLR4, bridges TLR4 with TRIF to allow activation of IKKε 
and TANK-binding protein (TBK-1) kinases for the phosphorylation of interferon 
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regulatory factor 3 (IRF3) (Fitzgerald et al., 2003).  IRF3 translocates to the nucleus and 
binds to interferon-sensitive response elements to allow transcription of inflammatory 
genes which include IFN-β (Fitzgerald et al., 2003).  
3.1.3. Antimicrobial Products 
The lack of immune cells in cornea during normal function causes the cornea to be reliant 
upon other components of the innate immune system present in tear film and surrounding 
tissues to evade attack from potential pathogens.  Tears contain a range of potent 
antimicrobial products against Gram-negative and Gram-positive bacteria, fungi and some 
viruses.  These antimicrobial products include iron metabolism protein such as hepcidin 
and lactoferrin; S100 family proteins such as psoriasin; elastase inhibitors such as elafin; 
granulysin produced by T-cells; chemokines such as CCL20 and CXCL9 and the classical 
cationic peptides such as cathelicidins and defensins which are the best characterised 
(Kolls et al., 2008). 
3.1.3.1. Cathelicidins 
Cathelicidins are released from neutrophils, in addition to expression on the surface of the 
cornea and conjunctiva, and therefore are important the first line of defence against 
pathogens (Zhang et al., 2008).  Cathelicidins contain a highly conserved N-terminal 
domain with a less conserved C-terminal antimicrobial region which varies among 
different species (Gordon et al., 2005).  The only type of cathelicidin found in humans is 
hCAP18.  The cathelicidin, hCAP18, is cleaved by serine proteases to produce the 
antimicrobial peptide LL37.  In addition to microbial activity, LL37 acts as a 
chemoattractant for monocytes, T cells, neutrophils, and mast cells, stimulates mast cell 
histamine release, modulates dendritic cell differentiation, and stimulates IL-8 secretion 
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(Gordon et al., 2005).  LL37 has several roles on the cornea and these may include 
regulating the ocular surface immune response, direct killing of invading pathogens and 
wound healing (Gordon et al., 2005). 
3.1.3.2. Defensins 
Defensins are a group of small cationic peptides which is involved in the opsonisation of 
pathogens leading to their elimination.  Defensins can be categorised into three main 
groups: α, β and θ according to their distribution and spacing between cysteine residues 
and disulfide bridges which typically consists of three disulfide bonds and six cysteine 
rich residues (Ganz and Lehrer, 1994, Chen et al., 2006a).  Currently there have been six 
human alpha-defensins and at least twenty eight human beta-defensins found to be 
involved in innate immunity in humans (Chen et al., 2006a, Schutte et al., 2002).  The 
alpha-defensins (α) were originally uncovered in human neutrophil cells (Selsted et al., 
1985) which then lead to their identification in paneth cells (epithelial cells found in the 
intestinal gland) and other epithelia of the female reproductive tract (Chen et al., 2006a, 
Quayle et al., 1998).  Theta (θ) defensins were first isolated from both leucocytes and 
bone marrow from rhesus monkeys, and although humans possess genes for these 
proteins, they are unable to be translated due to an unexpected codon that truncates the 
protein. However, the possibility has not been ruled out that some individuals may have 
the ability to produce these proteins (Tang et al., 1999, Yasin et al., 2004, Nguyen et al., 
2003). 
Human Beta-defensin 1 (HBD1) was first revealed and isolated from human plasma in the 
mid 1990s (Bensch et al., 1995) and has since been found to be constitutively expressed in 
many tissues.  This was followed by the discovery of human beta defensin 2 in psoriatic 
scales (Harder et al., 1997) and other beta defensins 3-6 were exposed by the basic local 
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alignment search tool (BLAST) and lead to their detection in various tissues which 
included testis, heart, muscle, lung, kidney and epididymis (Chen et al., 2006a, Jia et al., 
2001).   
The defensins produced in the human eye include alpha and beta but theta expression has 
not been established.  Beta-defensin 2 has increasingly become of interest in the corneal 
epithelia since its recent find in the late 1990 (McNamara et al., 1999, Haynes et al., 
1999).  LPS from PA has been implicated in the up-regulation of human beta defensin 2 
in corneal epithelial cells (Figure 3-2) through the TLR4 signalling pathway (Maltseva et 
al., 2007) and its up-regulation may have importance in the re-epithelization of the 
corneal epithelium (McDermott et al., 2001) in addition to anti-bactericidal properties. 
3.1.4. Gram-Negative Bacterial Keratitis and Contact Lens Wear 
In the case of bacterial infections of the cornea (bacterial keratitis), contact wearers are 
the most susceptible where Pseudomonas aeruginosa (PA) (an aerobic, gram-negative 
bacterium), is responsible for at least 70% of cases (Liesegang, 1997).  The condition is 
usually characterised by corneal infiltration of polymorphonuclear (PMN) cells leading to 
corneal ulceration and stromal destruction (Kessler et al., 1977).  Diagnosis of this 
condition normally involves a comprehensive eye examination and diagnostic tests which 
include corneal cultures and biopsies.   
Treatments for bacterial keratitis include antibiotics and antimicrobial agents (e.g. 
gentamicin, cefuroxime and ofloxacin) and corticosteroids for inflammation.  In some 
cases, however, the intense inflammatory response mediated through chemokines and 
cytokines may not be responsive to these treatments with resultant corneal damage and 
loss of sight.   
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3.1.5. Structure of Gram-Negative Bacteria 
The structure of a gram-negative bacterium (Figure 3-3) can consist of the cell wall which 
contains numerous peptidoglycans chains and contain lipopolysaccharide (LPS) chains in 
the outer membrane of the cell wall.  Not all gram-negative have a cell wall but those that 
do include Pseudomonas and Salmonella.  The cell membrane and the cell wall contain 
endotoxins and exotoxins that can damage host cells.  Other features of the bacterium 
include the flagella, plasmid, the cytoplasm which contains the nucleic material and 
ribosomes.    
 
Figure 3-3:  Structure of gram-negative bacterium. 
Structure shows the cell wall, which is associated with the outer membrane that 
contains LPS.  The other features include flagella, plasmid, nucleic material and 
ribosomes.  (LPS, lipopolysaccharide; PBP, penicillin-binding proteins).  Picture 
taken frompaper by Mascaretti and collegues (Mascaretti, 2003).  
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3.1.6. The Potential Role of 11β-HSD1 in the Regulation of Bacterial Infectious 
Keratitis 
The toll-like receptor 4 (TLR4) signalling pathway involves interaction with foreign 
matter such as LPS which may lead to the up-regulation of immunoregulatory 
components such as NFκB.  Many compounds can interact in this pathway to alter the 
outcome of events following pathogenic attack.  Glucocorticoids such as dexamethasone 
have already been found to inhibit NFκB (Mukaida et al., 1994, Scheinman et al., 1995a), 
a transcription factor involved in inducing transcription of many inflammatory cytokines.  
Its inhibition is thought to be due to the glucocorticoids ability to increase the expression 
of inhibitory molecule IκBα which inhibits NFκB activation (Scheinman et al., 1995a).  
The LPS component of a pathogenic bacterium such as pseudomonas interacting with 
TLR4 on the surface of the cornea is already known to modulate the production of anti-
bacterial products (MacRedmond et al., 2005, Caterina Romano et al., 2009) and could 
possibly lead to the induction of 11β-HSD1 to initiate the local regeneration of cortisol by 
11β-HSD1 for anti-bacterial properties (Figure 3-4); however, this has not been proven as 
yet.  Pro-inflammatory cytokines such as IL-6 and TNFα may also induce 11β-HSD1 to 
generate more cortisol.  Both LPS and cytokines acting together may induce 11β-HSD1 to 
activate cortisol and in doing so, may contribute to the regulation of gene transcription of 
defensins such as  human beta-defensin 2 (HBD-2) and repression of pro-inflammatory 
cytokines while increasing anti-inflammatory cytokine synthesis. 
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Figure 3-4:  Diagram showing the effect LPS may have on 11β-HSD1. 
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 (a) LPS interaction with CD14 with the help of LBP allows signal transduction to 
TLR4 with the aid of MD2, however, how this occurs is still not fully understood.  
This leads to one of  two main pathways.  One is  (b) activation of  the MyD88-
dependent pathway involving the adaptor proteins MyD88 and Mal activating a 
series of kinases which inturn activate the IKK complex.  The IKK complex 
releases IκB for degradation and activates NFκB leading to (c) cytokine and  
antimicrobial peptide transcription.  The other pathway, (d) MyD88-independent 
pathway or TRIF dependent pathway involves the adaptor proteins TRAM and 
TRIF to activate IKKi/IKKε and TBK-1 kinases for the phosphorylation of IRF3.  
This leads to immunoregulatory gene expression.  We hypothesise that another 
pathway (e) involving LPS induction of 11β-HSD1 maybe involved in local 
generation of cortisol which binds to GR and the activated GR may regulate 
transcription of cytokines and other transcription factors such as NFκβ.   
Human studies have shown cortisol is present in aqueous humour (Stokes et al., 2003, 
Rauz et al., 2003a), but it is not determined whether this cortisol is ultrafiltrated from the 
blood stream or generated locally by 11β-HSD1.  It is hypothesised that cortisol is 
generated locally and is one of the intraocular protection components. 
3.1.7. The Potential Role of 11β-HSD1 in Immune Privilege 
Immune privilege, a state of immune protection without intense inflammation is required 
to sustain current functioning of the eye components such as the ciliary body and the 
cornea.  It is well publicised that cortisol and other immunomodulatory factors such as 
TGFβ contribute to immune privilege (Knisely et al., 1994, D'Orazio and Niederkorn, 
1998).  As previously mentioned (chapter 1.8.2), cortisol is found in aqueous humour in 
the anterior chamber of the eye.  This cortsol produced may be under the control of 11β-
HSD1 in the cilliary NPE. 
3.1.8. Aim 
The aims of this chapter will be: 
• To evaluate the cortisol generating pathways in rabbit cells and tissues 
• To evaluate the cortisol generating pathways in human cells and tissues 
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3.2. Methodology 
NZWAR liver, kidney, eye, and conjunctiva embedded in paraffin wax blocks were 
processed as described in chapter 2.6.1. Haematoxylin and eosin, 11β-HSD1 and 11β-
HSD2 staining were performed as described in chapter 2.6.2, 2.6.3 and 2.6.4  respectively.  
Human corneoscleral tissue was processed as described in chapter 2.6.1.  Dewaxed and 
rehydrated sections underwent immunohistochemistry for human 11β-HSD1 and 11β-
HSD2 as described in chapter 2.6.3 and 2.6.4.  Immunocytochemistry for 11β-HSD1 and 
2 was performed on primary human and NZWAR corneal epithelial cells as described in 
chapter 2.7.1.  Immunocytochemistry for CD90 was also performed on primary human 
corneal and conjunctival fibroblasts as described in chapter 2.7.2. 
Primary NZWAR corneal epithelial cells, corneal fibroblasts, conjunctival fibroblasts, and 
primary human corneal epithelial cells, corneal fibroblasts, conjunctival fibroblasts and 
the immortalized corneal epithelial cell-line were cultured as described in chapter 2.3.  
Total RNA extraction and reverse transcription was carried as on human ocular cells 
described in chapter 2.4.1.  Reverse transcription and PCR was carried out as described in 
chapter 2.4.2 and 2.5.1.  PCR primers used for reaction are detailed in Table 3-1.  Table 
3-1 also shows the amplification stages for each gene.  The primers for TLR4 produced 
four bands due to TLR4 consisting of many variants, the primers were designed by R and 
D to detect 4 of these variants which are specific to TLR4.  
The positive cDNA control for 18s, GR, 11β-HSD1 and H6PDH was primary human 
liver, for MR and 11β-HSD2 was primary human placenta, for IL-6, TNFα, IL-1β, CD14 
and TLR4 was LPS treated macrophages and the negative control was nuclease free 
water.  All primers except for TLR-4 (R and D systems, Abingdon, UK) were obtained 
from Alta Biosciences, Birmingham, UK. 
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Table 3-1: Primer sequences, annealing temperature, cycle number and 
product size for target genes 
Gene Primer sequence Annealing 
temperature 
(°C)  
PCR 
cycle 
Product size 
(bp) 
11β-HSD1 S: 5′-ACCAGAGATGCTCCAAGGAA-3′  
A: 5′-ATGCTTCCATTGCTCTGCTT-3′ 
60 30 411 
11β-HSD2 S: 5′-TGGAGGTGAATTTCTTTGGC-3′  
A: 5′-GGATTCTTTAGGCCAGGGTC-3′ 
55 30 774 
H6PD S: 5′-AGAAGCGAGACAGCTTCCAC-3′ 
A: 5′-GCTGCTGGGAAAAGAACAAC-3′ 
60 30 603 
GRα S: 5′-TCGACCAGTGTTCCAGAGAAC-3′ 
A: 5′-TTTCGGAACCAACGGGAATTG-3′ 
60 30 693 
MR S: 5′-AACTTGCCTCTTGAGGACCAA-3′ 
A: 5′-AGAATTCCAGCAGGTCGCTC-3′ 
60 30 450 
IL-6 S: 5′-TCAATGAGGAGACTTGCCTG-3′ 
A: 5′-GATGAGTTGTCATGTCCTGC-3′ 
60 30 261 
TNFα S: 5′-AGGCGCTCCCCAAGAAGACA-3′ 
A: 5′-TCCTTGGCAAAACTGCACCT-3′ 
60 30 556 
IL-1β S: 5′-TTCTCTTCAGCCAATCTTCAT-3′ 
A: 5′-TAGAGTGGGCTTATCATCTTTC-3′ 
60 30 630 
CD14 S: 5′ CACAGGACTTGCACTTTCCA 3′  
A: 5′ CTGTTGCAGCTGAGATCGAG 3′ 
51 30 507 
TLR4 Manufacturer’s specification (R and D 
systems) 55 30 529, 409, 362, 242 
HBD-2 
S: 5′ TTTGGTGGTATAGGCGATCC 3′ 
A: 5′ GAGGGAGCCCTTTCTGAATC 3′ 
58 30 182 
 
Human and NZWAR corneal epithelial cells, fibroblasts and corneal fibroblasts were 
assayed as described in chapter 2.10.2.  Following the assay, steroid extraction and thin 
layer chromatography (TLC) were performed as described in section 2.11.  Reductase 
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activity was measured by calculating the rate at which the cortisol is generated and in the 
case of dehydrogenase activity, the rate at which cortisone is produced.  For studying the 
effects of cytokines and LPS on human ocular cells, the primary cultured cells were 
incubated with either tumour necrosis factor alpha (TNFα, 10ng/ml) or Interleukin-6 (IL-
6, 10ngml) in serum-free media for 24 hours or 1μg/ml LPS for 48 hours.  These doses 
were considered as they have previously been documented to elicit a response in other 
protein expression in corneal epithelial cells (Li et al., 2001, Burbach et al., 2001).  The 
enzyme assay was then performed as described in 2.10.2 with addition of the following 
treatments in separate wells: TNFα (10ng/ml), IL-6 (10ng/ml), LPS (1µg/ml) and GE 
(5µM).  All assays were performed in duplicate.  Reductase activity was measured as 
mentioned in chapter 2.11. 
Proliferation assays performed on primary NZWAR corneal epithelial cells are described 
as in chapter 2.12.  Cells were assayed at 0h, 48h and 96h after co-incubation with 100nM 
cortisone or cortisol.  The DNA binding ELISA was performed on the immortilized 
human corneal epithelial cell-line as described in chapter 2.13. 
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3.3. Results 
3.3.1. Rabbit Studies 
3.3.1.1. Immunohistochemistry of the NZWAR Corneal Epithelium and 
Conjunctival Epithelium 
Initial experiments were carried out to confirm that the human specific 11β-HSD1 and 
11β-HSD2 antibodies were able to identify respective rabbit proteins.  The control tissues 
used for 11β-HSD1 and 11β-HSD2 immunoreactivity were the rabbit liver and the kidney 
respectively (Figure 3-5).  These controls identified 11β-HSD1 staining around the central 
vein in the rabbit liver and 11β-HSD2 around the collecting ducts of the kidney cortex 
(Kyossev et al., 1996) in a similar pattern to that seen in humans and thus confirmed 
reactivity of the antibodies.  When using the blast program (National Center for 
Biotechnology Information website), the human peptide (19-33 ammino acids) used to 
raise the 11β-HSD1 antibody in sheep was shown to have 100% homology with the 
rabbit.  
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Figure 3-5:  11β-HSD1 and 11β-HSD2 immunohistochemistry in human control 
tissues. 
11β-HSD1 immunoreactivity in NZWAR liver, localised around the central vein 
(A), 11β-HSD1 preabsorbed with immunising peptide liver control section (B), 
11β-HSD2 immunoreactivity with the cuboidal epithelium of the collecting tubules 
in the NZWAR cortex of the kidney indicated by arrows (C), no primary antibody 
control kidney section (D).  All at x 40 magnification (CV, central vein). 
Once species reactivity had been confirmed, staining experiments were then carried out 
on the NZWAR tissues.  Immunoreactivity was seen for 11β-HSD1 but not 11β-HSD2 in 
the NZWAR corneal epithelium and endothelium (Figure 3-6).   
CV 
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Figure 3-6:  Immunohistochemistry of the NZWAR cornea with 11β-HSD1 and 
11β-HSD2. 
Immunostaining for 11β-HSD1 in the NZWAR corneal epithelium (A) and NZWAR 
corneal endothelium (B). No primary was used as a negative control for the  
NZWAR corneal epithelium (C) and NZWAR corneal endothelium (D). No 
immunostaining for 11β-HSD2 was seen in the NZWAR corneal epithelium (E) or 
corneal endothelium (F).  All at x 40 magnification  
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11β-HSD1 but not 11β-HSD2 was also localised to the NZWAR conjunctival epithelium 
around the goblet cells (Figure 3-7). 
      
 
 
Figure 3-7:  Immunohistochemistry of the NZWAR conjunctival epithelium with 
11β-HSD1 and 11β-HSD2. 
11β-HSD1 immunoreactivity was seen in the NZWAR conjunctival epithelium  
around the arrowed goblet cells (A) No primary control section (B), 11β-HSD2 
immunoreactivity was not localised to the NZWAR conjunctival epithelium (C).  
All at x 40 magnification. 
 
A 
C 
B 
  139 
3.3.1.2. Primary Culture Analysis of NZWAR Corneal Epithelial Cells, 
Conjunctival Cells and Keratocytes  
A confluent monolayer of corneal epithelial cells with distinctive hexahedral architecture 
was seen between 7 and 14 days of culture (Figure 3-8).   
After approximately 14 days in culture, outgrowth of stellate shaped keratocytes could be 
observed from the central corneal explants (Figure 3-8).  NZWAR conjunctival fibroblasts 
demonstrated characteristic, elongated morphology (Figure 3-8). 
  
 
Figure 3-8:  Photographs of primary NZWAR ocular cells. 
Established NZWAR corneal epithelial cells after approximately 7-14 days in 
cultre (A), NZWAR keratocytes after approximately 14 days (B) and NZWAR 
conjunctival fibroblasts after approximately 3 weeks (C).   
A B 
C 
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3.3.1.3. Immunocytochemistry Analysis of NZWAR Corneal Epithelial Cells 
Corneal epithelial cell phenotype was confirmed by cytokeratin-3 immunofluorescence 
staining (Figure 3-9). These cells also expressed 11β-HSD1 (Figure 3-9) which was 
absent when 11β-HSD1 antibody was preincubated with immunising peptide (Figure 3-9). 
  
 
Figure 3-9:  Immunocytochemistry of primary NZWAR corneal epithelial cells 
with 11β-HSD1 and cytokeratin 3. 
Corneal epithelial cell-type was confirmed in primary cultures of NZWAR corneal 
epithelial cells using anti-cytokeratin (A). 11β-HSD1 was immunoreactivity was 
established in NZWAR corneal epithelial cells (B) when compared to the 11β-
HSD1 preabsorbed with immunising peptide control (C).  The blue staining 
represents the nucleus of the cells.  All pictomicrographs are taken at x 20 
magnification.              
A B 
C 
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3.3.1.4. 11β-HSD1 Activity Assays on NZWAR Primary Cells   
Specific enzyme assay performed on primary NZWAR corneal epithelial cells revealed a 
predominant 11β-HSD1 reductase activity (p<0.05) compared to dehydrogenase (Figure 
3-10).  The 11β-HSD1 reductase activity from NZWAR corneal epithelial cells was 
significantly reduced (p<0.01) by the non-specific 11β-HSD inhibitor, glycyrrhetinic acid 
(GE), however, GE did not reduce dehydrogenase activity significantly further (Figure 
3-10).  Conjunctival fibroblasts and corneal keratocytes showed zero conversion of 
cortisone to cortisol (reductase activity) or cortisol to cortisone (dehydrogenase activity).                                        
 
Figure 3-10:  Specific enzyme assays for 11β-HSD1 in NZWAR primary corneal 
epithelial cells. 
11β-HSD1 reductase activity (3.7±0.5 pmol mg-1 h-1) was significantly higher 
(p<0.01) compared to dehydrogenase activity (0.82±0.2 pmol mg-1 h-1) in NZWAR 
corneal epithelial cells.  This reductase activity was reduced sigficantly(p<0.05)  
by GE (2.1±0.3). There was no significant change in dehydrogenase actvity by 
GE. Data are expressed as means and error bars as standard errors of the mean 
(SEM). 
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3.3.1.5. NZWAR Corneal Epithelial Cell Proliferation 
NZWAR corneal epithelial cells were shown to proliferate from baseline in medium 
without addition of steroids (Figure 3-11).  However, there appeared to be at least a 50% 
reduction in cell divisions over a 96 hour period (p<0.01) when cells were co-incubated 
with either cortisone or cortisol.   
 
Figure 3-11:  NZWAR primary corneal epithelial cell proliferation assay. 
Cells co-incubated with cortisol or cortisone elicited a 50% reduction in 
proliferation of corneal epithelial cells compared to baseline values (n=3 rabbits; 
p<0.01). 
 
3.3.1.6. Immunohistochemistry of the NZWAR Ciliary Body 
 
11β-HSD1 but not 11β-HSD2 was localised to the non-pigmented epithelium (NPE) and 
not the pigmented epithelium (PE) of the NZWAR ciliary body (Figure 3-12).    
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Figure 3-12:  Immunohistochemistry of the NZWAR ciliary body with 11β-HSD1 
and 11β-HSD2. 
Immunostaining for 11β-HSD1 in the NZWAR ciliary epithelium (A) and 11β-
HSD1 preabsorbed with immunising peptide as a negative control (B).  No 
immunoreactivity for 11β-HSD2 was seen in the NZWAR ciliary epithelium (C) 
negative control (D).  All at x 40 magnification. (NPE, non-pigmented epithelium; 
PE pigmented epithelium). 
3.3.1.7. 11β-HSD1 Reductase Activity in NZWAR Ciliary Body Explants 
NZWAR ciliary body explants showed predominantly 11β-HSD1 reductase activity and 
this was significantly higher (p<0.01) than 11β-HSD1 dehydrogenase activity from this 
tissue (Figure 3-13). 11β-HSD1 reductase activity was significantly reduced (p<0.05) 
with a non-specific 11β-HSD inhibitor, glycyrrhetinic acid (Figure 3-13). 
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Figure 3-13:  Specific enzyme assay for 11β-HSD1 in NZWAR ciliary body. 
11β-HSD1 reductase activity (median 2.1 pmol mg-1 h-1 and range 1.25-2.8 pmol 
mg-1 h-1) was significantly higher  (n= 12 rabbits; p<0.01) when compared to 
dehydrogenase activity (median 0.87 pmol mg-1 h-1 and range 0.5-2 pmol mg-1 h-1 ) 
in NZWAR ciliary body explant.  The reductase activity was reduced significantly 
(n=12 rabbits; p<0.05) by GE (median 0.4 pmol mg-1 h-1 and range 0.2-1.2 pmol 
mg-1 h-1).  Data is expressed as medians with full range plots.  
3.3.2. Conclusion 
These data suggest that the rabbit corneal epithelium is able to generate cortisol from 
cortisone and maybe involved in the autocrine regulation of cortisol which may be 
important in ocular surface renewal.  The ciliary body generates intraocular cortisol via 
11β-HSD1 and may be a pivotal defence mechanism protecting the intraocular 
environment. 
After studying the pre-receptor regulation of glucocorticoids in the rabbit, I wanted to 
move on to look at human tissues and relate this to human ocular disease processes. 
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3.3.3. Human Studies 
3.3.3.1. Immunohistochemistry of the Human Cornea 
The control tissues used for 11β-HSD1 and 11β-HSD2 immunoreactivity were the liver 
and the kidney respectively.   Figure 3-14 shows the localisation of 11β-HSD1 in the liver 
and type 2 in the kidney compared to their negative controls.   
 
   
   
Figure 3-14:  Immunohistochemistry of the human control tissues with 11β-HSD1 
and 11β-HSD2. 
A B 
C D 
CV 
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11β-HSD1 immunoreactivity of human liver around central vein (A), 11β-HSD1 
preabsorbed with immunising peptide liver control section (B), 11β-HSD2 
immunoreactivity with cuboidal epithelium of the collecting tubules in the human 
kidney medulla indicated by arrows(C), no primary antibody control kidney 
section (D) all at x 40 magnification (CV, central vein). 
Although immunostaining was successful for the liver and kidney, this was not true for 
the human cornea except for immunoreactivity of the human corneal endothelium with 
11β-HSD1 (Figure 3-15).  However, 11β-HSD1 expression has previously been 
confirmed in the basal cells of the human corneal epithelium (Rauz et al., 2001).  
However, some staining of the endothelium by 11β-HSD1 was shown (Figure 3-15) 
which was also found by Rauz and walker in 2001.  No immunostaining for 11β-HSD2 
was found in the human corneal epithelium (Figure 3-15).    
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Figure 3-15:  Immunohistochemistry of the human cornea with 11β-HSD1 and 
11β-HSD2. 
Immunoreactivity for 11β-HSD1 was seen in the human corneal endothelium as 
shown by arrow (A) and compared to the 11β-HSD1 preabsorbed with immunising 
peptide as a negative control (B).  No immunostaining for 11β-HSD2 was seen 
from the human epithelium (C) compared to the no primary negative control (D) 
Pictures taken at x 40 magnification.  (a, corneal epithelium; b, corneal 
endothelium)  
3.3.3.2. Primary Culture Analysis of Human Corneal Epithelial Cell, 
Conjunctival Cell and Corneal Fibroblast Morphology  
Primary human corneal epithelial cells possess a distinctive rounded shape with a 
centrally positioned nucleus which is in contrast to corneal fibroblasts which have a 
a 
C D 
a 
b b 
A B 
  148 
stellate appearance and conjunctival fibroblasts which are elongated and spindled in shape 
(Figure 3-16).  The differing characteristics qualitatively distinguish these cultures. 
      
 
Figure 3-16:  Photographs of primary human ocular cells. 
 (A) Primary human corneal epithelial cells (x40 magnification) (B) Primary 
human corneal keratocyte (40 magnification), (C) Primary human conjunctival 
fibroblasts (x40 magnification). 
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3.3.3.3. Identification of CD90 (ASO2) in Primary Human Conjunctival 
fibroblasts 
The fibroblast marker, CD90 (ASO2) was used as a marker to distinguish fibroblast cells.  
Conjunctival fibroblasts were shown to express CD90 when compared to the negative 
control (Figure 3-17) but the technique used was not successful for corneal fibroblasts 
perhaps due to the concentration of the primary antibody (ASO2) not optimally found.  A 
remedy for this could involve adjusting the final concentration of the primary antibody to 
a higher or lower concentration. 
  
Figure 3-17:  Immunocytochemistry of primary human fibroblast cells with CD90 
(ASO2). 
 (A) Conjunctival fibroblasts staining for fibroblast marker CD90 on the surface of 
the cell (arrowed) and (B) negative control. 
 
A B 
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3.3.3.4. Identification of Cytokeratin 3 and 11β-HSD1 in Primary Human 
Corneal Epithelial Cells 
Anti-cytokeratin 3 antibodies were used to identify corneal epithelial cells in culture.  
11β-HSD1 immunoreactivity was seen in primary corneal epithelial cells while 11β-
HSD2 immunoreactivity was minimal when compared to negative controls (Figure 3-18).   
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Figure 3-18:  Immunocytochemistry of primary human corneal epithelial cells 
with 11β-HSD1 and 11β-HSD2. 
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 (A) Immunocytochemistry of PHCEC using an anti-cytokertin 3 conjugated to 
FITC,  (B) Anti-11β-HSD1 conjugated to Texas red fluorescein (C) both combined 
(D) Anti-11β-HSD2 conjugated to FITC (E) Anti-cytokeratin conjugated to Texas 
red and (F) with both combined.  Neagtive controls were no primary antibody (G) 
and 11β-HSD1 preabsorbed with immunising peptide (H).  The same light density 
and background was used when comparing the negative controls with the stained 
samples. 
3.3.3.5. Glucocorticoid-Related and Cytokine-Related Gene expression in 
Human Corneal Epithelial, Corneal Fibroblast and Conjunctival 
Fibroblast Cells 
All the glucocorticoid related genes involved in the pre-receptor regulation and detection 
(GR) of glucocorticoids (11β-HSD1, H6PD and GR) and MR but not 11β-HSD2 were 
found to be expressed in primary human corneal epithelial cells (PHCEC), (Figure 3-19).  
Expression of H6PD and GR were also found in immortalised human corneal epithelial 
cell-line (HCEC) but no mRNA expression of 11β-HSD1 and MR were found in this cell-
line (Figure 3-19).  11β-HSD1, H6PD and GR were also expressed in primary corneal and 
conjunctival fibroblasts (HCoF and HCF respectively) (Figure 3-19).  IL-6 and IL-1β 
were expressed in PHCEC but not TNFα (Figure 3-19).  IL-6 and IL-1β were expressed in 
the HCEC but no expression of TLR4 was evident.  TLR4 was shown to express four 
gene variants in PHCEC (Figure 3-19).  HBD-2 was found to be expressed in both 
PHCEC and HCEC (Figure 3-19).  IL-1β and IL-6 were expressed in PHCEC and HCF 
(Figure 3-19) but TNFα was not expressed. 
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Figure 3-19:  Gene expression in human ocular cell-lines. 
PCR panel showing (A) expression of genes in primary human corneal epithelial 
cells and the immortalized human  corneal epithelial cell-line.  TLR4 has four 
specific variants  (B) expression of genes in primary human corneal fibroblasts 
and conjunctival fibroblasts.  18s was used as the housekeeping gene control for 
the PCR reaction.  (11β-HSD1, 11beta-hydroxysteroid dehydrogenase 1; H6PD, 
Hexose-6-phosphate dehydrogenase; GR, Glucocorticoid receptor; 11β-HSD2, 
11beta-hydroxysteroid dehydrogenase 2; MR, Mineralocorticoid receptor; IL-6, 
Interleukin 6; TNFα, Tumor Necrosis Factor alpha; IL-1β, Interleukin 1 beta; 
CD14, HBD-2, Human beta defensin 2; PHCEC, primary corneal epithelial cells; 
HCEC, immortalized human corneal epithelial cell-line; HCF, human 
conjunctival fibroblasts; HCoF, human corneal fibroblasts). 
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3.3.3.6. 11β-HSD1 Reductase Activity in Human Corneal Epithelial, Corneal 
Fibroblast and Conjunctival Fibroblast Cells  
Specific enzyme assay on primary human corneal epithelial cells revealed a predominant 
reductase activity (P<0.001) compared to dehydrogenase (Figure 3-20).  Reductase 
activity was also found to exist in primary human corneal and conjunctival fibroblasts 
(Figure 3-20).  Reductase activity from human conjunctival fibroblasts was highest but 
this was found not to be statistically significant. 
 
Figure 3-20:  Specific enzyme assay for 11β-HSD1 in primary human ocular 
cells. 
11β-HSD1 reductase activity (n=3, 2.3 ±0.5 pmol mg-1 h-1) is significantly higher 
compared to dehydrogenase activity (n=3, 0.2±0.1 pmol mg-1 h-1) in human 
corneal epithelial cells (PHCEC).  Reductase activity was also found in primary 
corneal fibroblasts (HCoF, n=3;1.66±0.9 pmol mg-1 h-1) and conjunctival 
fibroblasts (HCF, n=3; 2.86±1.5 pmol mg-1 h-1).  There was zero 11β-HSD1 
dehydrogenase activity from HCoF and HCF.  Data are expressed as means and 
error bars as standard errors of the mean.   
3.3.3.7. 11β-HSD1 Reductase Activity in Human Corneal Epithelial Cells After 
LPS/Glycyrrhetinic Treatment 
Treatment of primary human corneal epithelial cells with LPS mimicked the effect of 
pathogenic attack and showed a significant increase in 11β-HSD1 reductase activity 
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(P<0.01) which was inhibited (P<0.01) when the cells were co-incubated with the non-
specific 11β-HSD inhibitor, glycyrrhetinic acid (Figure 3-21).  LPS treatment of the other 
human ocular cell-lines was not performed. 
 
Figure 3-21:  Specific enzyme assay for 11β-HSD1 in primary human corneal 
epithelial cells after LPS treatment. 
11β-HSD1 reductase activity (cortisone to cortsol conversion) in human corneal 
epithelial cells increases after LPS (n=3, 6.3±1.7 pmol mg-1 h-1) compared to 
untreated cells (n=3, 0.13±0.1 pmol mg-1 h-1).  GE treatment significantly reduced 
LPS effect on increased reductase activity from PHCEC (n=3, 1.2±0.1 pmol mg-1 
h-1). (LPS, Lipopolysaccharide; GE, glycyrrhetinic acid; PHCEC, primary human 
corneal epithelial cells).  Data are expressed as means and error bars as standard 
errors of the mean. 
3.3.3.8. 11β-HSD1 Reductase Activity in Human Corneal Epithelial Cells After 
Pro-inflammatory Cytokine Treatment 
Primary human corneal epithelial cells subjected to TNFα stimulation had no significant 
effect on increasing 11β-HSD1 reductase activity compared to untreated cells (Figure 
3-22).  However, IL-6 was able to significantly increase reductase activity (P<0.01) 
compared to untreated and TNFα stimulated cells (Figure 3-22).  TNFα increased 
reductase activity from primary corneal and conjunctival fibroblasts while IL-6 was not 
able to produce this effect (Figure 3-22).  The TNFα effect on primary human corneal 
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fibroblast reductase activity was significantly higher (P<0.05) than in primary human 
corneal epithelial cells (Figure 3-22).             
                  
 
Figure 3-22:  Specific enzyme assay for 11β-HSD1 in primary human ocular cells 
after TNFα and IL-6 treatment. 
Reductase actvity does not increase after treatment with TNFα (n=8, 1.1±0.4 pmol 
mg-1 h-1) but does significantly increase after IL-6 stimultion (n=8, 5.4±1.4 pmol 
mg-1 h-1, p<0.01) in primary human corneal epithelial cells compared to untreated 
(n=8, 1.4±0.5 1  pmol mg-1 h-1).  Primary human corneal fibroblasts reductase 
activity is increased after TNFα treatment (n=3, 4.6±0.9 pmol mg-1 h-1)  when 
compared to untreated cells (n=3, 1.7±0.5 pmol mg-1 h-1).  IL-6 treatment of 
primary human corneal fibroblasts exhibts a reduced reductase activity (n=3, 
1.1±0.1 pmol mg-1 h-1) when compared to untreated and TNF treated cells.  A 
significant increase in reductase activity is shown by human conjunctival 
fibroblasts (n=3, 11.6±10.1  pmol mg-1 h-1, p<0.05) when compared to untreated 
cells (n=3, 2.9±1.1 1  pmol mg-1 h-1).  There is a slight increase in IL-6 treatment 
when compared to untreated cells (n=3, 3.5±0.1 pmol mg-1 h-1).  Data are 
expressed as means and error bars as standard errors of the mean.   
3.3.3.9. DNA-Binding of Activated GR Assay 
The DNA-binding ELISA relies on specific double-stranded oligonucleotides binding to 
the activated transcription factor, which in this case is the GR.  DNA-binding was shown 
to occur after dexamethasone treatment in immortalised human corneal epithelial cell-line 
(Figure 3-23).  The cell-line was easily accessible compared to the primary cell-line and 
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the technique was used to confirm glucocorticoid interaction with the GR which maybe 
involved in negative regulation of pro-inflammatory cytokines (Scheinman et al., 1995b, 
Ray and Prefontaine, 1994, Auphan et al., 1995).  To ascertain whether a component of 
pseudomonas could also activate GR, LPS was used.  LPS did not significantly increase 
GR binding of DNA (Figure 3-23).  The use of the GR inhibitor, RU486 reduced DNA 
binding of the activated GR by dexamethasone but not LPS (Figure 3-23). 
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Figure 3-23:  GR binding in immortilized human corneal epithelial cells. 
(A) The use of RU486 significantly decreased GR binding to baseline after 
dexamethasone treatment (n=3, 0.35±0.01. (B) LPS treatment had no effect on GR 
activity and RU486 also had no effect.  (Dex, dexamethasone; LPS, 
Lipopolysaccharide).  Data are expressed as means and error bars as standard 
errors of the mean. 
3.3.4. Conclusion 
These data confirm that an autocrine regulation of cortisol exists in the human corneal 
epithelium and in human ocular fibroblasts.  IL-6 and TNFα have great effects on ocular 
11β-HSD1 and this may have implications for cortisol generation for modulating 
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inflammatory events.  GR activity was also confirmed in corneal epithelial cells which is 
important in conferring glucocorticoid action in inflammatory settings. 
I have characterised the pre-receptor regulation of glucocorticoids and the components 
involved in the process in human ocular surface (corneal epithelial cells, corneal 
fibroblasts, conjunctival fibroblasts) and rabbit ocular surface (corneal epithelial cells, 
corneal fibroblasts, conjunctival fibroblasts) and intraocular (non-pigmented and 
pigmented epithelium) tissues (Table 3-2).  Results of studies yet to be determined are 
mostly from the rabbit and this is a result of time pressures in pursuing studies in the 
human further.  The immunostaining results not obtained in the human ocular tissue and 
cells such as that in corneal fibroblasts and conjunctiva will need further optimization. 
  
  160 
Table 3-2: Summary table comparing 11β-HSD1 expression/activity in rabbit 
and human eyes 
 Rabbit Human 
Corneal Epithelial Cells   
RT-PCR ? + 
IHC 11β-HSD1 + +  
IHC 11β-HSD2 - - 
11β HSD 1 Activity Regulators   
LPS ? + 
IL-6 ? + 
TNFα ? + 
Proliferation + ? 
Corneal Fibroblasts   
RT-PCR ? + 
ICC CD90  ? ? 
11β-HSD1 activity - + 
Conjunctiva   
IHC 11β-HSD1 +  (epithelium) ? 
ICC CD90 (fibroblasts) ? + 
11β-HSD1 (fibroblasts) - + 
Ciliary Body   
IHC 11β-HSD1 + + 
11β-HSD1 activity + + 
Quantification of cortisol + + 
+, positive; -, negative; ?, unknown; IHC, immunohistochemistry; ICC, 
immunocytochemistry; 11β HSD 1/2, 11 beta hydroxysteroid dehydrogenase 1/2; RT-
PCR, reverse transcription polymerase chain reaction. 
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3.4. Discussion 
The confirmation of active 11β-HSD1 reactivating cortisol from cortisone in corneal 
epithelial cells suggests a role in the local production of glucocorticoids to orchestrate 
transcription of glucocorticoid receptor genes that maybe involved in corneal repair in 
addition to anti-inflammatory action against unwanted pathogen.  This must be tissue 
specifically controlled as too high a level of glucocorticoids have been shown to have 
adverse effect on their proliferation (chapter 3.3.1.5) when used at therapeutic levels.  
Synthetic glucocorticoids at high concentrations are known to inhibit the corneal wound 
healing process (Bourcier et al., 2000) and our data suggests that active glucocorticoid as 
well as reactivated glucocorticoid (cortisone to cortisol) reduces corneal epithelial cell 
proliferation. 
There was no expression of 11β-HSD2 in the corneal epithelium, corneal endothelium and 
corneal epithelial cells of the NZWAR which is in parallel with the human corneal 
surface; however, there was expression of 11β-HSD1 in the NZWAR corneal epithelium 
and endothelium which was also comparable in the human (Rauz et al., 2001).    This was 
achievable as the human peptide used to raise the 11β-HSD1 antibody possesses 100% 
homology to the rabbit. 
The choice of using the New Zealand White Albino Rabbit (NZWAR) as a model is 
weighted by the fact that it has previously been used in different studies concerning the 
ocular surface and the intraocular environment.  For example a study showing the use of 
rabbits in corneal wound healing involved using carboxymethyl cellulose to stimulate 
corneal epithelial wound healing on rabbit eye model in vivo (Garrett et al., 2008).  The 
corticosteroid hormone profile of the rabbit is also similar to humans (i.e. cortisol rather 
than corticosterone in rodents), (Szeto et al., 2004, Fuentes and Newgren, 2008).  Rabbits 
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have been used to study ocular mucosal surfaces, for example a study focused on the use 
of rabbit oral mucosal epithelial cells in the reconstruction of the corneal epithelium 
surface (Hayashida et al., 2005).  Rabbit models are also used to study ocular surface 
diseases and conditions such as keratitis, dry eye and keratoconjunctivitis (Thomas et al., 
2008, Oh et al., 2007, Guzek et al., 1998).    
Expression of glucocorticoid related and certain pro-inflammatory cytokine genes suggest 
that the human corneal epithelium may have the necessary apparatus to respond to a 
potential inflammatory stimulus.  Confirmation of CD14, HBD-2 and TLR4 gene 
expression in primary human corneal epithelial cells supports other literature on these 
findings that are involved in  the regulation of inflammation (Song et al., 2001, Terai et 
al., 2004, Li et al., 2007).   
Attempts to show localisation of 11β-HSD1 on the human corneal epithelium as 
confirmed by other reports (Rauz et al., 2001) failed and this maybe attributable to many 
factors which may include optimal staining parameters not being reached and human 
error.  In contrast to this, 11β-HSD1 staining in cultured human corneal epithelial cells by 
immunocytochemistry confirmed expression of 11β-HSD1 enzyme protein.  Confirmation 
of 11β-HSD1 in NZWAR corneal and conjunctival epithelium with human anti-11β-
HSD1 antibody reconfirmed the cross-reactivity between these two models and 
highlighted the potential for these cell types to locally generate cortisol. 
To check whether the 11β-HSD1 protein is active, specific enzyme assays were used to 
assess activity in cultured NZWAR and human corneal epithelial cells, corneal 
fibroblasts, conjunctival fibroblasts and NZWAR ciliary epithelium tissue (NPE and PE).  
Predominant activity was present in NZWAR NPE compared to PE.  This suggests that 
the NPE is responsible for the local generation of cortisol in this tissue which can have 
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intracrine and paracrine effects to regulate aqueous humour production possibly by 
regulating SGK and ENaC expression (Rauz et al., 2003b).  This is important because 
aqueous humour provides the components for immunoprotection in the eye and cortisol 
may aid in these processes. 
The predominant reductase activity from NZWAR and human corneal epithelial cells 
suggests the ability of these cells to take part in the pre-receptor regulation of 
glucocorticoids in intact cells at least in-vitro.  Other studies have confirmed predominant 
reductase activity in intact cells, for example, from liver, lung, and adipose tissue 
(Jamieson et al., 1995, Hundertmark et al., 1995, Bujalska et al., 1997) and therefore 
highlights the role 11β-HSD1 plays in regulating local cortisol levels in these tissues.  No 
activity of 11β-HSD1 was shown from NZWAR keratocytes and conjunctival fibroblasts 
which were in stark contrast to the human form of these cells which did exhibit reductase 
activity.  A possible explanation for this is that 11β-HSD1 may play a bigger role in 
human ocular surfaces compared to in the rabbit. 
TLR signalling pathways are important in the elimination of pathogenic bacteria on the 
ocular surface (Wright et al., 1990, Song et al., 2001).  LPS has been shown to bind to 
CD14 and TLR4 to induce expression of pro-inflammatory cytokines and HBD-2 
(Maltseva et al., 2007).  The upregulation of 11β-HSD1 activity by LPS in human corneal 
epithelial cells may represent the functionality of 11β-HSD1 to produce cortisol to 
modulate immune events.  LPS a component of bacterial cell wall has been shown to 
upregulate immune components that facilitate the inflammatory process such as pro 
inflammatory cytokines (e.g. IL-6 and TNFα) and activates the innate immune response 
via CD14 and TLRs on the ocular surface (Liang et al., 2007b, Wu et al., 2005, Sun et al., 
2006, Lu et al., 2006).  However, LPS is also known to induce immunomodulatory 
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components to regulate inflammation such as mucins to protect the mucosal barrier 
(Smirnova et al., 2003).  In light of these data, LPS may induce the immunomodulatory 
properties of 11β-HSD1 in ocular tissue by promoting cortisol generation.   
It was shown that the pro-inflammatory cytokine IL-6 and not TNFα was able to 
upregulate 11β-HSD1 reductase activity in human corneal epithelial and TNFα and not 
IL-6 upregulates 11β-HSD1 reductase activity in corneal fibroblast and conjunctival 
fibroblast cells.  IL-6 has been shown to upregulate 11β-HSD1 activity in adipocytes 
(Friedberg et al., 2003) while TNFα has been shown to up-regulate 11β-HSD1 activity in 
other cell systems such as glomerular mesangial cells of the kidney and in osteoblasts 
(Escher et al., 1997b).  However, these data may suggest that specific cytokines have cell 
specific roles in modulating 11β-HSD1 activity on the ocular surface. 
GR has been localised in ocular tissues which include the cornea, ciliary body, trabecular 
meshwork, lens, retina and sclera (Rauz et al., 2001, Suzuki et al., 2001, Mirshahi et al., 
1997, Stokes et al., 2000).  GR interaction with glucocorticoids is important for genomic 
mediated responses during inflammation (Chinenov and Rogatsky, 2007).  Studies have 
shown that GR agonists such as dexamethasone can activate the GR in-vitro (Takahashi et 
al., 2000, Wenzel et al., 2001).  The immortalized human corneal epithelial cell-line does 
not express 11β-HSD1 and therefore is not able to reactivate cortisol from cortisone.  
However, although the immortilized human corneal epithelial cell-line cannot be used to 
study 11β-HSD1 directly (unless the enzyme can be transfected into the cell-line), it is 
still useful for the study of other glucocorticoid related components such as GR and H6PD 
on the ocular surface.  GR expression was shown in the immortalized human corneal 
epithelial cells and although some GR activation was shown in the immortalized human 
corneal epithelial cells by dexamethasone, this was not as strong as what might have been 
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expected.  This may suggest that the assay used for these particular cells, was not 
optimally sensitive to detect increases in GR DNA-binding.  LPS had no effect on GR 
activity and therefore does not influence GR mediated transcription.   
With respect to intraocular defence, clinical studies have quantified cortisol in aqueous 
humour where diffusion or ultrafiltration has been postulated to be the main source of 
intraocular cortisol (Rauz et al., 2003a, Rauz et al., 2001).  This study shows conclusively 
that the ciliary body has the capacity to synthesise cortisol and may have an additional 
role in the regulation of protective systems such as Fas-L and human beta defensins 
contributing to intraocular defence. 
To conclude, the potential for pre-receptor regulation of glucocorticoids has been 
uncovered in both NZWAR and human model and the pre-receptor regulation that occurs 
may regulate ocular surface renewal and may serve to regulate ocular surface 
inflammation caused by bacterial pathogenic attack. 
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4. Chapter 4 
The Putative Role of 11beta Hydroxysteroid 
Dehydrogenase 1 in Orbital Adipose Biology 
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4.1. Introduction 
4.1.1. Orbital Inflammatory Disease 
Different immune-mediated diseases can affect the tissues of the orbit.  These can include 
Wegner’s granulomatosis (WG), sarcoidosis and Graves’ disease which is the main focus 
of this chapter.  However, a great proportion of orbital inflammatory disease are 
idiopathic (IOI) or non-specific orbital inflammation (Lutt et al., 2008).  WG is a systemic 
disease which causes necrotic inflammation to small and medium sized vessels, lungs, 
protrusion of the eyeballs and affects the nervous system, skin and mucous membranes 
(Kowalewska et al., 2008).   Sarcoidosis is an inflammatory disease which causes the 
appearance of granulomas in organs which include the lungs, lymph nodes, skin, liver and 
eyes and is of unknown aetiology.  In some cases the disease can be self-limiting however 
in other cases the disease may promote a progression to postgranulomatous fibrosis in 
affected areas (Nagai et al., 2008). 
4.1.2. Thyroid Associated Ophthalmopathy 
Thyroid associated ophthalmopathy (TAO) is a specific autoimmune disorder 
characterised by an increase in orbital adipose/connective tissue and extraocular muscles 
within the orbit (Kumar et al., 2004, Crisp et al., 2000, Bahn, 2003).  The condition more 
frequently occurs with patients that have autoimmune hyperthyroidism which can be a 
clinical feature of Graves’ disease, however, the condition can precede or follow Graves’ 
disease (Garrity and Bahn, 2006, Wiersinga and Bartalena, 2002).  The condition can also 
occur in hypothyroid and euthyroid patients. 
TAO can be diagnosed by carrying out assessments conducted by primary care 
physicians, general practitioners and specialists and the more severe cases are passed on 
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to specialised thyroid eye clinics for further assessment (Bartalena et al., 2008).  The 
disease severity that they assess for can be split into mild, moderate and severe as dictated 
by degree of proptosis, extraocular muscle involvement and presence of optic neuropathy 
(El-Kaissi et al., 2004).  Clinical activity-scoring (CAS) systems have been set up to 
assess disease activity where an example of this involves a point given to each of the 
following parameters: spontaneous retrobulbar pain, pain on eye movement, eyelid 
erythema, eyelid oedema, chemosis, conjunctival injection and swelling of the caruncle 
(Bartalena et al., 2000).  A score equal or greater than 4 indicate active ophthalmopathy 
(Bartalena et al., 2000).  Different types of orbital imagery can be used to assess the 
extent at which the orbit is affect by TAO and help eliminate doubt about the diagnosis.  
The types of imagery that can be used include, computed tomography (CT), magnetic 
resonance imaging (MRI) ultrasound (US) and Octreoscan (Kahaly, 2001). 
Other tests can be performed if there is suspicion of optic neuropathy and these can 
include perimetry and visual evoked potentials (El-Kaissi et al., 2004, Dickinson and 
Perros, 2001). 
TAO management, especially for severe cases, can include the use of 
immunosuppressants such as steroids/glucocorticoids.  The time period for which 
glucocorticoids are used is usually reduced sequentially dependent on the outcome 
measures (Cawood et al., 2004).  Radiotherapy became a controversial treatment in TAO 
due to doubts in the efficacy of its use as some trials mistakenly correlated that the 
improvements seen were due to the treatment and not the natural resolution of the disease 
(Prummel et al., 2004, Mourits et al., 2000, Gorman et al., 2001).  When radiotherapy is 
used in conjunction with a glucocorticoid, there is an improvement in diplopia, however, 
there is a 12-24 week delay in response to treatment therefore is unsuitable for individuals 
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suspected of optic neuropathy which needs to be treated within 48 hours to avoid 
irreversible blindness (Cawood et al., 2004, El-Kaissi et al., 2004).     
The option of surgery is only recommended when the condition may become sight 
threatening, is unresponsive to other interventions or for functional and cosmetic purposes 
and only occurs after TAO becomes ‘inactive’ or ‘burnt out’ (Cawood et al., 2004).  The 
types of surgery performed include orbital decompression, eye muscle surgery and eyelid 
surgery.  Eye muscle surgery is executed when patients are shown to have diplopia in 
normal gaze or reading position (El-Kaissi et al., 2004).  Eyelid surgery improves lid 
retraction (seen as the characteristic ‘stare’ in TAO) whilst orbital decompression surgery 
consists of relieving orbital content by either removing floor and medial orbital bony wall, 
or roof, lateral and anterior bony wall with some orbital adipose tissue at the same time 
(El-Kaissi et al., 2004).  
Graves’ disease is the most common form of hyperthyroidism (Khoo and Bahn, 2007).  In 
the normal thyroid, thyrotropin-releasing hormone (TRH) released from the hypothalamus 
stimulates thyrotropin (TSH) production from the anterior pituitary.  TSH then targets the 
follicle cells of the thyroid where iodine is combined with the amino acid tyrosine to form 
thyroxine (T4) and the active thyroid hormone, triiodothyronine (T3).  The levels of T3 and 
T4 can positively or negatively feedback on the hypothalamus-pituitary-thyroid axis.  The 
characteristic of the hyperthyroidism seen in Graves’ disease is increased levels of 
thyrotropin secondary to autoantibodies against thyroid antigens.  One of these thyroid 
antigens is the thyroid-stimulating hormone receptor (TSHR) which mediates active 
thyroid hormone action.  Thyroid-stimulating autoantibodies (TSAB) against the TSHR 
on thyrocytes of the thyroid mediate the heightened production of thyroid hormone 
(Akamizu, 2001). 
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Some patients with Graves’ disease do not experience ophthalmopathy, however, some 
may experience general lid lag, lid retraction and stare, all of which are features of TAO.  
Features of ocular involvement in Graves’ disease can be moderate or severe in nature 
(Figure 4-1) with experiences of chemosis, conjunctival injection (redness of the 
conjunctiva), periobital oedema (swelling of the eyelids) and pain (Bahn and Heufelder, 
1993).  However those with severe ocular disease are at risk of blindness due to 
compression of the optic nerve (Garrity and Bahn, 2006).   
 
Figure 4-1:  An example of the features in thyroid associated ophthalmopathy. 
(A) Female patient with moderate to severe proptosis and eyelid retraction.  (B) 
Seven months after orbital decompression and eyelid retraction surgery, there 
appears to still be some eyelid retraction but a 4mm reduction in proptosis.  (C) 
After additonal eyelid retraction surgery, intervention appears to improve 
appearance and gives residual eyelid retraction.  Taken from(Ben Simon et al., 
2005) 
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In addition to Graves’ disease, TAO can be associated with other forms of thyroid 
dysfunction which are very much less common and these include, hypothyroidism, a  
condition characterised by decreased circulating thyroid hormone, Hashimoto’s 
thyroiditis, which is an acquired form of hypothyroidism, most common in adolescence 
and euthyroid, where individuals have no apparent thyroid dysfunction but still have 
TSHR antibodies or thyroglobulin or thyroid peroxidase antibodies (Bahn, 2001, 
Demirbilek et al., 2007, Weetman, 1991, El-Kaissi et al., 2004). 
4.1.2.1. Epidemiology of Thyroid Associated Ophthalmopathy 
TAO is thought to affect an estimated 400,000 individuals in the United Kingdom (based 
on a population of 59 million people) with a prevalence of TAO in Graves’ disease at 25-
50% (Cawood et al., 2004).  Women are 5 times more likely to develop the condition 
when compared to men, however when men develop the condition, the condition is likely 
to be more severe, particularly with increasing age (Marcocci et al., 1989, Kendler et al., 
1993, Manji et al., 2006, Perros et al., 1993).   
There have been many susceptibility genes that have been proposed to be involved in 
TAO including human leukocyte antigen (HLA, 6p21.3) (Kendalltaylor et al., 1988), 
cytotoxic T-lymphocyte antigen 4 (CTLA-4, 2q33) (Vaidya et al., 1999), tumour necrosis 
factor (TNF, 6p21.3) (Kamizono et al., 2000), interferon gamma (IFNγ, 12q14) (Kaijzel et 
al., 1998), intracellular adhesion molecule-1 (ICAM-1, 19p13) (Kretowski et al., 2003) 
and thyroid-stimulating hormone receptor (TSHR, 14q31) (Bahn et al., 1994).  However, 
the results of these studies are not conclusive and need further replications with larger 
cohorts.  A recently discovered susceptibility gene, IL-23R, has been associated with 
several autoimmune diseases that include Crohn’s disease (Duerr et al., 2006), rheumatoid 
arthritis (Farago et al., 2008) and Graves’ disease (Huber et al., 2008). IL-23R is thought 
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to be involved promoting cell survival of Th1- derived cells and production of IL-17 
produced from Th17 cells that have been implicated in chronic inflammatory responses 
and tissue damage (Lankford and Frucht, 2003). 
Finally, another factor to affect progression of TAO is smoking.  It is actually considered 
to be the most important factor and has an independent association with ophthalmopathy 
as there is increasing evidence that individuals who smoke while being affected by 
Graves’ disease are more likely to have an increased risk of TAO compared to individuals 
that do not smoke (Vestergaard, 2002, Manji et al., 2006, Shine et al., 1990, Bartalena et 
al., 1989, Prummel and Wiersinga, 1993, Cawood et al., 2007). 
4.1.2.2. Pathogenesis of Thyroid Associated Ophthalmopathy 
Individuals with severe TAO are frequently found to have high levels of circulating 
thyrotropin receptor antibodies (Gerding et al., 2000).  The thyrotropin-stimulating 
receptor (TSR) has also been found to be expressed on orbital differentiating 
preadipocytes (Valyasevi et al., 1999, Crisp et al., 2000).  TSHR is considered to be a 
shared antigen in Graves’ disease and TAO but this is yet to be proven.  The events 
leading to progression of the disease process in TAO are considered to be quite complex 
and it may be the case that TSHR may be  involved in mediating cytokine role in TAO 
(Cawood et al., 2004).  Figure 4-2 shows an overview of the immune cells/mediators 
involved in the process of inflammation which can infiltrate orbital fibroblasts, 
preadipocytes, adipocytes and muscle cells in the pathogenesis of oedema, hyperplasia 
and hypertrophy that occurs in TAO.   
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Figure 4-2:  Overview of the mediators of inflammation and adipogenesis which 
may be involved in expanding of orbital fibroblasts and orbital 
adipocytes in orbital adipose tissue. 
1. Thyroid stimulating antibodies (TSAB) and TSH interact with the TSHR to 
activate orbital fibroblasts.  This increases cell growth and cortisol production 
which causes a change in morphology to orbital preadipocytes.  Preadipocytes 
release adipogenic factors such as PPARγ, leptin and adiponectin and cortisol and 
induces differentiation to mature-like adipocytes. 2. T and some B lymphocytes 
release cytokines such as IL-6 to increase glycosaminoglycan (GAG) and 
matrixmetalloproteinase production which cause muscle oedema. 3. Cytokines 
released from immune cells such as T lymphocytes increase preadipocyte 
proliferation and stimulate the differentiation process of preadipocytes to mature-
like adipocytes.  These actions ultimately result in the hyperplasia and 
hypertrophy of adipose tissue and oedma in muscle tissue that causes the clinical 
presentation associated with thyroid associated ophthalmopathy.    
4.1.2.2.1 Thyroid Stimulating Autoantibodies 
Reports have shown that TSHR antibodies are directed against orbital muscle and 
connective tissue, however, these antibodies are not restricted to these areas (Atkinson et 
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al., 1984, Kadlubowski et al., 1986).  Previous data has suggest that autoantibodies may 
play a main role in TAO and recently there has been data on a possible involvement of 
insulin-like growth factor 1 receptor (IGF-R1) activated by immunoglobulins (IgG) from 
Graves disease patients which mediates stimulation of activated T cell infiltration into 
inflammatory areas (Garrity and Bahn, 2006, Tandon et al., 1994).   
4.1.2.2.2 The Role of T Lymphocytes 
There is increasing evidence suggesting a role for activated T cells in the pathogenesis of 
TAO which include T helper/inducer (Th1 CD4+ cells) and T suppressor/cytotoxic (Th2 
CD8+ cells) which secrete certain cytokines that are involved in propagating the immune 
response, such as interleukin 2 (IL-2) from Th1 cells and IL-4 from Th2 cells (Otto et al., 
1996, Grubeckloebenstein et al., 1994, Heufelder and Bahn, 1993a, Xia et al., 2006, Bahn, 
2003).  Additionally, macrophages are increased in TAO orbital adipose tissue compared 
to those without TAO and this may be mediated by the increase of monocyte chemotactic 
protein 1 (MCP-1), (Chen et al., 2008). 
Adhesion molecules such as ICAM-1 (inter-cellular adhesion molecule-1), ELAM-1 
(endothelial cell leukocyte adhesion molecule-1), VCAM-1 (vascular cell adhesion 
molecule-1) and LFA-1 (lymphocyte function-associated antigen-1) stimulated by pro-
inflammatory cytokines aid the infiltration of lymphocytes and monocytes into the orbit 
during the progression of TAO (Heufelder and Bahn, 1993b, Ludgate and Baker, 2002).  
Furthermore, chemoattractants such as IL-6, IL-16, IL-8, RANTES (regulated on 
activation, normal T expressed and secreted) and MCP-1 are available to traffic CD4+ T 
cells into the orbit (Sciaky et al., 2000, Ludgate and Baker, 2002).  The CD40/CD154 
costimulatory pathway has been found to possibly induce the expression of IL-6 and IL-8 
in orbital fibroblasts (Ludgate and Baker, 2004, Sempowski et al., 1998).  When T cells 
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enter the orbit, the antigen presentation to these T cells by antigen presenting cells (APC) 
such as dendritic cells and macrophages is thought to be mediated through major 
histocompatibility complex (MHC) class II HLA DR antigen (Hiromatsu et al., 1995).  
The processing of antigen and presentation to lymphocytes could also involve heat shock 
proteins that have been shown to be expressed in severe cases of TAO orbital and 
pretibial fibroblasts (Heufelder et al., 1991, Heufelder et al., 1992b). 
4.1.2.2.3 Activation of Orbital Fibroblasts 
Activation of orbital fibroblasts during the course of TAO may undergo one of two 
pathways.  One involves production of prostaglandins that induce inflammatory 
cytokines, glycosaminoglycans (GAGs), in which hyaluronan dominates.  This causes 
GAGs to accumulate through the action of inflammatory cytokines such as leukoregulin 
(Smith et al., 1995b).  Matrix metalloproteinases (MMPs) then aid the movement of water 
into the orbital tissues which is the characteristic swelling seen with orbital fibroblasts and 
muscles cells implicated in the pathogenesis of TAO (Bahn and Heufelder, 1993, Wang et 
al., 1996, Smith et al., 1991, Kaback and Smith, 1999).  The ability of IFNγ to stimulate 
GAGs appears to be restricted to orbital fibroblasts, as the same effect is not seen in 
fibroblasts from the skin (Korducki et al., 1992).  Moreover, other inflammatory cytokines 
in addition to thyrotropin, growth factors and immunoglobulins, do not have an effect on 
GAGs whereas IL-1α and TGFβ are potent stimulators, suggesting a differential role of 
inflammatory mediators in TAO (Bahn, 2003). 
The other pathway of fibroblast activation during the inflammatory process in TAO could 
also involve a subset of fibroblasts known as preadipocytes undergoing a state of 
differentiation leading to adipogenesis (Sorisky et al., 1996, Crisp et al., 2000).    Their 
proliferation can also be stimulated by cytokines which include IL-4, IL-1α, IGF-1, TGFβ 
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and PDGF-1, but glucocorticoids can oppose this effect (Bahn and Heufelder, 1993).  In 
addition, there is an increase in expression of genes for leptin, adiponectin and 
peroxisome proliferators-activated receptor gamma (PPARγ) which are mediators and 
known markers of adipogenesis, within preadipocytes and differentiated adipocytes from 
TAO individuals, compared to unaffected individuals (Kumar et al., 2004).  Other subsets 
of orbital fibroblasts that exist in the orbit include Thy-1 positive (CD90) and Thy-1 
negative. These fibroblasts have an unknown function as yet, however, they  may have 
some role in mediating the inflammation seen in TAO (Smith et al., 2002, Laura Koumas, 
2002, Smith et al., 1995a).   
4.1.2.2.4 Smoking     
Smoking is associated with a poor prognosis for TAO and affects the incidence, severity 
and response to treatment of the disease (Thornton et al., 2006, Manji et al., 2006).  The 
dose response of cigarette smoking is found to strongly correlate with TAO where 
patients who are current heavy smokers develop more severe TAO (Bartalena et al., 1989, 
Pfeilschifter et al., 1996).  It has also been suggested that cigarette smoke may be 
involved in oxidative stress which has also been shown to correlate with disease activity 
of TAO (Tsai et al., 2008). Cigarette smoke increases GAG production and adipogenesis 
in an in-vitro model of TAO (primary cultures of orbital adipose tissue from TAO 
patients) and a correlation has been found with the increase in volume of connective tissue 
in certain parts of the orbit of TAO patients.  Extraocular muscle volume, however, is not 
affected by smoking in TAO patients (Cawood et al., 2007, Szucs-Farkas et al., 2005).   
4.1.2.2.5 Animal Models 
The development of an animal model to understand pathogenic mechanisms in TAO dates 
back to Smelser in 1936.  He reproduced signs of exophthalmos in guinea-pigs, first with 
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injection of pituitary extract and then a more severe case after thyroidectomy (Smelser, 
1936).   Other models include inserting TSHR primed T cells into BALBc (albino, 
laboratory-bred strain of the house mouse) and NOD (non-obese diabetic) mice, which 
produced thyroidtis (Many et al., 1999).  When their orbits were examined, the BALBc 
mice showed signs of adipose tissue accumulation and cytokine infiltration into the orbit, 
where as NOD mice and control BALBc mice appeared to have no eye pathology (Many 
et al., 1999).  
4.1.3. Hypothesis and Aims 
To date, no studies have evaluated the putative role of 11β-HSD1 in the pathogenesis of 
TAO.  It has already been found that macrophages express 11β-HSD1 and there is now 
evidence that TNFα can induce 11β-HSD1 activity and expression in subcutaneous and 
omental adipose tissue depots (Friedberg et al., 2003).   The increase in 11β-HSD1 
expression has already been linked to visceral obesity and the metabolic syndrome 
phenotype which consists of hypertension, insulin resistance and dyslipidaemia and 
involves the circulation of excess glucocorticoids as shown with the phenotype of 
Cushing’s syndrome (Wake & Walker, 2004).   
It may be possible that the release of other cytokines and growth factors released from 
immune cells such as macrophages may be involved in enhancing 11β-HSD1 mediated 
cortisol action.  This could therefore contribute to enhanced differentiation involved in the 
adipogenesis process which occurs in TAO human orbital adipose tissue (HOAT) This 
may include hyperplasia (orbital adipose tissue proliferation) and hypertrophy (increase in 
size of orbital adipose tissue).  As a consequence, direct or indirect inhibition (via the 
manipulation of inflammatory cytokines) of 11β-HSD1 may become a novel target for 
treatment of local adipose tissue inflammation  
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The research aims are therefore to: 
• Compare SC and OM and HOAT depots morphologically and with PCR of 
glucocorticoid genes, including 11β-HSD1, GR, H6PD and some cytokines and 
chemokines. 
• Study glucocorticoid activation in HOAT. 
• Compare normal control HOAT (cHOAT), (HOAT which has had no known 
previous inflammation) vs. quiescent HOAT (qHOAT), (HOAT that was 
previously inflamed but is no longer inflamed) vs. inflamed HOAT (iHOAT), 
(active inflammation) tissue morphologically and study transcription of 
glucocorticoid-related genes (11β-HSD1, GRα, H6PD), adipose tissue 
differentiation-related genes (fatty acid binding protein 4 - FABP4 and glycerol-
3-phosphate dehydrogenase - G3PDH), myeloid-related genes (Cluster of 
Differentiation 200 - CD200, CD123 and CD68), cytokine-related genes (IL-6, 
TNFα, TNFR, tumour necrosis factor- alpha induced protein - TNFαIP, IL-1β, 
IL-1R and transforming growth factor-beta - TGFβ), chemokine-related genes 
(chemokine (C-C motif) receptor 2 - CCR2 and chemokine (C-C motif) ligand 2 
- CCL2) and TSHR. 
• Compare 11β-HSD1 activity between preadipocytes from cHOAT tissue, 
qHOAT tissue and iHOAT. 
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4.2. Methodology 
The definitions of the samples used for the study are as follows: 
cHOAT = normal control human orbital adipose tissue.  These samples are taken from 
individuals that have no inflammation or TAO. 
qHOAT = quiescent human orbital adipose tissue.  These samples are taken from 
individuals that previously experienced TAO but have currently no clinical signs of 
inflammation. 
iHOAT = inflamed human orbital adipose tissue.  These samples are taken from 
individuals that are currently experiencing TAO and have clinical signs of inflammation 
which include exophthalmos (increased volume in the orbit which causes the eye to 
protrude from the eye socket), increased palpebral fissure width (separation between the 
upper and lower eyelids), conjunctival injection (non-uniform redness of the conjunctiva 
due to inflammation) and chemosis (swelling of the conjunctiva and the membranes lining 
the eyelids), (Yoon et al., 2009). 
Throughout the whole of the study a total of 136 HOAT samples were collected (Table 
4-1).  Table 4-1 shows the age range and median age of the participants in the study.  
There were more women in the study compared to men (58 men compared to 87 women). 
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Table 4-1: Sample demographics showing total number used for study, their 
age range and median age 
 Total cHOAT qHOAT iHOAT 
Number of Samples 136 66 51 17 
Age range (years) 24-93 26-93 24-80 34-81 
Median age (years) 61 69 52 56 
 
Orbital adipose tissues were processed as described in chapter 2.2.3.2 in preparation of 
immunohistochemistry, cell culture and RNA extraction.  Haematoxylin and eosin 
staining was performed on HOAT, SC and OM samples (chapter 2.6.2) while 
immunohistochemistry for CD68, 11β-HSD1 and 2 was performed on HOAT samples 
(chapter 2.6.3, 2.6.4 and 2.6.5).  CD68 counts on HOAT, SC and OM samples were 
achieved by visually counting the CD68+ cells in triplicate per slide for each adipose 
depot.  Histomorhometric analyses were performed on HOAT, SC and OM samples as 
described in chapter 2.8.  HOAT specimens were homogenised using a rotar-stator blade 
in a class 3 laminar flow cell culture hood.   RNA extraction and subsequent Real-time 
RT-PCR was performed on whole HOAT, SC tissue and OM tissue samples (chapter 2.4 
and 2.5.2).  Real-time RT-PCR analysis was carried out on the genes: FABP4, CD163, 
CD68, G3PDH, GRα, H6PDH, and 11β-HSD1, IL-6, TNFα, TNFR, TNFαIP, CD200, 
CCR2, CCL2, IL-1β, IL-1R, TGFβ and TSHR.   
Preadipocytes were cultured from HOAT samples (chapter 2.3.1.7) and differentiated as 
detailed in chapter 2.3.1.8.  The 11β-HSD activity assay was performed the cultured 
preadipocytes from HOAT and separate assays were performed where cultures were co-
incubated with either the cytokines TNFα (Peprotech, New Jersey), IL-6 (Peprotech, New 
Jersey), IL-1β (Peprotech, New Jersey) or TGFβ for 24 hours prior to carrying out 11β-
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HSD enzyme assay.  For assessment of proliferation, HOAT preadipocytes grown in a 96 
well plate were assessed on day 1 (untreated).  The cells were treated with 1μM cortisol 
(F) for 4 days and the cells untreated were assessed on day 4 of growth while the cells 
treated with 1μM cortisol (F) were also assessed on day 4 of growth.  The proliferation 
assay was performed as detailed in chapter 2.12.       
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4.3. Results 
4.3.1. Comparative Analysis of Orbital, Subcutaneous and Omental Adipose 
Tissue Depots 
4.3.1.1. Characterisation of Whole Tissue Adipose Morphology 
To compare whole cHOAT with subcutaneous (SC) and omental (OM) adipose tissue, a 
number of parameters were chosen to study differences in cell morphology.  These were 
cell area, minimum and maximum diameter, radius ratio, roundness, minimum and 
maximum feret (dimensions are taken from a rectangle drawn around the cell) and 
perimeter.     
  
  183 
Figure 4-3 shows an example of photographs of the three depots (SC, OM and HOAT) 
used for the histomorphometric analysis. 
        
 
 
Figure 4-3:  Haematoxylin and Eosin staining in human adipose tissue. 
 (A)  Human subcutaneous adipose tissue, (B) omental human adipose tissue, (C) 
normal control human orbital human adipose tissue. HOAT, human orbital  
adpose tissue.  All at x 40 magnification 
 
When comparing area amongst the different adipose tissue types, cHOAT area was 
significantly smaller when compared to subcutaneous (SC) adipose (Figure 4-4).  The 
cHOAT depot has a significantly lower maximum diameter (Figure 4-4), maximum feret 
(Figure 4-4), minimum feret (Figure 4-5), perimeter (Figure 4-5) and radius ratio (Figure 
4-5) when compared to SC adipose.  The measure of roundness showed that cHOAT 
appears to be significantly rounder when compared to OM (Figure 4-5).  When the 
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minimum diameter of cHOAT was compared to the other depots (SC, OM, qHOAT and 
iHOAT), there was no significant difference (Figure 4-4).  The cHOAT depot was not 
found to be significantly different in area, maximum diameter, minimum diameter, 
maximum feret, minimum feret, perimeter, radius ratio or roundness when compared to 
qHOAT and iHOAT.  These parameters from cHOAT were not significant when 
compared to OM except for roundness which was found significant.  Figure 4-4 A, B and 
Figure 4-5 B are different from figure 1 published in the paper Bujalska, 2007 due to 
different presentation of the values in the graph.  Figure 1 from the published paper 
Bujalska, 2007 refers to the means of the values for each of the parameters.  Figure 4-4 A, 
B and Figure 4-5 B was produced from a different data set and the graphs show the 
median value and the full ranges for the parameters in each HOAT, OM and SC tissue 
sample. 
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Figure 4-4:  Histomorphometic analysis of whole adipose tissue depots part 1. 
The cHOAT depot has significantly (p<0.05) smaller area (A), maximum diameter 
(B) and maximum feret when compared to SC (D).  The cHOAT was not found to 
be significantly different in minimum feret with  any of depots (SC, OM, qHOAT 
and iHOAT), (C).   Data in table shows the full ranges.  The median line for each 
parameter is shown on the graph.  OM, omental; SC, subcutaneous. cHOAT, 
control human orbital adipose tissue; qHOAT, queiscent control human  orbital 
adipose tissue; iHOAT, inflamed control human  orbital adipose tissue. 
cHOAT OM SC qHOAT iHOAT
cHOAT OM SC qHOAT iHOAT
cHOAT OM SC qHOAT iHOAT
cHOAT OM SC qHOAT iHOAT
* *
*
A B
C D
cHOAT OM SC qHOAT iHOAT
Area min 1620.99 1981.82 790.61 996.58 1604.69
max 4771.71 6325.23 6313.72 3938.06 4593.11
Max Diameter min 35.39 47.07 32.83 37.57 41.85
max 64.36 77.31 79.13 64.74 67.48
Min Diameter min 14.65 20.72 13.93 15.74 21.52
max 42.47 44.42 49.73 38.62 42.89
Max Feret min 37.01 48.03 34.06 39.08 43.03
max 65.37 79.66 81.25 65.92 68.72
n=5 n=16 n=9 n=8 n=15 n=5 n=14 n=9 n=8 n=14 
n=5 n=16 n=9 n=8 n=15 n=5 n=16 n=9 n=8 n=15 
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Figure 4-5:  Histomorphometic analysis of whole adipose tissue depots part 2. 
The cHOAT depot has significantly (p<0.05) smaller minimum feret (A), perimeter 
(B) and radius ratio when compared to SC (C).  The cHOAT was also significantly 
( p<0.05) rounder when compared to OM (D).   Data in table shows the full 
ranges.  The median line for each parameter is shown on the graph.  OM, 
omental; SC, subcutaneous. cHOAT, control human  orbital adipose tissue; 
qHOAT, queiscent control human  orbital adipose tissue; iHOAT, inflamed control 
human  orbital adipose tissue. 
cHOAT OM SC qHOAT iHOAT cHOAT OM SC qHOAT iHOAT
**A B
cHOAT OM SC qHOAT iHOATcHOAT OM SC qHOAT iHOAT
* *DC
cHOAT OM SC qHOAT iHOAT
Min Feret min 20.18 28.79 19.80 21.73 27.26
max 46.67 51.78 55.22 42.41 47.69
Perimeter min 107.47 134.47 102.18 113.24 127.76
max 185.70 223.18 225.38 183.67 194.87
Radius Ratio min 2.63 2.59 2.52 2.19 2.43
max 7.20 6.19 6.80 6.60 5.84
Roundness min 1.31 1.27 1.37 1.22 1.30
max 2.20 1.87 1.90 2.22 2.12
n=5 n=16 n=9 n=8 n=15 n=5 n=16 n=9 n=8 n=15 
n=5 n=16 n=9 n=8 n=15 n=5 n=16 n=9 n=8 n=15 
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4.3.1.2. Evaluation of CD68+ protein and mRNA In Human Control Orbital, 
Subcutaneous and Omental Adipose Tissue 
The CD68 antibody was used to identify CD68+ cells that could be representative of 
resident macrophages within adipose tissue.  CD68 positive (CD68+) cells were found in 
the thin stromal beds of the normal control HOAT samples, SC and OM adipose tissue 
samples (Figure 4-6).  When comparing the number of CD68+ cells in each adipose tissue, 
there is significantly (p<0.001) higher counts per field of view from cHOAT compared 
SC and OM (Figure 4-7).  Real-time RT-PCR analysis found that CD68 mRNA 
expression was significantly higher in cHOAT compared to SC and OM (Figure 4-8).   
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Figure 4-6:  Immunohistochemistry in human adipose tissue with CD68. 
CD68+ stained cells (arrowed) in cHOAT (A), SC adipose (B) and OM adipose 
(C).  cHOAT, control human  orbital adipose tissue; SC, subcutaneous; OM, 
omental.  All at x 20 magnification 
C 
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Figure 4-7:  Comparison of CD68+ cell count in human adipose tissue. 
Cell count of CD68+ stained cells revealed cHOAT as having the significantly 
(p<0.001) larger basal population of macrophages when compared to SC and 
OM.  Results displayed are medians with full ranges. cHOAT, control human  
orbital adipose tissue; OM, omental; SC, subcutaneous.   
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Figure 4-8:  Real-time RT-PCR analysis of CD68+in human adipose tissue 
depots. 
There is significantly higher expression (p<0.05) from cHOAT compared to SC 
and OM.  Results are expressed as fold change when compared to cHOAT and dCt 
and standard error of the mean (SEM) values are shown in table. 
4.3.1.3. Localisation of 11β-HSD1 in Control Human Orbital Adipose Tissue 
11β-HSD1 immunoreactivity is localised to the cytoplasm of control HOAT adipocytes 
(Figure 4-9).  The preabsorbed 11β-HSD1 antibody with immunising peptide was used as 
a control for the staining (Figure 4-9).  The positive control tissue used for this staining 
was human liver which was found centripetally around the central vein (Figure 4-9).  11β-
HSD2 immunostaining was also performed on cHOAT; however, no staining was found 
(Figure 4-9).  The positive control for this was human kidney where staining was found 
on many tubules of the kidney cortex (Figure 4-9). 
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Figure 4-9:  Immunohistochemistry in human control orbital adipose tissue and 
control tissues with 11β-HSD1 and 11β-HSD2 
Immunoreactivity for 11β-HSD1 (arrowed)  in cHOAT (x 40 magnification), (A), 
compared to negative control section which is 11β-HSD1 preabsorbed with 
immunising peptide (x 40 magnification), (B).  No 11β-HSD2 was found in cHOAT 
(x 40 magnification), (C) and negatve control (x 40 magnification), (D).  The 
positive control for 11β-HSD1 was human liver, (x 20 magnification), (E) and for 
11β-HSD2 was human kidney cortex, (x 20 magnification), (E).  cHOAT,  normal 
control human orbital adipose tissue.   Arrows represent examples of 11β-HSD1 
staining. 
C D 
E F 
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4.3.1.4. Evaluation of Glucocorticoid-Related and Marker of Adipogenesis-
Related Gene Expression in Whole Adipose Tissue Depots 
Real-time RT-PCR analysis of glucocorticoid-related genes (11β-HSD1, GR and H6PD) 
showed that basal levels of 11β-HSD1 and H6PD mRNA expression were significantly 
higher in SC (p<0.001 and p<0.05 respectively) and OM (p<0.001 and p<0.05 
respectively) compared cHOAT (Figure 4-10).  GR mRNA expression was significantly 
lower in SC (p<0.05) and OM (p<0.05) compared to cHOAT (Figure 4-10). 
 
Figure 4-10: Real-time RT-PCR analysis of glucocorticoid-related genes in 
human adipose tissue depots. 
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11β-HSD1 and H6PD mRNA expression is significantly higher in SC (p<0.001 
and p<0.05 respectively) and OM (p<0.001 and p<0.05 respectively) compared to 
cHOAT.  GRα mRNA expression is significantly lower in SC and OM compared to 
cHOAT (p<0.05).  Results are expressed as fold change when compared to 
cHOAT and dCt and standard error of the mean (SEM) values are shown in table.  
 
Real-time RT-PCR analysis of markers of differentiation genes (FABP4 and G3PDH) 
showed that basal levels of FABP4 and G3PDH were significantly higher in SC (p<0.05 
for both FABP4 and G3PDH) and OM (p<0.05 for both FABP4 and G3PDH) compared 
cHOAT (Figure 4-11). 
 
Figure 4-11:  Real-time RT-PCR analysis of adipogeneic-related genes in human 
adipose tissue depots. 
FABP4 and G3PDH  mRNA expression is significantly higher in SC (p<0.05 for 
both FABP4 and G3PDH) and OM (p<0.05 for both FABP4 and G3PDH) 
compared to cHOAT.  Results are expressed as fold change when compared to 
cHOAT and dCt and standard error of the mean values are shown in table. 
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4.3.2. Comparative Analysis of Control Orbital, Quiescent and Inflamed Orbital 
Adipose Tissue  
4.3.2.1. Characterisation of Whole Tissue Morphology  
When comparing cHOAT with qHOAT and iHOAT (Figure 4-12), there were no 
significant differences in the morphological parameters studied (area, diameter, perimeter, 
radius ratio, roundness and feret), (Figure 4-4 and Figure 4-5).   
 
  
Figure 4-12:  Haematoxylin and Eosin staining in human orbital adipose tissue. 
(A) control orbital adipose tissue (B) quiescent orbital adipose tissue and (C) 
inflamed orbital adipose tissue. 
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4.3.2.2. Evaluation of CD68 Positive Protein and mRNA in Human Control 
and Quiescent Orbital Adipose Tissue 
Two methodologies were employed to assess the relative levels of CD68 in orbital 
adipose tissue: cell staining and mRNA expression.  Using a specific antibody, CD68+ 
cells were localised to the stromal bed of qHOAT (Figure 4-13).   
 
Figure 4-13:  Immunohistochemistry in human orbital adipose tissue with CD68. 
Localisation of CD68+ (arrowed) in stromal bed of qHOAT.  qHOAT, queiscent  
human orbital adipose tissue at x 20 magnification.  
 
When control HOAT was compared with inactive TAO HOAT, there was also no 
significant difference in the number of CD68+ cells per area (Figure 4-14). 
A 
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Figure 4-14:  Comparison of CD68+  cell count in human orbital adipose tissue. 
 Cell count of CD68+ staining macrophages revealed no difference in macrophage 
populations between cHOAT and qHOAT samples.  Results displayed are medians 
with full ranges. cHOAT, control human  orbital adipose tissue; qHOAT, 
queiscent  human  orbital adipose tissue. 
When comparing CD68+ mRNA expression between cHOAT with qHOAT, expression 
was higher in inactive TAO HOAT but was found non-significant (Figure 4-15).   
 
 
 
 
 
 
 cHOAT qHOAT
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Figure 4-15:  Real-time RT-PCR analysis of CD68+in human orbital adipose 
tissue. 
CD68+ showed no significant difference in expression between cHOAT and 
qHOAT.  Results are expressed as fold change when compared to cHOAT and dCt 
and standard error of the mean values are shown in table. 
4.3.2.3. Localisation of 11β-HSD1 in Quiescent and Inflamed Human Orbital 
Adipose Tissue 
11β-HSD1 was localised to the thin film of cytoplasm in qHOAT cells compared to the 
negative control (preabsorbed 11β-HSD1 with immunising peptide), (Figure 4-16 and 
Figure 4-16).  Similarly to qHOAT, 11β-HSD1 immunoreactivity was also localised to 
the cytoplasm of the iHOAT cells when compared to its control (Figure 4-16 and Figure 
4-16).  The positive control tissue used for this staining was human liver (Figure 4-16). 
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Figure 4-16: Immunohistochemistry in human orbital adipose tissue with 11β-
HSD1. 
Immunoreactivity for 11β-HSD1 in qHOAT (A), compared to negative control (B) 
and 11β-HSD1 in iHOAT (C) compared to negative control section (D)  which 
was 11β-HSD1 antibody pre-absorbed with immunising peptide.  qHOAT, 
quiescent human orbital adipose tissue; iHOAT, inflamed human orbital adipose 
tissue.  Arrows correspond to examples of 11β-HSD1 staining.  All at x 40 
magnification. 
4.3.2.4. Immunohistochemistry with 11β-HSD2 in Quiescent and Inflamed 
Human Orbital Adipose Tissue 
There was no expression of 11β-HSD2 found in qHOAT and iHOAT (Figure 4-17) when 
compared to their negative control sections (Figure 4-17). 
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Figure 4-17: Immunohistochemistry in human orbital adipose tissue with 11β-
HSD2. 
11β-HSD2 immunohistochemistry showed no expression within qHOAT (A) vs 
negative control (B) and iHOAT (C) vs negative control (D). All at x 40 
magnification.  Negative control was no primary antibody. 
4.3.2.5. Evaluation of Glucocorticoid-Related Gene Expression and Marker of 
Adipogenesis-Related Gene Expression in Whole Orbital Adipose 
Tissue  
Real-time RT-PCR analyses revealed that qHOAT exhibited significantly higher 
expression of 11β-HSD1 when compared to cHOAT (Figure 4-18).  This was also true for 
the glucocorticoid related genes, H6PD and GRα (Figure 4-18).  There was significantly 
higher FABP4 expression, a known marker of adipogenesis in qHOAT compared to 
cHOAT.  Although higher expression was shown for the marker of adipogenesis, G3PDH, 
this was found not to be significant (Figure 4-19). 
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C D 
  200 
 
Figure 4-18: Real-time RT-PCR analysis of glucocorticoid-related genes in 
human orbital adipose tissues. 
qHOAT showed significantly higher 11β-HSD1 (p<0.05) , GRα (p<0.05) and  
H6PD (p<0.01) mRNA expression in qHOAT compared to cHOAT.  Results are 
expressed as fold change when compared to cHOAT and dCt and standard error 
of the mean values are shown in table. 
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Figure 4-19: Real-time RT-PCR analysis of adipogeneic-related genes in human 
orbital adipose tissue. 
FABP4 mRNA expression in qHOAT was significantly higher when compared to 
cHOAT.   G3PDH was higher in qHOAT compared to cHOAT but was found not 
to be significant.  Results are expressed as fold change when compared to cHOAT 
and dCt and standard error of the mean values are shown in table. 
 
4.3.2.6. Evaluation of Cytokine-Related Gene Expression in Whole Orbital 
Adipose Tissue 
There is higher expression of all of the inflammatory cytokine related gene expression 
(IL-1β, IL-R, IL-6, TNFα, TNFR, TNFαIP, TGFβ, CCL2, CD200 and TSHR) in qHOAT 
compared to cHOAT except for CCR2 where there was no expression in cHOAT or 
qHOAT (Figure 4-20). The significantly expressed genes in qHOAT compared to cHOAT 
were IL-1β (p<0.05), IL-6 (p<0.05), TNFα (p<0.05) and TGFβ (p<0.05). 
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Figure 4-20: Real-time PCR analysis of inflammatory-cytokine related gene in 
human orbital adipose tissue. 
There is significantly higher expression of IL-1β, IL-R, IL-6, TNFα, TNFR, 
TNFαIP, TGFβ, CCL2, CD200 and TSHR in qHOAT compared to cHOAT.  
However, there was no expression of CCR2 in cHOAT or qHOAT.  Results are 
expressed as fold change when compared to cHOAT and dCt and standard error 
of the mean values are shown in table. 
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4.3.3.  Comparative Analysis of Cultured Preadipocytes: Control Orbital 
Preadipocytes vs. Quiescent Orbital Preadipocytes vs. Inflamed Orbital 
Preadipocytes 
4.3.3.1. Analysis of Cultured Preadipocytes 
After attempting to culture 28 samples of qHOAT, 18 samples were successful and 
carried forward for enzyme activity studies compared to 15 out of 30 cHOAT samples and 
7 out of 13 iHOAT samples successful for the same enzyme activity studies.  Figure 4-21 
shows photographs of preadipocytes from HOAT cultured (A) and after 14 day of 
differentiation – termed ‘day 14’, where cells exhibited lipid droplets in the cell which are 
representative of mature-like adipocytes (B).   
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Figure 4-21:  Photographs of human preadipocyes before and after 
differentiation. 
Naive human orbital preadipocytes (A).  Cell phenotype changes to mature-like 
adipocytes filled with lipid droplets (arrowed) after differentiating in chemically 
defined media (B). 
4.3.3.2. Characterisation of 11β-HSD1 Activity in Human Orbital 
Preadipocytes 
Predominant 11β-HSD1 reductase activity (Figure 4-22) is exhibited by untreated 
preadipocytes from cHOAT when compared to dehydrogenase activity.  Preadipocytes 
from qHOAT and iHOAT also showed predominately reductase activity compared to 
dehydrogenase activity (Figure 4-22).  From the HOAT samples cultured for 
A 
B 
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differentiation for 14 days, 3 inflamed orbital preadipocytes, 11 quiescent orbital 
preadipocytes and 6 control orbital preadipocytes were successfully differentiated.   
An 11β-HSD enzyme assay performed showed that 11β-HSD1 reductase activity was 
higher after differentiation of the cells to mature-like adipocytes.  This increase was 
significant in the preadipocytes from cHOAT, qHOAT and iHOAT following 
differentiation (Control orbital preadipocytes, 1.1±0.13 pmol mg-1 h-1 day 0 vs. 2.17±0.11 
pmol mg-1 h-1 day 14, p<0.05; quiescent orbital preadipocytes, 3.05±0.15 pmol mg-1 h-1 
day 0 vs. 9.42±0.36 pmol mg-1 h-1 day 14, p<0.01; inflamed orbital preadipocytes, 
1.83±0.05 pmol mg-1 h-1 day 0 vs. 5.62±0.11 pmol mg-1 h-1 day14, p<0.05), (Figure 
4-22). 
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Figure 4-22: Specific enzyme assay for 11β-HSD1 in primary human orbital 
preadipocytes before and after differentiation. 
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(A) Predominant reductase activity was exhibited by control orbital  
preadipocytes, (B) quiescent orbital preadipocytes and (C) inflamed orbital 
preadipocytes.  This activity increased after differentiation of the preadipocytes 
(termed ‘day14’) to mature-like adipocytes.  (*, p<0.05; **, p<0.01; values 
represent means with error bars as standard error of the mean) 
The treatment of preadipocytes from qHOAT with IL-6, TNFα and TGFβ (Figure 4-23) 
showed an increase in 11β-HSD1 reductase activity compared to preadipocytes from 
cHOAT.  TNFα exhibited a significant increase in reductase activity in quiescent orbital 
preadipocyte, however, IL-1β failed to show an increase in quiescent preadipocyte 
(quiescent preadipocytes with TNFα, 8.32±2.2 pmol mg-1 h-1 vs. control orbital 
preadipocyte with TNFα, 2.16±0.18 pmol mg-1 h-1, p<0.01). 
 
Figure 4-23:  Specific enzyme assay for 11β-HSD1 in primary human orbital 
preadipocytes before and after cytokine treatment. 
11β-HSD1 reductase activity after cytokine treatment.  11β-HSD1 reductase 
activity increased by IL-6, TNFα and TGFβ in preadipocytes from qHOAT when 
compared to preadipocytes from cHOAT.  IL-1β did not increase 11β-HSD1 
reductase activity in quiescent preadipocytes, however, TNFα had a significant 
effect on quiescent preadipocyte 11β-HSD1 reductase activity when compared to 
preadipocytes from cHOAT (**, p<0.01; values represent means with error bars 
as standard error of the mean).  
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4.3.3.3. Human Orbital Preadipocyte Proliferation  
There was a significant increase in the number of control orbital preadipocytes following 
4 days in culture (day 1, 0.09±0.02 vs. day 4, 0.19±0.03, p<0.05).  The proliferation of 
control orbital preadipocytes did not significantly increase further after the addition of 
cortisol (Figure 4-24).  Quiescent orbital preadipocytes also underwent proliferation at 
approximately the same rate as the control orbital preadipocytes (day 1, 0.18±0.05 vs. day 
4, 0.37±0.07, p< 0.05) and this proliferation was significantly reduced upon co-treatment 
with cortisol (day 4 untreated, 0.36±0.08 vs. day 4 + cortisol, 0.31±0.07, p<0.05), (Figure 
4-24). 
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Figure 4-24:  Human orbital preadipocyte proliferation. 
(A) Control orbital preadipocytes demonstrated a significant increase in cell 
number following 4 days in culture.  This increase was not altered by treatment 
with 1μM cortisol.  (B) Preadipocytes from qHOAT underwent significant 
proliferation from day 1 to day 4.  This increase in cell number by day 4, was 
significantly reduced by co-incubation with cortisol  (*, p<0.05;  values represent 
means with error bars as standard error of the mean). 
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4.4. Discussion 
In light of the knowledge that adipose tissue from different depots possess differing 
adipocyte biology and glucocorticoid metabolism (Goedecke et al., 2006), this chapter 
sought to investigate the morphological and biological differences between SC, OM and 
HOAT depots.  The novel reproducible automated method for the histomorphometric 
analysis of adipose tissue from different depots has allowed us to note the adipose cell 
characteristic differences in a quantitative manner.  The method revealed that cHOAT 
adipocytes are generally smaller than SC and OM adipocytes and cHOAT adipocytes 
expressed lower levels of adipocyte differentiation markers (FABP4 and G3PDH).  
Histomorphometric analysis of qHOAT and iHOAT revealed no significant difference in 
morphological parameters when compared to cHOAT suggesting that they are of similar 
size and shape. 
The three adipose depots, SC, OM and cHOAT all expressed GRα mRNA as previously 
found in other studies (Heufelder et al., 1992a, Burnstine et al., 1998, Muhlberg et al., 
2000, Boullu-Ciocca et al., 2003), however this was much higher in cHOAT.  In addition 
to this data, I defined 11β-HSD1 activity and mRNA expression along with its regulatory 
enzyme, H6PDH in cHOAT and qHOAT tissue and preadipocytes.  These observations 
highlight that HOAT is distinct from SC and OM as each depot has differing propensities 
of adipocyte differentiation, proliferation, apoptosis and lipid metabolism (Niesler et al., 
1998, Baglioni et al., 2009, Mito et al., 2009, Lundgren et al., 2008, Tchkonia et al., 
2005).   
Orbital fibroblasts are known to have defining characteristics such as expression of 
surface receptors, cellular proteins (such as orbit specific (OS) proteins, cytokine 
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responsive  proteins (CRP) and actin neighbour proteins (ANP)), (Young et al., 1998), 
response to cytokines and the ability to secrete matrix proteins (Smith and Smith, 2004, 
Ajjan et al., 2004, Prabhakar et al., 2003).   
The higher CD68+ cells and CD68 mRNA in cHOAT compared to SC and OM is 
important because the cytokines they produce may have effects on adipocyte biology.  In 
addition to this, these data reflect an orbital molecular environment that has an increased 
potential and plasticity that is vital to combat inflammatory, immune-mediated or 
infective insult.  Recent studies have shown that chronic inflammation activates adipose 
tissue in simple obesity which is defined by an increase in CD68+ macrophages, increased 
adipocyte size and increased TNFα in patients with high BMIs (Weisberg et al., 2003, 
Neels et al., 2006, Pietilainen et al., 2006).   
There is a great deal of heterogeneity in monocyte-derived lineages (such as 
macrophages) and these different subsets from monocytes have specific roles in 
physiology.  For example, when adipose tissue increases during weight gain, this causes a 
range of signalling pathways to activate the adipose vascular stromal fraction thus 
allowing monocyte migration into the adipose tissue via the endothelial layer where they 
differentiate into macrophages (Neels et al., 2006). No significant difference in CD68+ 
cell number or mRNA expression between cHOAT and qHOAT suggests this is 
confirmatory of the non-inflamed status of qHOAT.  
Crosstalk between adipocytes, macrophages and endothelial cells aggravates the 
inflammatory state, resulting in increased secretion of pro-inflammatory 
cytokines/chemokines, adipokines and angiogenic factors (Lolmede et al., 2003, Trayhurn 
et al., 2006, Neels et al., 2006, Hutley et al., 2001). Furthermore, the interaction of 
cytokines and glucocorticoid metabolism may be an additional contributing factor.  TNFα, 
  212 
IL-6 and IL-1β are potent inducers of 11β-HSD1 expression and activity in adipose tissue 
(Friedberg et al., 2003, Tomlinson et al., 2001b).  Macrophage-derived cytokine 
production in vivo may serve to augment cortisol generation through induction of 11β-
HSD1.  
TNFα specifically, in addition to modulating 11β-HSD1 activity, can potentially inhibit 
adipocyte differentiation and promotes apoptosis and de-differentiation (Torti et al., 1989, 
Tejerina et al., 2009, Domingo et al., 2005).  This process may be of considerable 
relevance to the orbital fat microenvironment as the high macrophage content and the 
increased expression of IL-6, IL-1β and TNFα in HOAT maybe regulating adipocyte 
biology.  For example, qHOAT is the status which represents clinically non-inflamed 
HOAT and as a consequence, the increased expression of TNFα maybe an indicator of a 
once inflamed tissue.  
TGFβ inhibits TSHR expression and adipogenesis by orbital fibroblasts, which would 
indicate favourably towards disease remission and its is presumed that these inhibitory 
and stimulatory cytokine effects occurring simultaneously within the orbit maybe 
contributing to the severity of TAO (Bahn and Bahn, 2002). Therefore, the only slight 
increase in TGFβ expression from qHOAT compared to cHOAT may suggestive of 
disease remission in qHOAT.  
The expression of other chemokines such as CD200 and CCL2 maybe of interest, for 
example, CD200, the myeloid cell regulator, exhibited an expression slightly higher in 
qHOAT compared to cHOAT.  This maybe involved in regulating myeloid immune cell 
infiltration into qHOAT which may include macrophages.   
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With respect to MCP-1 (CCL2), this was also increased in qHOAT compared to cHOAT.  
MCP-1 has a significant part to play in TAO due to its involvement in macrophage 
infiltration into the tissue.  MCP-1 has already been characterised in adipose tissue from 
obese individuals and is also linked to the Th2 chemokine (Karpus et al., 1997, Chen et 
al., 2008).  One study by Chen et al, 2008, found a correlation between MCP-1 and the 
degree of infiltration of macrophage into the HOAT of Graves’ individuals (Chen et al., 
2008).  This may indicate that MCP-1 may well be an important mediator of lymphoid 
cell interactions with HOAT in TAO individuals.  The lack of expression of the receptor 
for MCP-1, CCR2 in orbital adipose tissue may suggest that CCL2 from orbital adipose 
tiisue may be recruiting macrophages by interacting with CCR2 on macrophage surface. 
Studies have shown that there is increased expression of the TSH receptor on both 
preadipocytes and differentiated adipocytes derived from primary cultures of orbital 
adipose tissue taken from patients with TAO when compared to controls (Crisp et al., 
2000).  TSH receptor gene expression in TAO preadipocytes, however, is inhibited by 
cytokines such as TNFα, IFNγ and TGFβ.  Downstream TSH-dependent cAMP 
production is also decreased.  In addition, TNFα and IFNγ attenuate morphological 
adipocyte maturation, indicating that TSH receptor expression may not be essential for 
adipogenesis, but may be a characteristic feature of mature differentiated adipocytes 
(Valyasevi et al., 2001).  However, increased positive correlations between expression of 
TSH receptor mRNA and obesity-related markers (leptin, adiponectin, PPARγ) are also 
seen in TAO fibroblasts compared with controls (Kumar et al., 2004).  We confirmed 
TSHR is expressed in HOAT and therefore these data suggest de novo adipogenesis 
within orbital tissues in patients with TAO. 
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Glucocorticoids are essential for adipocyte differentiation (Hauner et al., 1987), inhibit 
omental preadipocyte proliferation (Tomlinson et al., 2002), but interestingly, promote 
proliferation in the SC depot (Bader et al., 2002).  Previous data has shown that 
fibroblasts can be differentiated to mature-like adipocytes using glucocortiocoids in a 
similar manner as I have done with the orbital preadipocytes and this suggests the unique 
nature of the orbital molecular environment accounts for its underlying susceptibility to 
autoimmune diseases (Kaminski et al., 2003). 
The identification of 11β-HSD1 in human orbital adipose tissue is an important finding 
and raises the possibility that the local generation of GC within this depot may be 
functionally important to these processes.  11β-HSD1 potently regulated by cytokines (up-
regulated by TNFα, IL-1, IL-4) which is tissue specific (Tomlinson et al., 2001b, 
Tomlinson et al., 2004).  We have shown that IL-6, TNFα and TGFβ increase local 
generation of cortisol in preadipocytes from cHOAT and qHOAT which suggests the 
cytokine effect on 11β-HSD1 to generate cortisol may modulate adipocyte biology.  The 
low response of 11β-HSD1 activity after IL-1β treatment is a surprising one as IL-1β is a 
potent regulator of 11β-HSD1 in other tissues (Friedberg et al., 2003, Peter et al., 2002). 
Cell-types that play a role in the adipogenesis process that occurs in qHOAT include 
activated fibroblasts, preadipocytes and immune cells such as T cells and macrophages 
(Bahn, 2003).  These cells release pro-inflammatory cytokines which can induce 11β-
HSD1 to generate cortisol locally in orbital adipose tissue and in doing so; cortisol may 
enhance adipogenesis (Figure 4-25).  Therefore, we postulate that the intracrine regulation 
is a key determinant of adipogenic and inflammatory pathways in the pathogenesis of 
TAO and modulation of 11β-HSD1 may provide a novel therapeutic target for this sight-
threatening condition. 
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Figure 4-25: The role of pre-receptor cortisol metabolism in the pathogenesis of  
TAO. 
Pro-inflammatory cytokines increase 11β-HSD1 activity and expression 
enhancing the local generation of cortisol thus promoting preadipocyte/fibroblast 
differentiation and potentially limiting proliferation. In addition, increased 
cortisol generation  may have a local anti-inflammatory action to suppress 
cytokine production. Therapeutic use of glucocorticoids suppresses pro-
inflammatory cytokine production and therefore relieves the induction of 11β-
HSD1.  However, cortisol generation by 11β-HSD1 involved in differentiation and 
increased cell proliferation may contribute to the enhanced adipogenesis in TAO. 
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5. Final Conclusions and Future Perspectives 
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Glucocorticoids affect physiological process which include carbohydrate metabolism, 
adipocyte biology and they have an important role in immunomodulation of inflammatory 
processes due their anti-inflammatory and immunosuppressive properties.  As a 
consequence of these properties, glucocorticoids are used abundantly in ophthalmic 
practice for the treatment of ocular ailments such as orbital diseases for example in 
thyroid associated ophthalmopathy and idiopathic orbital and ocular inflammatory 
diseases such as uveitis, diabetic macular oedema, and ocular surface inflammation such 
as allergic conjunctivitis and peri-operatively and post-operatively in peripheral ulcerative 
keratitis (Leibovitch et al., 2007, Toker et al., 2002, Grenga et al., 2008, Arcangelo and 
Peterson, 2005, Wahid et al., 2008). 
However, the therapeutic use of glucocorticoids can have adverse effects on cellular 
processes.  For example, glucocorticoids have been shown to induce osteoporosis and 
osteonecrosis; induce diabetes mellitus; are associated with obesity; delay wound healing 
and promote dyslipidaemia and atherosclerosis (Adam and Epel, 2007, Chedid et al., 
1996, Da Silva et al., 2006, Dalle Carbonare et al., 2001, McCurdy and Friedman, 2006, 
Weinstein et al., 2000).  As a consequence of this, there is a need for a tissue specific 
regulator of glucocorticoids and one way to achieve this is to through the pre-receptor 
regulation of glucocorticoids via 11β-HSD. 
The enzyme, 11β-HSD, interconverts cortisone and cortisol to regulate their levels locally 
in tissues such as the liver, kidney and adipose tissue.  The two isozymes which are 
responsible for these reactions are 11β-HSD1 and 11β-HSD2.  11β-HSD1 is typically 
located in GR rich tissues while 11β-HSD2 is found in MR rich tissues.  
11β-HSD1 has numerous roles in physiology, which include, inflammation (Chapman and 
Seckl, 2008, Gilmour et al., 2006), adipogenesis (Bujalska et al., 1997), and bone 
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regulation (Hong et al., 2008, Delany et al., 1995).  Its role in vivo is to act primarily as an 
oxo-reductase converting biologically inactive cortisone to active cortisol.  
There are a handful of studies into specific roles of 11β-HSD1 in the eye.  These include 
expression of 11β-HSD1 in ocular tissues (Rauz et al., 2001, Suzuki et al., 2001, Stokes et 
al., 2000, Mirshahi et al., 1997) and studies concerning the manipulation of 11β-HSD1 
with non-specific inhibitor carbenoxolone to reduce IOP (Rauz et al., 2003a). 
The aim of this thesis was to study putative roles in the eye and orbit in normal and 
diseased states.  This was achieved by using animal and human tissue to study generation 
of glucocorticoids in intraocular environment, in the anterior ocular surface and in orbital 
adipose tissue.   
The limitations of the study involve the restricted availability of human ocular tissues and 
the quantity required for each specific experiment.  However, we have confirmed active 
11β-HSD1 in reactivating cortisol from cortisone in corneal epithelial cells.  The local 
production of glucocorticoids could be up-regulated by inflammatory cytokines such as 
IL-6 and could lead to the up-regulation of glucocorticoid receptor genes that maybe 
involved in corneal wound repair and anti-inflammatory action against pathogens; 
however, this still needs to be determined.   
The use of synthetic glucocorticoids at high concentrations are known to inhibit the 
corneal wound healing process (Bourcier et al., 2000) and our data suggests that 
reactivated glucocorticoid (cortisone to cortisol) reduces corneal epithelial cell 
proliferation. 
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As no expression of 11β-HSD2 was found in the corneal epithelium and corneal epithelial 
cells of the NZWAR which is comparable to the human (Rauz et al., 2001), it is deduced 
that this enzyme has no major role in these cell-types.   
The New Zealand White Albino Rabbit (NZWAR) was used as a model in these studies 
because the model has previously been used in different studies concerning the ocular 
surface and the intraocular environment.  There are still many tissue types to be 
investigated for possible 11β-HSD1 action, however, tools such as the use of an animal 
model just like the NZWAR can accelerate research and provide good comparisons with 
the limited human data to eventually lead to novel therapeutic treatments. 
To help establish 11β-HSD1’s role in human ocular tissues, I have characterised the pre-
receptor regulation of glucocorticoids and the components involved in the process in 
human ocular surface (corneal epithelial cells, corneal fibroblasts and conjunctival 
fibroblasts) and rabbit ocular surface (corneal epithelial cells, corneal fibroblasts, 
conjunctival fibroblasts) and intraocular (non-pigmented and pigmented epithelium) 
tissues. 
11β-HSD1 staining in cultured human corneal epithelial cells by immunocytochemistry 
confirmed that 11β-HSD1 protein is present in the corneal epithelium.  11β-HSD1 was 
also confirmed in NZWAR corneal and conjunctival epithelium using a human anti-11β-
HSD1 antibody.  This proved that cross-reactivity of the 11β-HSD1 antibody exists 
between the rabbit and human models and highlighted the potential for these cell types to 
locally generate cortisol. 
We checked whether this enzyme was active by using a specific 11β-HSD enzyme assay 
on cultured NZWAR and human corneal epithelial cells, corneal fibroblasts, conjunctival 
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fibroblasts and NZWAR ciliary epithelium (non-pigmented and pigmented) of which 
predominant activity was present in NZWAR NPE compared to PE.   
With respect to intraocular defence, clinical studies have quantified cortisol in aqueous 
humour where diffusion or ultrafiltration has been postulated to be the main source of 
intraocular cortisol (Rauz et al., 2003a, Rauz et al., 2001).  This study shows conclusively 
that the non-pigmented epithelium has the capacity to generate cortisol locally in tissue 
cortisol which can have intracrine and paracrine effects to regulate aqueous humour 
production.  This is important because aqueous humour provides an additional role in the 
regulation of protective systems which may include Fas-L and human beta defensins 
contributing to intraocular defence. 
One way to test the effect of cortisol on Fas-L on the cornea and in the ciliary epithelium 
could be carried out by showing Fas-L mRNA expression (real-time RT-PCR) or protein 
expression (western blot or ELISA) in these cell-lines.  The expression of antimicrobial 
products such as human beta defensin 2 and LL37 after cortisol and LPS treatment in 
primary corneal epithelial cells can be evaluated using ELISA and western blotting 
techniques.   
There was predominant reductase activity from NZWAR and human corneal epithelial 
cells which highlights the ability of these cells to take part in the pre-receptor regulation 
of glucocorticoids in intact cells.  This is in addition to cells from other  systems having 
predominantly reductase activity in intact cells, for example, from liver, lung, and adipose 
tissue (Jamieson et al., 1995, Hundertmark et al., 1995, Bujalska et al., 1997) and 
therefore highlights the role 11β-HSD1 plays in regulating cortisol levels at a tissue 
specific level.  No activity of 11β-HSD1 was shown from NZWAR keratocytes and 
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conjunctival fibroblasts; however, the human form of these cells did exhibit this reductase 
activity suggesting a possible role in these human cells also. 
The use of the NZWAR and human eye as an in-vitro means of studying the effects of 
many other cytokines (such as IL-1) involved in ocular diseases can be performed on 
other primary cells which could include retinal epithelial cells and decipher what 
consequences this may have for autoimmune condition of the eye and how this affects 
11β-HSD1 activity.  This may involve specific 11β-HSD enzyme assays, protein analysis 
such as western blotting or and quantitative mRNA expression with real-time RT-PCR. 
TLR signalling pathways are important in the elimination of pathogenic bacteria on the 
ocular surface such as that shown with TLR4 (Wright et al., 1990, Song et al., 2001).  
LPS has been shown to bind to CD14 and TLR4 to induce expression of pro-
inflammatory cytokines and human beta defensin 2 (Maltseva et al., 2007).  There was 
confirmed expression of glucocorticoid related and certain pro-inflammatory cytokine 
genes (IL-1β and IL-6) in the human corneal epithelial cells which may be the necessary 
apparatus in responding to a potential inflammatory stimulus such as LPS.  The 
confirmation of CD14, HBD-2 and TLR4 gene expression in primary human corneal 
epithelial cells was also keeping in-line with other literature (Song et al., 2001, Terai et 
al., 2004, Li et al., 2007).   
The upregulation of 11β-HSD1 activity by LPS in human corneal epithelial cells may 
represent the functionality of 11β-HSD1 to produce cortisol to modulate immune events.  
LPS a component of bacterial cell wall has been shown to upregulate immune 
components that facilitate the inflammatory process such as pro-inflammatory cytokines 
(e.g. IL-6 and TNFα) and activates the innate immune response via CD14 and TLRs on 
the ocular surface (Liang et al., 2007b, Wu et al., 2005, Sun et al., 2006, Lu et al., 2006).  
  222 
However, LPS is also known to induce immunomodulatory components to regulate 
inflammation such as mucins to protect the mucosal barrier (Smirnova et al., 2003).  In 
light of these data, LPS could induce the immunomodulatory properties of 11β-HSD1 in 
ocular tissue by promoting cortisol generation.   
The pro-inflammatory cytokine IL-6 and not TNFα was able to upregulate 11β-HSD1 
reductase activity in human corneal epithelial while TNFα and not IL-6 upregulates 11β-
HSD1 reductase activity in corneal fibroblast and conjunctival fibroblast cells.  IL-6 has 
been shown to upregulate 11β-HSD1 activity in adipocytes (Friedberg et al., 2003) while 
TNFα has been shown to up-regulate 11β-HSD1 activity in other cell systems such as 
glomerular mesangial cells of the kidney and in osteoblasts (Escher et al., 1997b).  
However, these data may suggest that specific cytokines have cell specific roles in 
modulating 11β-HSD1 activity on the ocular surface. 
GR has been localised in ocular tissues which include the cornea, ciliary body, trabecular 
meshwork, lens, retina and sclera (Rauz et al., 2001).  GR interaction with glucocorticoids 
is important for genomic mediated responses during inflammation (Chinenov and 
Rogatsky, 2007).  Studies have shown that GR agonists such as dexamethasone can 
activate the GR in vitro (Takahashi et al., 2000, Wenzel et al., 2001).   
GR expression was shown in the immortalized human corneal epithelial cells and 
although some GR activation was shown in the immortalized human corneal epithelial 
cells by dexamethasone, this was not as strong as what might have been expected.  This 
may suggest that the assay used for these particular cells, was not optimally sensitive to 
detect large increases in GR activity.  LPS had no effect on GR activity and therefore does 
not influence GR mediated transcription.   
  223 
Further studies on 11β-HSD1 in corneal epithelial cells and its role in inflammation can 
include studying the effects locally generated cortisol by 11β-HSD1 reductase has on the 
immune response that is mediating TLR regulated immunoprotective mechanisms.  We 
hypothesize that the induction of TLR signalling pathway by infectious agents can 
promote 11β-HSD1 reductase to generate cortisol.  In doing so, the cortisol generated 
could trigger anti-inflammatory or anti-microbial GR responses which could contribute to 
the immune privilege state of the cornea and provide ocular surface immunoprotection.  
The experiments that can be carried out will include, immunohistochemistry analysis of 
TLRs in formalin-fixed paraffin embedded corneas to ascertain which resident and 
recruited cells express specific TLRs.  Sections could also be co-incubated with TLR 
antibodies and markers of immune cells (such as CD4 and MHC I) to visualise antigen-
antibody interactions.   
Further experiments will focus on obtaining purified corneal epithelial cells and using the 
immortalized corneal epithelial cells to study TLR expression after co-incubation with 
specific ligands.  Specific inhibitors will also be used to ascertain whether the downstream 
signalling is mediated through induction of 11β-HSD1 and GR.  
Co-cultures of macrophages and dendritic cells with corneal epithelial cells could also be 
established to study their crosstalk through direct cell-cell contact and establish whether 
corneal epithelial cells influence the function of macrophages and dendritic cells. 
Adipose tissues from different depots possess differing adipocyte biology and perform 
glucocorticoid metabolism.  In this thesis, we sought to investigate the morphological and 
biological differences between SC, OM and HOAT depots.  The novel reproducible 
automated method for the histomorphometric analysis of adipose tissue from different 
depots has allowed us to note the adipose cell characteristic differences in a quantitative 
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manner.  The method revealed that cHOAT adipocytes are generally smaller than SC and 
OM adipocytes and cHOAT adipocytes expressed lower levels of adipocyte 
differentiation markers (FABP4 and G3PDH.  Histomorphometric analysis of qHOAT 
and iHOAT revealed no significant difference in morphological parameters when 
compared to cHOAT suggesting that that are of similar size and shape. 
SC, OM and cHOAT all expressed GRα mRNA as previously found in other studies 
(Heufelder et al., 1992a, Burnstine et al., 1998, Muhlberg et al., 2000, Boullu-Ciocca et 
al., 2003), however this was much higher in cHOAT.  In addition to this, the data defined 
11β-HSD1 activity and mRNA expression along with its regulatory enzyme, H6PDH in 
cHOAT and qHOAT tissue and preadipocytes.  These observations highlight that HOAT 
is distinct from SC and OM as each depot has differing propensities of adipocyte 
differentiation, proliferation, apoptosis and lipid metabolism (Niesler et al., 1998, 
Baglioni et al., 2009, Mito et al., 2009, Lundgren et al., 2008, Tchkonia et al., 2005).  
Further work related to this will include glucocorticoid-related gene expression in iHOAT 
to establish whether this is different to qHOAT.   
The different properties between SC, OM and HOAT, maybe indicative of the difference 
in cell lineage as SC and OM ‘peripheral' fibroblasts originate from the mesoderm and the 
cHOAT fibroblasts originally come from the neuroectoderm (Smith and Smith, 2004).  It 
has already been shown that fibroblasts can be differentiated to mature-like adipocytes in 
the same manner as we have done with the orbital preadipocytes and this suggests the 
unique nature of the orbital molecular environment accounts for its underlying 
susceptibility to autoimmune diseases (Kaminski et al., 2003). 
CD68+ cells and CD68 mRNA was higher in cHOAT compared to SC and OM which is 
important because the cytokines they produce may have effects on adipocyte biology.  In 
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addition to this, these data reflect an orbital molecular environment that has an increased 
potential and plasticity that is vital to combat inflammatory, immune-mediated or 
infective insult.  Recent studies have shown that chronic inflammation activates adipose 
tissue in simple obesity which is defined by an increase in CD68+ macrophages, increased 
adipocyte size and increased TNFα in patients with high BMIs (Weisberg et al., 2003, 
Neels et al., 2006, Pietilainen et al., 2006).   
There is a great deal of heterogeneity in monocyte-derived lineages (such as 
macrophages) and these different subsets from monocytes have specific roles in 
physiology.  No significant difference in CD68+ cell number or mRNA expression 
between cHOAT and qHOAT suggests this is confirmatory of the non-inflamed status of 
qHOAT. Obtaining more samples of iHOAT and other inflamed responses such as 
dermatitis will help establish if there is a difference in expression of CD68+ when 
compared to cHOAT and qHOAT.  This could confirm the use of this technique a an 
indicator of active inflammation.  
The crosstalk that occurs between adipocytes, macrophages and endothelial cells 
aggravates the inflammatory state, resulting in increased secretion of pro-inflammatory 
cytokines/chemokines, adipokines and angiogenic factors. Furthermore, the interaction of 
cytokines and glucocorticoid metabolism may be an additional contributing factor.  TNFα, 
IL-6 and IL-1β are potent inducers of 11β-HSD1 expression and activity in adipose tissue.  
Macrophage-derived cytokine production in-vivo may serve to augment cortisol 
generation through induction of 11β-HSD1.  TNFα specifically, in addition to modulating 
11β-HSD1 activity, inhibits adipocyte differentiation, proliferation and promotes 
apoptosis and de-differentiation.  This process may be of considerable relevance to the 
orbital fat microenvironment as the high macrophage content and the increased expression 
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of IL-6, IL-1β and TNFα in HOAT maybe regulating adipocyte biology.  For example, 
qHOAT is a clinically non-inflamed state and as a consequence, the increased expression 
of TNFα is an indicator of a once inflamed tissue, however the expression of TNFα in 
qHOAT maybe lower that that in iHOAT and needs to be defined.   
TGFβ inhibits TSHR expression and adipogenesis by orbital fibroblasts, which would 
indicate favourably towards disease remission and its is presumed that these inhibitory 
and stimulatory cytokine effects occurring simultaneously within the orbit maybe 
contributing to the severity of TAO (Bahn and Bahn, 2002). Therefore, the only slight 
increase in TGFβ expression from qHOAT compared to cHOAT may suggestive of 
disease remission in qHOAT.  CD200, the myeloid cell regulator, exhibited an expression 
slightly higher in qHOAT compared to cHOAT.  This maybe involved in regulating 
myeloid immune cell infiltration into qHOAT which may include macrophages.   
With respect to CCL2 (also known as MCP-1) this was also increased in qHOAT 
compared to cHOAT.  CCL2 has a significant part to play in TAO due to its involvement 
in macrophage infiltration into the tissue.  CCL2 has already been characterised in adipose 
tissue from obese individuals and is also linked to the Th2 chemokine (Karpus et al., 
1997, Chen et al., 2008).  One study by Chen et al, 2008, found a correlation between 
CCL2 and the degree of infiltration of macrophage into the HOAT of Graves’ individuals 
(Chen et al., 2008).  This may indicate that CCL2 may well be an important mediator of 
lymphoid cell interactions with HOAT in TAO individuals.  These studies looking at 
cytokine expression in HOAT can be extended to iHOAT to establish whether there are 
any differences.  Other cytokines can be studied for effects on 11β-HSD1 expression and 
activity in HOAT which can include IFNγ and TGFβ. 
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Studies have shown that there is increased expression of the TSH receptor on both 
preadipocytes and differentiated adipocytes derived from primary cultures of orbital 
adipose tissue taken from patients with TAO when compared to controls (Crisp et al., 
2000).  TSH receptor gene expression in TAO preadipocytes, however, is inhibited by 
cytokines such as TNFα, IFNγ and TGFβ.  Downstream TSH-dependent cAMP 
production is also decreased.  In addition, TNFα and IFNγ attenuate morphological 
adipocyte maturation, indicating that TSH receptor expression may not be essential for 
adipogenesis, but may be a characteristic feature of mature differentiated adipocytes 
(Valyasevi et al., 2001).  However, increased positive correlations between expression of 
TSH receptor mRNA and obesity-related markers (leptin, adiponectin, PPARγ) are also 
seen in TAO fibroblasts compared with controls (Kumar et al., 2004).  We confirmed 
TSHR is expressed in HOAT and therefore these data suggest de novo adipogenesis 
within orbital tissues in patients with TAO.   
Glucocorticoids are essential for adipocyte differentiation (Hauner et al., 1987), inhibit 
omental preadipocyte proliferation (Tomlinson et al., 2002), but interestingly, promote 
proliferation in the SC depot (Bader et al., 2002).  The identification of 11β-HSD1 in 
human orbital adipose tissue is an important finding and raises the possibility that the 
local generation of GC within this depot may be functionally important to these processes.  
With respect to TAO, this may see some of the beneficial effects of regulating 11β-HSD1 
activity at least in the active stages of the disease.   
11β-HSD1 is potently regulated by cytokines (up-regulated by TNFα, IL-1, IL-4) which is 
tissue specific (Tomlinson et al., 2001b, Tomlinson et al., 2004).  I have shown that IL-6, 
TNFα and TGFβ increase local generation of cortisol in preadipocytes from cHOAT and 
qHOAT which suggests the cytokine effect on 11β-HSD1 to generate cortisol may 
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modulate adipocyte biology.  The low response of 11β-HSD1 activity after IL-1β 
treatment is a surprising one as IL-1 is a potent regulator of 11β-HSD1 in other tissues 
(Friedberg et al., 2003, Peter et al., 2002). 
Studies into 11β-HSD1 activity and expression with active TAO samples could be 
performed to show whether down-regulation of 11β-HSD1 in the early stages of TAO will 
be beneficial or detrimental.  This work may include a mouse animal model of over 
expression of 11β-HSD1 specifically in orbital adipose tissue to see if adipose biology 
mimics that seen in TAO.  Other avenues for mouse models to study ocular disease could 
include a knockout model of 11β-HSD1 to establish effects on eye pathology and 
inflammation following treatment with bacterial endotoxins. 
To conclude, data presented here emphasise the putative role of 11β-HSDs in the ocular 
microenvironment.  An important facet of this study is that it highlights the possible 
therapeutic application of 11β-HSD modulators in the treatment of a variety of ocular and 
orbital diseases.  Specific 11β-HSD1 inhibitors are currently being tested in a variety of 
model systems and it will be interesting to see if there are any benefits of these inhibitors 
in ocular orientated diseases. 
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